',6&/2685(
5('$&7('[ZIP_CODE]&2/
$%,367
$3+$6(08/7,&(17(523(1/$%(/ '26(),1',1*678'<72$66 (66
7+(6$)(7<72/(5$%,/,7<$1'35(/,0,1$5<()),&$&<2):((./<
QDEÂŠ3$&/,7$;(/,13(',$75,&3$7,(176:,7+5(&855(1725
5()5$&725<62/,'780256 

7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1([ZIP_CODE],(7$5<,1)250$7,21<
WEHVKDUHGREHVKDUHG
KHUVDQGSDWLHUVDQGSDWL
XODWLRQVUHTDWLRQVU
RUFRUFRQWUDFWXRQWUDFW
RFHUWDLQSDUFHUWDLQSD
QLQIRUPDWLRLQIRUPDW
&HOJHQHÂ¶VFR&HOJHQHÂ¶VF
LQFLSOHVLQFLSOHV
VSDFHPDLQVSDFHPD
FDWLRQRILQFDWLRQRILQ
FRQILGHQRQILGHQWLDOWL
QLGHQWLILDEQLGHQWL
RPD\FRQWDRPD\FRQWD
VJHQHUDWLQJJHQHUDWLQJ
WDFKPHQWVWDFKPHQWV
RIWKHUHSRUWWKHUHSRUW
&HOJHQHYHQ&HOJHQHY
DWLQIRUPDWLRWLQIRUPDWL
ERXWRXUYHERXWRXUYH
QDERXW&HOJDERXW&HOJ
GDWKWWSZZGDWKWWSZ
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069312]-001 Amendment 5.0 Final: 13 Jul 2016TITLE PAGE
A PHASE 1/2, MULTICENTER, OPEN-LABEL, DOSE-
FINDING STUDY TO ASSESS THE SAFETY, 
TOLERABILITY, AND PRELIMINARY EFFICACY OF 
WEEKLY nabÂ®-PACLITAXEL IN PEDIATRIC 
PATIENTS WITH RECURRENT OR REFRACTORY 
SOLID TUMORS
INVESTIGATIONAL PRODUCT (IP): nab-PACLITAXEL (ABRAXANEÂ®)
PROTOCOL NUMBER: ABI-007-PST-001
ORIGINAL DATE FINAL: 13 May 2013
AMENDMENT 1.0 DATE FINAL: 10 Sep 2013
AMENDMENT 2.0 DATE FINAL: 12 Mar 2014
AMENDMENT 3.0 DATE FINAL: 11 Jun 2014
AMENDMENT 4.0 DATE FINAL: 25 Mar 2015
AMENDMENT 5.0 DATE FINAL: [ADDRESS_1069313] NUMBER: 2013 -000144 --26
IND NUMBER: 122810
SPONSOR NAME / ADDRESS: Celgene Corporation
[ADDRESS_1069314]
Summit, NJ [ZIP_CODE], [LOCATION_003]
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
[CONTACT_10825], your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by [CONTACT_27614].  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by [CONTACT_476].
CCI&(/*(1(is protocol is pis protocol is p
you, your stou, your 
documendocume
mm
P1([ZIP_CODE],(7$5<,1)250$7,21Y Y
EL (ABRAEL (ABRA
-[PHONE_16207]
p 2013p 20
MarMar [ZIP_CODE]
11 Jun 211 Ju
25MM
S:S:
1(1(
(/(/
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069315]-001 Amendment 5.0 Final: 13 Jul 2016MEDICAL MONITOR / EMERGENCY CONTACT [CONTACT_27615]:
Name:
[CONTACT_1641]:
Address:
Phone:
E-mail:
Note: The back-up [ADDRESS_1069316] call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up [ADDRESS_1069317] Call Center: 
CCI[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
&(/*(1([ZIP_CODE],(7$5<,<,,1)250$7,210500
250
only be usenly be use
onitor or dnitor or d
1
<,1
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069318]-001 Amendment 5.0 Final: 13 Jul 2016CELGENEÂ®THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_72655] [CONTACT_27616], I indicate I have reviewed this protocol and find its content to be 
acceptable.  
CCI&(/*(1([ZIP_CODE],(7$5<,1,1,1)250$7,210$0$5000
content to content to
,1
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069319]-001 Amendment 5.0 Final: 13 Jul 2016SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]:_______________________________________
By [CONTACT_27616], I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in  compliance with the protocol, informed 
consent/assent, Institutional Review Board (IRB)/Ethics Co mmit tee (EC) procedures, 
instructions from Celgene representatives, the Declaration of Helsinki, ICH Good 
Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies.
CCI&(/*(1([ZIP_CODE],(7$7$7$5<,1)250$7,210$0$5000
s studys study  at m atyy
, informnform ed d
mmitmitee (EC(EC
n of Helsinkn of Hels
verning theerning th
7$
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069320]-001 Amendment 5.0 Final: 13 Jul 2016COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_27504]:_______________________________________
By [CONTACT_27616], I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as needed.
CCI&(/*(1([ZIP_CODE],(7$5<5<5<,1)wiwi1)250$7,210$0$[ADDRESS_1069321]
5<
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069322]-001 Amendment 5.0 Final: 13 Jul 2016PROTOCOL SUMMARY
Study Title
A Phase 1/2, multicenter, open-label, dose-findi ng study to assess the safety, tolerability, and 
preliminary efficacy of weekly nabÂ®-paclitaxel in pediatric patients with recurrent or refractory 
solid tumors. 
Indication 
Phase 1 Portion: Pediatric patients with recurrent or re fractory solid tumors (excluding brain 
tumors). 
Phase 2 Portion: Pediatric patients with recurrent or refractory neuroblastoma, 
rhabdomyosarcoma, and Ewingâ€™s sarcoma. 
Objectives
Primary Objective
!Phase 1 portion: To determine the ped iatric maximum tolerated dose (MTD)/ 
pediatric recommended Phase 2 dose (RP2D), safety and tolerability
!Phase 2 portion: To characterize antitumor activity at RP2D assessed by [CONTACT_178975] (ORR)
Secondary Objectives
!Phase 1 portion: To evaluate pharmacokinetics (PK) and characterize ORR
!Phase 2 portion: To characterize duration of response (DOR), disease control rate 
(DCR), progression-free survival (PFS), 1-year survival. To confirm safety and to evaluate PK
Study Design
The Phase 1 portion of the study will be a rolling-6 dose escalation design to determine the 
MTD/RP2D. A safety monitoring committee (SMC) will be formed to make dose escalation 
decisions. Approximately 64 patients are planned to be e nrolled in this portion of the study; 
approxi mately 44 into the Dose Determining Sets (DDS), and about 20 additional patients at 
dose levels evaluated as safe by [CONTACT_4484].
The Phase 2 portion of the study will enroll additional patients at the RP2D (240 mg/m
2in 
patients weighing > 10 kg, and 11.5 mg/kg in patients weighing â‰¤ 10 kg) into one of three solid 
tumor groups using a Simon two-stage minimax  design for each group:
!Neuroblastoma ( â‰¤ 23 patients)
!Rhabdomyosarcoma ( â‰¤ 23 patients)
!Ewingâ€™s sarcoma ( â‰¤ 23 patients)
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21brain rain 
tololerated dated d
yand toland ty era
vitty at RP2y at RP
acokineticscokinetic
e duration oduration 
vival (PFS)vival (PF
udyudy will be will beyy
nitoring oring co
ely ely 6464patatiei
to the o the DDosos
ated as safeated as safe
portion of tportion of t
eighing ghing > >1
groupsroups usinusin
!!NeNe
!!
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069323]-001 Amendment 5.0 Final: 13 Jul 2016Both phases of the study will be open-label a nd conducted at multiple centers. The study will be 
conducted in compliance with International Council for Harmonisation (ICH) Good Clinical 
Practices (GCPs).
Study Population
The Phase 1 portion of the study will be conducted in patients â‰¥ 6 months and < 18 years of age 
with recurrent or refractory solid tumors  (excluding primary or metastatic brain tumors). 
The Phase 2 portion of the study will be conducted in patients â‰¥ 6 months and â‰¤ [ADDRESS_1069324] 1.1 (for neuroblastoma,
evaluable disease by 123I-metaiodobenzylguanidine (MIBG)/Curie score is also acceptable) in 
several discrete recurrent or refractory solid tumor types (neuroblastoma, rhabdomyosarcoma, and Ewingâ€™s sarcoma).
Length of Study
In both the Phase 1 and 2 portions of the study, patients will enter a 14 day screening period, and 
if eligible (and the cohort/group is open for recruitment) will proceed to the treatment phase.  
Patients may remain on treatment until disease progression, unacceptable toxicity, until they 
begin a new anticancer therapy, withdrawal of consent, parent/guardian/patient refusal, physician decision or death. 
All patients in both portions of the study will be followed for [ADDRESS_1069325] study 
treatment for safety, monitoring of advers e events and for response until progression (if 
applicable). Patients will be followed for [ADDRESS_1069326] patient that is required for primary, 
secondary and/or exploratory analysis, as pre -specified in the protocol and/or the Statist ical 
Analysis Plan, whichever is the later date.
Study Treatments
In both the Phase [ADDRESS_1069327] 
(IP)nab-paclitaxel, administered intravenously over approximately 30 minutes, on Days 1, 8,
and 15 of a 28-day cycle until disease progression or as described above. The starting dose for the Phase 1 portion will be 120 mg/m
2. The dose will be escalated in subsequent cohorts until the 
MTD/RP2D has been identified. The Phase 2 por tion will treat patients at th e RP2D identified 
during the Phase 1 portion. In January 2016 , the RP2D was identified as 240 mg/m2in patients 
weighing > 10 kg and 11.5 mg/kg in patients weighing â‰¤ 10 kg.
Overview of Efficacy Assessments
All patients will be assessed by [CONTACT_20420] (CT) or magnetic resonance imaging 
(MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at screening 
and every 8 weeks from Cycle 1 Day 1 until di sease progression, the start of a new anticancer 
therapy or withdrawal of consent.  In patien ts with neuroblastoma, a MIBG scan will be 
performed according to the same schedule to assess MIBG response.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e))in in 
arcorcoma, ma, 
screening pscreening 
the treatmehe trea
able toxicitable toxicit
rdian/dian/ patpat///iei
or [ADDRESS_1069328] t data poindata po
lysis, as prelysis, as p
e later datelater date
d 2 portid 2 port on
administeradminister
ayay cyclecycleyy unu
ortiortion will on will
D has beenD has been
the hPhasehase 11
hing hing >>10 k10 
Overview oOverview o
All Allpatipat
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069329]-001 Amendment 5.0 Final: [ADDRESS_1069330], abdomen, and pelvis, MIBG scan 
(for neuroblastoma), any other studies require d for tumor imaging, and (for neuroblastoma) bone 
marrow biopsy for verification of confirmed complete response.
Overview of Safety Assessments
All patients will be monitored for adverse events, starting from the time the 
parent/guardian/patient signs the informed conse nt/assent form until [ADDRESS_1069331] dose of 
IP and at the end of treatment (EOT) visit. A thorough evaluation of medical conditions will be conducted during screening for eligibility. Physical examination (source documented only), vital 
signs, laboratory assessments (eg, serum ch emistry, hematology), 12-lead electrocardiogram 
(ECG), left ventricular shortening fraction (LVSF) assessment by [CONTACT_6751]/multi-gated acquisition (MUGA) scan/ other medica lly approved method, and Lansky/ Karnofsky 
performance status will be monitored regularly. The full schedule of assessments is described in 
Table 4 and Section 6. 
Overview of Statistical Methods
The Phase 1 portion uses a rolling-6 patient dose escalation design to establish the MTD/RP2D 
and the Phase 2 portion uses a Simon two-stag e minimax design to monitor p atient enrollment 
for each group separ ately.
Sample Size
During the Phase 1 portion of  the study, up to approximately 64 patients will be enro lled, 
depending on the number of dose level cohorts ev aluated and the number of additional patients 
enrolled at dose levels evaluated as safe by [CONTACT_3433] e SMC. In the Phase 2 portion, up to 69 efficacy 
evaluable patients ( â‰¤ 23 with neuroblastoma, â‰¤ 23 with rhabdomyosarcoma, and â‰¤ 23 with 
Ewingâ€™s sarcoma) will be enrolled at the RP2D determined in the Phase [ADDRESS_1069332] stage, 14 efficacy evaluable patients will be enrolled. If < 2
of the 14 patients within a group has a respons e, the enrollment for this group will be stopped
upon determination of the number of responders. If â‰¥ [ADDRESS_1069333] a response, the 
enrollment will continue until 23 efficacy evaluable patients are enrolled. At the final analysis, 
the regimen will be concluded with more than 5% true response rate if â‰¥ [ADDRESS_1069334] a 
response according to the maximum likelihood estimator. The sample size is based on an 80% power and 10% significance having fixed the lower and upper boundaries to 10% and 28%, 
respectively.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21talal
m
-gated ated 
y y
s described describe
stablish thestablish th
monitor onitor pa
atelyely6464patp
tedtedand thend the
MCC. In the P. In the P
[ADDRESS_1069335] stage, stage, 1414
pphahassa respa resp
mber of resmber of re
ntil 23 il 23 effifi
ncluded witncluded wi
to ththe e mamaxix
ignificanceignificance
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069336]-001 Amendment 5.0 Final: [ADDRESS_1069337] OF ABBREVIATIONS ....................................................................................................16
1. INTRODUC TION ..................................................................................................19
1.1. Pediatric Indication Background .............................................................................19
1.1.1. Neuroblas toma ........................................................................................................ 19
1.1.2. Rhabdom yosarcoma ...............................................................................................19
1.1.3. Other Pediatric Solid Tu mors ..................................................................................20
[IP_ADDRESS]. Nonrhabdomyosarcoma S oft Tissue Sarcoma .........................................................20
[IP_ADDRESS]. Ewingâ€™s Sarcoma ....................................................................................................20
[IP_ADDRESS]. Mela noma............................................................................................................... [ADDRESS_1069338] udy Desi gn..................................................................................... 29
[IP_ADDRESS]. Rationale for Patien t Populat ion..............................................................................30
[IP_ADDRESS]. Rationale for Phar macokinet ics...............................................................................30
1.3.3. Rationale for Dosing ...............................................................................................31
2. STUDY OBJE CTIVES ...........................................................................................32
2.1. Primary Objective ...................................................................................................32
2.2. Secondary Objectiv es .............................................................................................32
2.3. Exploratory  Objectiv es ...........................................................................................32
3. STUDY ENDPOI NTS............................................................................................33
3.1. Primary Endpoint(s) ...............................................................................................33
3.2. Secondary Endpoint(s) ............................................................................................33
3.3. Exploratory Endpoints ............................................................................................33
4. OVERALL STUDY DESIGN ................................................................................34
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_1069339]
.1..1.
.2..2.
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069340]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].1. Study De sign..........................................................................................................34
4.2. Study D uration .......................................................................................................36
4.3. End of Tr ial ............................................................................................................36
5. TABLE OF EVENTS.............................................................................................37
6. PROCEDURES......................................................................................................41
6.1. Treatment Period ....................................................................................................43
6.1.1. End of Tr eatment....................................................................................................43
6.2. Follow-up Period ....................................................................................................44
6.2.1. 28-Day Fo llow-up ..................................................................................................44
[IP_ADDRESS]. Speci al Monitoring .................................................................................................[ADDRESS_1069341] 1.1 ................................................46
[IP_ADDRESS]. Other Assessments ..................................................................................................[ADDRESS_1069342](s) ................................................................52
8.2. Treatment Administration and Schedule .................................................................52
8.2.1. Phase 1 Portion:  Dose Escal ation ........................................................................... 52
[IP_ADDRESS]. Definition of Dose- limiting Toxicity .......................................................................53
[IP_ADDRESS]. Safety Moni toring Co mmittee .................................................................................54
[IP_ADDRESS]. Dose Escalation Procedure s....................................................................................54
[IP_ADDRESS]. Recommended Ph ase 2 Dose ..................................................................................55
8.2.2. Phase 2:  Dose  Expansion .......................................................................................55
8.2.3. Treatment Modification ..........................................................................................55
[IP_ADDRESS]. Body Surface Area or Weight Cha nges ...................................................................55
[IP_ADDRESS]. Treatment Delay .....................................................................................................55
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_1069343] igat
AdministrAdmini
1 Portion:1 Portion:
efinitfinitioion on o
SafSafetetfffy yMM
3.3. DosDo
.2.1.4..2.1.4.
8.2.2..2.2.
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069344]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].2.3.3. Missed Treatment ...................................................................................................56
[IP_ADDRESS]. Dose Adju stment ....................................................................................................56
[IP_ADDRESS]. Intrapatient Dose Escalation ...................................................................................[ADDRESS_1069345] Compliance ........................................................................59
9. CONCOMITANT MEDICATI ONS AND PROC EDURES ....................................60
9.1. Permitted Concomitant Med ications and P rocedure s...............................................60
9.2. Prohibited Concomitant Medications and Procedures ..............................................60
9.3. Required Concomitant Medications and Procedures ................................................61
10. STATISTICAL ANALYSES ..................................................................................62
10.1. Overvi ew................................................................................................................62
10.2. Study Population Definitions ..................................................................................62
10.3. Sample Size and Po wer Consider ations ...................................................................62
10.4. Demographic and Bas eline Character istics ..............................................................63
10.5. Patient Dis positi on..................................................................................................63
10.6. Efficacy Analysis ....................................................................................................63
10.7. Safety An alysis.......................................................................................................64
10.8. Interim An alysis .....................................................................................................65
10.9. Other T opi[INVESTIGATOR_1102] ...........................................................................................................65
10.9.1. Pharmacokinetic Analysis .......................................................................................65
11. ADVERSE EV ENTS ..............................................................................................66
11.1. Monitoring, Recording and Re porting of Advers e Even ts .......................................66
11.2. Evaluation of A dverse Events.................................................................................66
11.2.1. Se riousness............................................................................................................. 66
11.2.2. Severity / Intensi ty..................................................................................................68
11.2.3. Caus ality ................................................................................................................68
11.2.4. Dur ation ................................................................................................................ .69
11.2.5. Action Taken .......................................................................................................... 69
11.2.6. Outco me................................................................................................................. 69
11.3. Abnormal Laborat ory Valu es..................................................................................69
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,2199
.......595
..............595
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
sticsstics...........
........................
.......................
.................
.......................
.....................
tic AnalysAnalys
E EVENTE EVEN
toring, Rectoring, Rec
valuataluat ioion on o
SeriSeriousou
2.2. SeveSe
[IP_ADDRESS].2.3.
[IP_ADDRESS].2.4.
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069346]-001 Amendment 5.0 Final: [ADDRESS_1069347] .................................................................................................73
13.2. Emergency Identification of Investigational Products .............................................73
14. REGULATORY CONSIDERATIONS ...................................................................74
14.1. Good Clinical Practice ............................................................................................74
14.2. Inve stigator Responsibilities ...................................................................................74
14.3. Patient Information and Informed Consent / Assent ................................................[ADDRESS_1069348]/Independent Ethics Committee Review and 
Approval ................................................................................................................ [ADDRESS_1069349] / Ethics Committee ..........[ADDRESS_1069350] udy...............................................................................................76
15. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .....................................................77
15.1. Data / Do cuments ...................................................................................................[ADDRESS_1069351] Retention ....................................................................................................77
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................................79
16.1. Study Monitoring and S ource Data Veri ficatio n......................................................79
16.2. Audits and Inspections............................................................................................79
17. PUBLICATIONS ...................................................................................................80
18. REFERENCES.......................................................................................................81
19. APPENDICES ........................................................................................................87
19.1. Appendix A:  RECIST 1.1......................................................................................87
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,2111
.......727
..............727
.........................
..........................
..........................
..........................
..........................
..................
.........................
/ Assent/ Assent
.........................
........................
dependent Edependent E
...........................
r the Instthe Inst iti
dyy....................
LING ANDING AN
umentsumen ...
ManagemenManagemen
cord Retencord Rete
QUALITQUALIT
StudyStudy
.2. AA
&17.7
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069352]-001 Amendment 5.0 Final: 13 Jul 201619.1.1. Defini tions............................................................................................................. .87
[IP_ADDRESS]. Measurable Disease ................................................................................................87
[IP_ADDRESS]. Nonmeasurable Diseas e..........................................................................................87
[IP_ADDRESS]. Special Considerations for Lesion Measurability ....................................................87
19.1.2. Tumor Response Evaluation ...................................................................................87
[IP_ADDRESS]. Target Lesions ........................................................................................................ 87
[IP_ADDRESS]. Nontarget Lesions...................................................................................................88
[IP_ADDRESS]. Response Criteria ....................................................................................................88
[IP_ADDRESS]. Symptomatic D eteriorati on.....................................................................................90
19.2. Appendix B: Curie Scale for MIBG Response ........................................................90
19.2.1. MIBG Scan Assessable ...........................................................................................91
19.2.2. Tumor Response Evaluation ...................................................................................91
19.2.3. Response Criteria ....................................................................................................92
19.3. Appendix C: Pe rformance S tatus ............................................................................92
19.3.1. Lansky Performan ce Statu s.....................................................................................92
19.3.2. Karnofsky Perfor mance Statu s................................................................................93
19.4. Appendix D:  Pharmacokinetic Sample Handling Instructions ................................93
19.4.1. Bl ood Sample Lab eling ..........................................................................................93
19.4.2. Bl ood Sample Collection: .......................................................................................94
19.4.3. PK Sample Shipme nt.............................................................................................. 94
[IP_ADDRESS]. Sample Collection Documents to  Accompany Sh ipment( s).....................................94
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177
.......888
..............888
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
e Handling e Handling
........................
.......................
.................
ocuments tocuments to
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069353]-001 Amendment 5.0 Final: [ADDRESS_1069354] OF TABLES
Table 1: Abbreviations and Specialist Terms ........................................................................16
Table 2: Phase 1 Trials of Taxanes in Children.....................................................................25
Table 3: Phase 2 Trials of Taxanes in Children.....................................................................26
Table 4: Table of Events.......................................................................................................37Table 5: Dense PK Sampling................................................................................................47
Table 6: Sparse PK Sampling ...............................................................................................47
Table 7: Phase 1 Portion Example Dose Levels ....................................................................53Table 8: Hematologic Toxicity:  Recommended Dose Reductions........................................57
Table 9: Nonhematologic Toxicity:  Recommended Dose Reductions ..................................57
Table 10: Time Point Response: Patients With Target (Â± Nontarget) Disease .........................90
Table 11: Time Point Response: Patients With Nontarget Disease Only .................................90
Table 12: Lansky Performance Scale ......................................................................................92
Table 13: Karnofsky Performance Status Scale .......................................................................93
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,214747
......4747
....................... 535
...........................
.........................
easease..........
nlynly.................
..........................
..........................
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069355]-001 Amendment 5.0 Final: [ADDRESS_1069356] OF FIGURES
Figure 1: Phase 1 Study Design .............................................................................................35
Figure 2: Phase 2 Study Design .............................................................................................35
Figure 3: Curie Score Anatomical Regions ............................................................................91
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069357]-001 Amendment 5.0 Final: [ADDRESS_1069358] OF ABBREVIATIONS
Table 1: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Explanation
AE Adverse event
ALT Alanine aminotransferase (SGPT)
ANC Absolute neutrophil count
AST Aspartate aminotransferase (SGOT)
AUC Area under the curve
Î²-hCG Î²-subunit of human chorionic gonadotropin
BSA Body surface area
BUN Blood urea nitrogen
CBC Complete blood count
CL Clearance
Cmax Maximum plasma concentration of drug
CNS Central nervous system
CR Complete response
CRO Contract research organization
CRF Case report form
CRP Clinical Research Physician
CRS Clinical Research Scientist
CT Computed tomography
CTCAE Common Terminology Criteria for Adverse Events
DCR Disease control rate
DDS Dose Determining Set
DEHP di (2-ethylhexyl) phthalate
DLT Dose-limiting toxicity
DMSO Dimethyl sulfoxide
DOR Duration of response
EC Ethics committee
ECG Electrocardiogram
EE Efficacy evaluable
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21)
<,15<n of drugof drug$57$(7 organizationorganization5,(ormrm35 Research Phesearch P23cal Researccal Researc52Computed toComputed35 CommoComm3(DisDis(((1(1(1((1((1*
SOSO(/* DORDOR&(CC&
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069359]-001 Amendment 5.0 Final: 13 Jul 2016Table 1: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
EEA European Economic Area
EOT End of treatment
ESMO European Society for Medical Oncology
FDA Food and Drug Administration
GCP Good Clinical Practice
HIV Human immunodeficiency virus
HSCT Hematopoietic stem cell transplantation
HVA Homovanillic acid
ICF Informed c onsent form
ICH International Council for Harmonisation
IND Investigational New Drug
IP Investigational Product
IRB Institutional Review Board
IRT Integrated Response Technology
IV Intravenous
LDH Lactate dehydrogenase
LVSF Left ventricular shortening fraction
MCR Maintained complete response
MedDRA Medical Dictionary for Regulatory Activities
MIBG123I-metaiodobenzylguanidine
MR Minor response
MRI Magnetic resonance imaging
MTD Maximum tolerated dose
MUGA Multi-gated acquisition
NCI National Cancer Institute
NE Inevaluable
NRSTS Nonrhabdomyosarcoma soft tissue sarcoma
NSCLC Non-small cell lung cancer
ORR Overall response rate
OS Overall survival
CCI777$7$7$7$70$5025)21),1
5<$5ologyology7$(7 nasenase,(
ar shorteninar shorten5
ed completed comple23cal Dictionacal Dictiona52I-I-metaiodometaio5
Minor renor3(MaMa(((1(1(1((1((1*(/*
NRSTSNRSTS&(SCLCSCLC&
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069360]-001 Amendment 5.0 Final: 13 Jul 2016Table 1: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
PFS Progression-free survival
PNET Primitive neuroendocrine tumors
PK Pharmacokinetics
PR Partial response
PVC Polyvinyl chloride
RBC Red blood cell count
RECIST Response Evaluation Criteria in Solid Tumors
RP2D Recommended Phase [ADDRESS_1069361] operating procedure
SPARC Secreted protein acidic and rich in cysteine
S[LOCATION_003]R Suspected unexpected serious adverse reaction
t1/[ADDRESS_1069362] Upper limit of normal
[LOCATION_003] [LOCATION_002] of America
USP [LOCATION_002] Pharmacopeia
VMA Vanillylmandelic acid
Vss Volume of distribution
WBC White blood cell count
CCI&s&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$7$7$70$5025)21),1
5<and End Rnd End $5 c transaminac transami7$ ic transaminic transam(7 y y ofof Pediat Pediatff5,(oring commring comm35 operating poperating 23eteted proteined protein52Suspected uSuspected35 Halff--flifli3(TreTre(((1(111(*
P(/* VMVMA&(&
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069363]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE]. INTRODUCTION
1.1. Pediatric Indication Background
Sixty percent of all pediatric malignant neoplasms are solid tumors ( Dome, 2008 ). Although 
brain tumors such as gliomas and medulloblastomas frequently occur in the pediatric population, 
patients with brain tumors will not be enrolle d in this study as there are no data to-date that 
would indicate that Abraxane has any efficacy in primary or metastatic brain tumors. Therefore, 
brain tumors are not further discussed in this protocol. The most common non-central nervous 
system (CNS) solid tumors in the pediatric population (age 0 â€“ 19 years, in the [LOCATION_003]) are 
comprised of the following tumor types: neuroblastoma (7%), Wilmsâ€™ tumor (5%), rhabdomyosarcoma (3%), retinoblastoma (3%), osteosarcoma (3%), and Ewingâ€™s sarcoma (1%) 
(ACS, Cancer Facts and Figures, 2012 ). 
Although childhood cancer is rare and the 5-year survival rate in non-CNS solid tumors is 
relatively high in the 0- to 19-years- old pediatric populat ion (68% to 88%), chil dhood cancer is 
the leading cause of death by [CONTACT_778540] ( ACS, Cancer Facts and Figures, 2012 ). The 
main reason for cancer death in the pediatric population is refractory and relapsed disease, and improved therapeutic options are needed in this population.
1.1.1. Neuroblastoma
Neuroblastoma is a malignant embryonal tumor of the neural crest cells. In children < [ADDRESS_1069364] common tumor ( Heck, 2009 ). The 5-year survival rates for children 
aged 0 to 19 years are in the range of 75% in the [LOCATION_003] ( SEER Table 29.6 ).  
The treatment options for neuroblastoma include surgery, particularly for low-risk tumors, 
multiagent chemotherapy, and radiation therapy ( Ullrich, 2012 ). For high risk patients, standard 
treatment generally consists of induction chemo therapy to achieve remission, surgery, and 
radiotherapy for local control, high-dose chemoth erapy with autologous hematopoietic stem-cell 
rescue and oral 13-cis-retinoic acid for consolidation and immunotherapy ( Modak, 2010 ). The 
risk of local relapse has decreased with mode rn surgery and radiotherapy practices along with 
induction chemotherapy; however, in high-risk ne uroblastoma refractory or recurrent disease in 
bone and bone marrow occurs in most patients ( Modak, 2010 ).
Various combinations of cyclophosphamide, doxorubicin, cisplatin, carboplatin, etoposide, 
topotecan, vincristine, temozolomide, and irinotecan have been used with response rates of 50%
to 60%.  Preclinical and clinical pediatric studies  showed potential ut ility of chemotherapy with 
paclitaxel and docetaxel in neuroblastomas ( Izbicka, 2006 ; Table 2 and Table 3 ).
1.1.2. Rhabdomyosarcoma
Rhabdomyosarcoma is a malignant childhood soft-t issue sarcoma of mesenchymal origin with a 
5-year survival rate of 70%.  The prognosis depends on the location and disease stage ( Dasgupta, 
2012 ).
Treatment is also driven by [CONTACT_778541], which defines the 
clinical group, and generally includes some combination of pre-operative chemotherapy, surgery, irradiation, and systemic chemotherapy. Standard chemotherapeutic agents include vincristine, 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21re, e
ous us 
e 
sarcoma (1arcoma (
sosolid tumolid tumo
%)),childhochil
s and Figurand Figu
oryryand relnd rely
neural creneural cre
0909). The 5). The 5
e [LOCATION_003] [LOCATION_003] ((SES
clude surgeclude surge
therapytherapy ((yyU
oon n chemotchem
dose chemdose chem
cid cid fofor conrc o n
eased with eased with 
howeverweve ,ini
occurs in moccurs in 
ons of cyclons of cycl
ististine, ine, ttemem
clinical andclinical and
and docetand doceta
. RhaRh
RhabdomyoRhabdomyo
5--year suyear 
1212))
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069365]-001 Amendment 5.0 Final: [ADDRESS_1069366] high-risk disease, more intensive use of 
multiagent chemotherapy with other agents is being evaluated in clinical trials ( Arndt, 2011 ).
Although rhabdomyosarcoma is sensitive to first line therapy with a complete response (CR)
achieved in the majority of patients, local recurrences still occur in a substantial number of patients ( Dantonello, 2008 ). The prognosis of patients who recur or progress after first line 
therapy is poor.  However, patients who remain disease free after [ADDRESS_1069367] a good prognosis 
and relapses are uncommon, and at 10 years only 9% of patients have late events. However, patients who have gross residual disease following initial surgery in unfavorable sites and those 
who initially present with metastatic disease more commonly experience relapse ( Sung, 2004 ). 
The prognosis has not improved significantly in the la st 15 years for the more than 15% of 
children who present with metastatic rhabdomyosarcoma, and the overall cure rate remains 
below 30% despi[INVESTIGATOR_778524] ( Oberlin, 2008 ).
Both docetaxel and paclitaxel have antitumor activity in pediatric rhabdomyosarcoma solid 
tumor models ( Izbicka, 2006 ), as well as in Phase 1 and 2 clinical studies; however,
hypersensitivity and neurological reactions, among others, were dose- limiting with p aclitaxel,
and clinical activity with taxa nes was short-lived ( Table 2 andTable 3 ). The central 
neurotoxicity of conventional solvent-based p aclitax el has been attributed to the large amount of 
alcohol and Cremophor contained in the formulation (see Section 1.2.2 ).
1.1.3. Other Pediatric Solid Tumors
[IP_ADDRESS]. Nonrhabdomyosarcoma Soft Tissue Sarcoma
Among pediatric nonrhabdomyosarcoma soft tissue sarcomas (NRSTSs), the most common 
include dermatofibrosarcoma protuberans, malignant fibrous histiocytoma, synovial sarcoma, 
malignant peripheral nerve sheath tumor, and fibrosarcoma.  Other NRSTS that occur in children 
but not adults (except in rare cases) are infantile fibrosarcoma, infantile rhabdomyofibrosarcoma,and infantile malignant rhabdoid tumor ( Spunt, 2008 ). 
The likelihood of local invasion and distant metastases of NRSTSs is dependent on histological 
grade, dividing into low-grade and high-grade. The outcome of the initial surgical resection is the prognostic variable with the highest importance for nonmetastatic tumors .  Overall survival 
nearly reaches 90 % if tumors are completely resected (generally low-grade). However, 5 year 
survival is 55% and event free survival is 33% in unresected tumors (generally high grade and invasive). The poorest prognosis among NRSTS is  in metastatic tumors, where 5-year s urvival 
is only 15% ( Levy, 2011 ).
Accordingly, complete surgical resection is the standard treatment for NRSTS with or without 
adjuvant radiotherapy for prevention of local recurrence ( Agarwala, 2006 ).  Combinations of 
ifosfamide, cyclophosphamide, vi ncristine, doxorubicin a nd etoposide seem to be the most active 
chemotherapy agents ( Chui, 2007 ).  
[IP_ADDRESS]. Ewingâ€™s Sarcoma
After osteosarcoma, the second most common bone tumor in the pediatric population is Ewingâ€™s 
sarcoma ( Dome, 2008 ). Patients who develop recurrent diseas e within the initial [ADDRESS_1069368] 5-
year survival rates of 7%, as compared to 30% if recurrent disease occurs after 2 years 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e  
44))..
f f 
mains ains
rcorcoma soma so li
oweverowever ,,
itting with pi[INVESTIGATOR_007] w
). ). The cenThe cen
ributed to thibuted to
n [IP_ADDRESS]).
comacoma
ue sarcomue sarcom
lignant fibrgnant fibr
nd fibrosarcd fibrosarc
nfantile fibnfantile fib
or (or (Spunt, 2Spunt, [ADDRESS_1069369] progno
vyvy, 2011, 2011 ).)
yy, , cocompmpletelete
radidiothotheraer
midemide , cyyclclo
emotherapymotherapy
[IP_ADDRESS]..1.3.2
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069370]-001 Amendment 5.0 Final: 13 Jul 2016(Jain, 2010 ). The 5-year survival rate in patients with bone metastases (< 20%) is lower than 
those with lung/pleura metastases (20% to 40%) ( Paulussen, 2009 ).
Treatment of Ewingâ€™s sarcoma combines both ne oadjuvant and adjuvant chemotherapy along
with local control measures such as surgery and/or radiation. In patients with localized disease, this approach has improved 5-year survival to â‰¥ 60% ( Paulussen, 2009 ). Commonly used
therapeutic agents either as single-agent or primarily in combination include vincristine, 
dactinomycin, cyclophosphamide, doxorubicin, et oposide, topotecan, irinotecan and ifosfamide
(Paulussen, 2009 ), while clinical activity has also been observed with paclitaxel and docetaxel 
(Table 2 and Table 3 ).
[IP_ADDRESS]. Melanoma
There has been a rise in the incidence of both adult and pediatric melanoma and it now occurs 7 
times more frequently in pe diatric patients > 10 years old co mpared to those < 10 years old
(Mills, 2009 ; Morelli, 2011 ).The incidence of the disease in children and adolescents younger 
than 19 years is approximately 4.9 per 1,000,000 ( SEER Table 29.1 ). Although in children with 
melanoma the overall mortality has declined stead ily from 1968 to 2004 in the [LOCATION_003], the overall 
mortality rate in both children and adults remains at about 40% ( Lewis, 2008 ; Morelli, 2011 ). 
The 5-year survival in pediatric patients with malignant melanoma is 96% ( SEER Table 29.6 ), 
but is only 57% for patients with distant metastasis ( Strouse, 2005 ).
Despi[INVESTIGATOR_778525], the most effective approach for melanoma is prevention 
and early detection ( Morelli, 2011 ). The treatment of melanoma in the pediatric populations is at 
present extrapolated from the adult population. Surgery is the primary course of treatment with 
adjuvant therapy mainly given only for advanced disease ( Brenn, 2007 ) including chemotherapy, 
immunotherapy and to a limited extent radiation ( Jen, 2009 ). Dacarbazine has been the standard 
chemotherapeutic treatment for metastatic melanoma for the past 3 decades. In 2011 two new 
agents, ipi[INVESTIGATOR_489011], were approved for the treatment of metastatic melanoma.Vemurafenibâ€™s benefit is limited to patients with BRAF V600E mutations, which is 
approximately 40-45% of  treatable patients. The eff icacy of nab-paclitaxel in adult melanoma is 
described in Section 1.2.1.
1.1.4. Conclusion
In the last decades, the prognosis of children with cancer has been improved and 70% of children 
can now be cured. However, some cancers display a 5-year survival rate of less than 50% and 
there is a clear unmet medical need in these patient populations. 
1.2. Taxanes
Microtubule-stabilizing agents such as taxanes and epothilones are powerful antitumor agents
and commonly have been used in adults as anticancer agents. Taxanes specifically alone or in 
combination are approved in breast, prostate, non-small cell lung cancer (NSCLC), ovarian, 
gastric, and head and neck cancer. They have been investigated and have shown to be active in other refractory malignancies such as previously treated lymphomas, small cell lung cancer 
(SCLC), oesophageal, endometrial, and bladder cancer ( AndrÃ©, 2006 ). 
CCI&(/*(1([ZIP_CODE],mm5,(7$5<,1)250$7,21now occurnow occur
10 years old0 years 
olescents yolescents 
hough in chhough in ch
44in the USin the U
wis, 2008s, 2008 ;
ma is is96% (%
20052005 )).
pproach forpproach fo
melanoelano ma ma ini
gerygery iiyys the s the
disease (disease ( BB
on(n(Jen, 20Jen, 20
elanoma elanoma
ere approveere appro
atients withatients w
e patpatientts.sTT
e prognosise prognosis
However, sHowever, s
unmet mediunmet med
TaxanesTaxanes
tubuleubu -stabstab
cocommommo nlynly
combinatombinat ioio
gastrigastri c,c,
er
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069371]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].2.1. nab -Paclitaxel
nab-Paclitaxel (ABI-007, ABRAXANEÂ®for Injectable Suspension [Celgene Corporation, 
Summit, New Jersey, [LOCATION_002], the Sponsor]) is a human serum albumin bound nanoparticle 
formulation of paclitaxel with a mean particle size of approximately 130 nanometers.  nab-
Paclitaxel has been developed to improve the therapeutic index of paclitaxel; the 
chemotherapeutic effect is enhanced by [CONTACT_778542] ( Desai, 2006 ), while at the same time the toxicities 
associated with conventional solvent-base d paclitaxel formulations using a  CremophorÂ®EL 
 and ethanol vehicle are reduced.  
nab-Paclitaxel is bound to albumin in amorphous state and, unlike conventional solvent-based 
paclitaxel formulations where micellar entrapment is observed ( Ibrahim, 2002 ; Sparreboom, 
1999 ; ten Tije, 2003 ), has linear pharmacokinetic (PK) characteristics.  Based on these 
pharmacokinetic properties, the dose and short infusion time, an increase of the maximum concentration (C
max) of free paclitaxel up to 10-fold greater than with conventional solvent-based 
paclitaxel has been reported in the literature ( Gardner, 2008 ).  The transport of paclitaxel across 
the endothelium is enhanced through albumin receptor mediated transcytosis, and the delivery of paclitaxel to tumors may be enhanced by [CONTACT_778543]-bound paclitaxel to interstitial 
albumin binding proteins, such as secreted protein acidic and rich in cysteine 
(SPARC; also 
known as osteonectin) ( Desai, 2006 ).  nab-Paclitaxel is not known to cross the blood-brain-
barrier. 
Although it has been hypothesized that SPARC expression may result in an increased 
concentration of nab-paclitaxel in tumors due to its albu min-binding ability, and may play a role 
in the enhanced antitumor activity, clinical studies remains conflicting ( Alvarez-Gallego, 2012 ; 
Blackwell, 2010 ; Desai, 2009 ; Yardley, 2009 ) and therefore there is not sufficient data 
supporting the relationship of SPARC expression to clinical outcomes of nab-paclitaxel 
treatment.  
Type of solid tumors had no significant effect on paclitaxel pharmacokinetics in patients who 
received nab-paclitaxel.  Ethnic origin had no discernible effect upon PK parameters according 
to the studies conducted in Western countries, Japan and China.
The novel nab-paclitaxel nanoparticles conferred th e ability to achieve a higher maximum 
tolerated dose (MTD) based on every 3-weeks dosing: 300 mg/m2for nab-paclitaxel (DM97-
123) versus 175 mg/m2for conventional solvent-based paclitaxel ( Nyman, 2004 ).  The use of 
albumin also enables nab-paclitaxel to be given in a shorter, more convenient infusion time of 30 
minutes compared with 3 hours to 24 hours with conventional solvent-based paclitaxel.  nab-
Paclitaxel is given without steroid and antihistamine premedication, which is required for 
conventional solvent-based paclitaxel to prevent so lvent-related hypersensitivity reactions ( Taxol 
Label ).  Cremophor EL has been shown to leach plasticizers, specifically di (2-ethylhexyl)
phthalate (DEHP), from polyvinyl chloride (PVC) bags and polyethylene-lined tubing ( Allwood, 
1996 ; Gelderblom, 2001 ; Pfeifer, 1993 ; Song, 1996 ; Venkataramanan, 1986 ; Xu, 1998 ).  
Although no controlled epi[INVESTIGATOR_426048], severe effects (eg, carcinogenicity, cardiopulmonary toxicity, hepatotoxicity, and 
nephrotoxicity) have been observed in experimental models.  The Taxol product information 
instructs users to prepare, store, and administer solutions in glass, polypropylene, or polyolefin containers; non-PVC-containing infusion sets (eg, those with polyethylene lining) should be used CCI
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21based ased
eboomeboom , , 
hese hese 
e maximummaximu
ntntioional nasosolv
ort of pacliort of p
cytosis, andcytosis, an
und paclitaund pacl
h in cysteinh in cystei
nown to croown to c
siosionnmamay ryr
albuminalbumin --bib
es rems rem ains s
) and theref) and theref
ressiossion to cn to c
cant effect ant effec
oriorigin had ngin had 
estern counestern cou
nanopartinopa cl
based on evbased on e
/mm22mmmfofor conr con
bles bles nabnab--pap
ared with 3red with 
s given wits given wit
onal alsoslvenlve
).  Crem).  Crem opo
hthalate (DEthalate (DE
1996996; GeldGel
AltAlthoughou
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069372]-001 Amendment 5.0 Final: 13 Jul 2016(Taxol Label ).  By [CONTACT_2163], standard tubing and intravenous (IV) bags may be used for the 
IV administration of nab-paclitaxel ( Ibrahim, 2002 ; Nyman, 2004 ).  
Clinical studies of nab-paclitaxel conducted in patients with breast cancer have demonstrated:
1. The ability to achieve a higher MTD of nab-paclitaxel at 300 mg/m2vs 175 mg/m2for 
conventional solvent-based paclitaxel. 
2. Elimination of the need for premedication, which is required with conventional solvent-
based paclitaxel to prevent solvent-related hypersensitivity r eactions.  
3. Shortened infusion times (infusion time of 30 minutes with nab-paclitaxel vs 3 hours for 
conventional solvent-based paclitaxel).
4. Elimination of the need for specialized infusion set apparatus (standard infusion sets 
suffice whereas non-DEHP [diethylhexylphthalate] sets are required for conventional
solvent-based paclitaxel).
A Phase 3 comparison study (Study CA012-0) conducted in patients with metastatic breast 
cancer compared nab-paclitaxel (260 mg/m2) with conventional solvent-based paclitaxel (175 
mg/m2).  nab-Paclitaxel demonstrated greater efficacy (higher response rates, longer times to 
tumor progression [TTP], longer progression-free survival [PFS], and a 2.3 months overall 
survival advantage in patients previously treated for metastatic disease) with toxicity similar to 
that of conventional solvent-based paclitaxel, despi[INVESTIGATOR_778526]-paclitaxel.  Grade 4 neutropenia occurred less frequently in the nab-paclitaxel group, 
and did not appear to be related to cumulative dose.  Instances of neutropenia were clinically 
asymptomatic and transient.  Grade 3 sensory neuropathies occurred more frequently in the nab-
paclitaxel group but improved in a median of 22 days.
A Phase 3 comparison study (Study CA031) conducted in patients with advanced NSCLC 
compared weekly nab-paclitaxel (100 mg/m2) and once every three weeks carboplatin (area 
under the curve [AUC] = 6) against once ever y three weeks conventional solvent-based 
paclitaxel (200 mg/m2) and carboplatin (AUC = 6)  as first-line therapy. nab-Paclitaxel 
demonstrated significantly greater efficacy by [CONTACT_193924] (ORR), with a trend toward 
greater response in PFS and overall survival (OS). There were significantly more â‰¥ Grade 3 
events of sensory neuropathy, neutropenia, arth ralgia, and myalgia in the conventional solvent-
based paclitaxel arm, but more events  of thrombocytopenia and anemia in the nab-paclitaxel arm 
(Socinski, 2012 ).  
A Phase 3 comparison study conducted in patients with metastatic malignant melanoma
compared nab-paclitaxel (150 mg/m2) on days 1, [ADDRESS_1069373] (28 day cycle) 
against once every three weeks dacarbazine (1000 mg/m2) as first line therapy.  nab-Paclitaxel 
demonstrated significantly greater efficacy by [CONTACT_16625] (median PFS 4.8 vs 2.5 months) with a trend 
towards improvement in OS (interim OS 12.8 vs  10.7 months). Neuropathy and neutropenia 
occurred significantly more often in the nab-paclitaxel arm ( Hersh, 2012 ).
A Phase 3 comparison study conducted in pati ents with metastatic adenocarcinoma of the 
pancreas compared nab-paclitaxel (125 mg/m2) with gemcitab ine 1000 mg/m2on Days 1, 8, and 
[ADDRESS_1069374] gemcitabine 1000 mg/m2alone weekly for seven weeks with one week 
rest, then weekly for three weeks with one week rest as first line therapy.  nab-Paclitaxel with 
gemcitabine demonstrated statistically signif icant improvement in OS (8.5 versus 6.7 months 
CCIs for for 
ioion sets n sets 
onventnvent ioionana
metastatic metastatic 
-based based pacp
nse rates, lse rates, l
and na 2.3 2.3 
c disease) wc disease
gher dose oher dose o
frequently iequently
Instances ofnstances o
opathiopathi esesococ
2 days.days.
) conducted) conducte
g/mg/m22mmm) and o) and o
nce everynce eve thy
attin (AUCin (AUC
ter efficacyter efficacy
overall survoverall surv
thyy, neutro, neutro
ut mut more oevev
parison studarison stud
b-paclitaxepaclitaxe
ce everye every ththy
trated sitrated si gngn
ards improvards impro
ccurred siccurred si gg
A PhaseA Phas
ncr
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069375]-001 Amendment 5.0 Final: 13 Jul 2016respectively) and all efficacy endpoints overall and across subgroups when compared to 
gemcitabine alone.  The most common â‰¥ grade 3 adverse events reported in the nab-paclitaxel 
and gemcitabine combination arm included neutropenia, fatigue and neuropathy ( Von Hoff, 
2013 ).
In Phase 1 studies conducted in the adult population with advanced solid tumors designed to 
determine the MTD of nab-paclitaxel, the following dose- limiting tox icities were observed:
keratitis, blurred vision, sensory neuropathy, st omatitis, and Grade 4 neutropenia. In general, 
hematologic toxicities were not important dose- limiting events; no life-threatening neut ropenic 
infections and no Grade [ADDRESS_1069376] frequently 
(> 50%) reported toxicities were all expected for this therapeutic drug class, namely fatigue, 
myalgia, nausea, alopecia, and stomatitis.
nab-Paclitaxel is approved globally for the treatment of metastatic breast cancer at a dosage of 
260 mg/mÂ² administered IV over 30 minutes once every 3 weeks, in the [LOCATION_003] for the treatment of locally advanced or metastatic NSC LC at a dosage of 100 mg/m
2on Days 1, 8, and 15 in 
combination with carboplatin (AUC = 6) on Da y 1, every [ADDRESS_1069377]-line metastatic pancreatic adenocarcinoma at a dosage of 125 mg/m2
(followed immediately by [CONTACT_35421]) on Days  1, 8, and 15 of each 28-day cycle.
Please refer to the Investigator Brochure for detailed information concerning the available 
pharmacology, toxicology , drug metabolism, clinical studies and adverse event (AE) profile of 
the IP.
1.2.2. Taxanes in Pediatrics
In children, taxanes have been studied in nine Phase [ADDRESS_1069378] activity in children, mainly because of dose-
limiting toxicities that limit efficacious dose delivery ( Table 2 and Table 3 ). Standard taxanes, 
conventional solvent-based paclitaxel and docetaxel , have shown antitumor activity, but have 
also produced dose- limiting toxicities such as severe hypersensitivity requiring prophylactic 
medication and/or neutropenia ( Blaney, 1997 ; Geller, 2009 ). It is also notable that the alcohol in 
Cremophor EL (polyoxyethylated castor oil) produces central nervous system toxicity in pediatric patients receiving IV infusion of conventional solvent-based paclitaxel over 3 hours
(Doz, 2001 ).
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21gue, ue, 
t a dosage oa dosage 
or the treatr the tre
, 8, 8,and 15 and 15
the [LOCATION_003] athe US
osage of 12osage of 1
h 28h 28--daydaycy
n concernin con
s and adverand adver
hase 1 and hase 1 an
elyely. . AltAlthouhou
tienttients with s with 
aclitaxel in clitaxel in
ted modestd modes
cacious doscacious dos
aclitaxel anaclitaxel an
ng toxicitoxic tiie
ropeniropen a ((BlB
yoxyethylatoxyethyla
receiving Ireceiving I
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069379]-001 Amendment 5.0 Final: 13 Jul 2016Table 2: Phase 1 Trials of Taxanes in Children
Reference Agent NAge 
(eligible/ 
enrolled) ScheduleMaximum 
Tolerated 
DoseDose-Limiting 
Toxicity Responsea
Hurwitz, 
1993paclitaxel 31 â‰¤ 22 
years / 
2-22 
years24-h 
infusion/
21 days350 mg/m2Neurological 1 CR (papi[INVESTIGATOR_69122])
2 PR 
(rhabdomyosarcoma, hepatocellular carcinoma)
9 SD (3 Ewing tumors, 2 
osteosarcomas, 2 synovialosarcoma, 1 glioma, 1 intrathoracic chordoma)
Doz, 2001 Paclitaxel 17 6 months 
to 20years/ 
1.6 - 19 
years3-h infusion/
21 daysNo Neurological, allergic 0 CR
1 PR
(rhabdomyosarcoma)
1 SD
(rhabdomyosarcoma)
Woo, 1999 Paclitaxel 7 â‰¤ 21 
years / 
6 â€“ 18 
years24-h 
infusion/21 daysTarget AUC 
31 to < 45 mM hMucositis 1 patient (leukaemia) 
responded sufficiently (response or SD) to receive a second cycle
Liu, 2001 Paclitaxel and 
radiotherapy11 3-18 
years/ 
4 â€“ 16 
years24-h infusion 
times 7 days4 mg/m2/day Obstipation 2 PR: glioma
Hayashi, 
2003Paclitaxel 16 â‰¤ 21 
years / 
7 â€“ 15 
years3-h infusion 
twice weekly Ã—6/28 days50 mg/m
2
/doseHematologic 0 CR
0 PR
3 SD (2 osteosarcomas, 1
ependymoma)
Horton, 
2008Paclitaxel 63 â‰¤ 21 
years at 
diagnosis/ 
0.8 â€“ 23 
years24 h 
infusion/ 21 
days or weekly for 3 weeks every 28 days430 mg/m2 
every 21 day, 
182 mg/m2 weeklyHypertension, 
coagulopathy, 
metabolic, hepatic, neurological, stomatitis, typhitis1 CR (ALL)
3 PR (ALL)
4 SD 
Blaney, 
1997Pocetaxel 44 1 â€“ 21 
years/ 
1 â€“ 22 
years1-h infusion/
21 days125 mg/m2
/doseHematologic, general 1 CR 
(rhabdomyosarcoma)
1 PR (PNET)
4 SD (3 PNET, 1 colon
carcinoma)
Seibel, 
1999Docetaxel and 
filgrastim17 1 â€“ 21 
years/ 
2 â€“ 20 
years1-h infusion/
21 days
5Î¼g/kg/
day185 mg/m2
/doseDermatologic, 
myalgias0 CR
1 MR(colon carcinoma)
SD: not mentioned
CCI&(/&(/*Docetaxecetaxe/*(1(35t 
gnosisnosis
0.8
([ZIP_CODE],(7$5<,1)250$7,21umors, 2 umors, 2 
s, 2 2
arcoma, 1 rcoma, 1 
1 intrathoracic1 intrathorac
doma)ma)$7
CRCR
1 PR1 PR
(rhabdom(rh
1 SD1 S
(r(25
1)tis,1
$dayday ObstipaObstipa$$$57$
ekly kly 
daysdays50 mg/m50 mg/m 2
/dose/dose,(
35
â€“â€“232
yeyears24 h 24
infusion/infusion
daydays s
wew23
(35
44 1 â€“44 1 â€“ 22
yy(((
(11(
filgrasfilgra/*(/
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069380]-001 Amendment 5.0 Final: 13 Jul 2016Table 2: Phase 1 Trials of Taxanes in Children (Continued)
Reference Agent NAge 
(eligible/ 
enrolled) ScheduleMaximum 
Tolerated 
DoseDose-Limiting 
Toxicity Response
Geller, 
2009Paclitaxel and 
ifosfamide15â‰¤ 21 
years/ 
2 â€“ 18.8 
yearsPac 6-h 
infusion D1/  
ifos 2 g/m2
over 1 hour w/ mesnaD1-3, q3-4 wk425 mg/m
2Hypersensitivity, 
neurologic, 3 MR
5 SD
Table adapted from AndrÃ©, 2006 .
ALL = acute lymphocytic leukemia, AUC = area under the curve, CR = complete response, D = Day, DLT = dose-limiting toxicity, h = hour(s), ifos = ifosfamide, mesna = 2-mercaptoethane sulfonate sodium, MTD = maximum tolerated dose, MR = minor response, PNET = primitive neuroendocrine tumors, PR = partial response, SD = stable disease.
Table 3: Phase 2 Trials of Taxanes in Children
Reference Agent N Age Dose/Schedule Resultsa
Hurwitz, 2001 Paclitaxel 73 â‰¤ 21 years 
at diagnosis/ 
4 months â€“
19 years350 mg/m
2
24-h infusion/ 
21 daysToxicities: mild nausea, central nervous 
system toxicity, myelosuppression, and febrile neutropenia, including one septic death. One Grade 2 and two Grade 3 
allergic reactions. No cardiac toxicities 
or arthralgias reported.
CR: 1 (meduloblastoma), PR: 3 
(astrocytoma, glioma, and primitive neuroectodermal)
SD (> 2 months): 20
Kretschmar, 
2004Paclitaxel, topotecan, 
topotecan-
cyclophosphamide100 total,
33 paclitaxel1 â€“ 21 
years/ 
13 months 
â€“ 17 years 8 
months33 patients: 
350 mg/m2 
intravenously for 24 h every14â€“21 daysGrade 3/4 allergic reactions to paclitaxel 
in 4 patients. Grade 3/4 neutropenia in 
16 patients, Grade 3/4 thrombocytopenia in 6 patients.
CR= 1; PR = 5; MR=2, PD =  12, 
Objective responses (defined as complete responses + partial responses + mixed responses) documented in 25% patients treated with paclitaxel. 
Zwerdling, 2006Docetaxel 160 â‰¤ 21 years 
old at diagnosis/ 
1-27 years125 mg/m
2, 1-h 
infusion/[ADDRESS_1069381] common 
during therapy. Dermatologic, neurologic, pulmonary, infectious side effects, and edema were significant. 
CR: 2 (1 patient with osteosarcoma and 
1 patient with rhabdomyosarcoma)
PR:  6 (3 patients with Ewing sarcoma, 
1 patient with osteosarcoma, 1 patient
with squamous cell carcinoma, 1 patient
with medulloblastoma) 
SD: 17 patients
The 1-year and 5-year overall survival 
rates for the 160 evaluable patients were 24% (standard error = 4%) and 6% (standard error = 2%).
CCI&(/*(1(35233235,(7$5<,1)250$7,210$$7$ limiting imiting 
d dose, d dose, MRMR==
ResR1)oxicities: mildicities: mild
sysystem toxicm toxic
febrile neufeb
death. Odeath
alleral
o1
,(5<
2121
yeears/ ars/ 
13 months13 mont
â€“â€“17 ye1
monmo33335,(,(,(
23,(
160160333
/*(3
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069382]-001 Amendment 5.0 Final: 13 Jul 2016Table 3: Phase 2 Trials of Taxanes in Children (Continued)
Reference Agent N Age Dose/Schedule Results
TaxotereÂ®
prescribing 
informationDocetaxel, cisplatin, 
5-fluorouracil (5-FU)75 (50 
docetaxel 
combination arm)Not 
reported/ 1
â€“ 22 yearsDocetaxel 75 
mg/m2, 
cisplatin 75 mg/m2, 5-FU 750 mg/m2Safety data not reported
CR: 1 (out of 50) in docetaxel/cisplatin/
5-FU arm
0 (out of 25) in cisplatin/5-FU arm
Harris, 1999 Paclitaxel 186 â‰¤ 21 years\
not 
reported350 mg/m2, 
24-h infusion every 3 weeks(Safety presented by [CONTACT_778544])
Neutropenia Grade 3/4: 297 courses
Neurotoxicity Grade 3/4: 2 courses
Hypersensitivity Grade 4: 1 courses
Cardiac toxicity Grade 3: 1 courses
CR+PR =11 (1 neuroblastoma, 1 
Ewingâ€™s sarcoma, 3 rhabdomyosarcoma, 2 nonrhabdo soft-ti ssue sarcoma, 2 
Wilmsâ€™ tumor, 1 Merkels tumor)
MR+SD = 56
PD= 99
aCR =  complete response, MR = minor response, PD = progressive disease, PR = partial response, SD = stable disease.
1.2.3. nab-Paclitaxel Preclinical Studies 
In preclinical studies of neuroblastoma models, nab-paclitaxel inhibited cell proliferation in vitro 
and reduced tumor growth in xenograft models, and increased survival in metastatic 
neuroblastoma mouse models with intratumoral concentration of nab-paclitaxel 40 times higher 
compared to paclitaxel (data on file). In vitro, inhibition of cell proliferation was observed in all 
rhabdomyosarcoma cell lines studied (RH4, RH30, and RD) and a modest response was seen in 
the osteosarcoma cell line used in the study (KHOS). 
In Study S758, seven neuroblastoma cell lines (CHLA-20, CHLA-15, CHLA-90, LAN-5, SK-N-
BE(2), BE(2)C, and SH-SY5Y), three rhabdomyosarcoma (RH4, RH30, and RD), and one 
osteosarcoma cell line (KHOS) were exposed to increasing concentrations of nab-paclitaxel in 
vitro for 72 hours.
For the seven neuroblastoma cell lines, nab-paclitaxel exhibited dose-dependent cytotoxicity in 
vitro, as measured by [CONTACT_778545]. In addition, all three 
rhabdomyosarcoma cell lines were responsive to nab-paclitaxel treatment in a dose-dependent 
manner as measured by [CONTACT_778546], while limited response was observed in the osteosarcoma 
cell line. nab-Paclitaxel was also more effective than an equivalent dose of paclitaxel dissolved 
in dimethyl sulfoxide (DMSO) after 72-hour treatment in all neuroblastoma cell lines tested. 
In a separate experiment, athymic nude mice bearing CHLA-20 human neuroblastoma 
xenografts were treated with nab-paclitaxel (10 mg/kg/day IV for 5 consecutive days, or 50 
mg/kg IV weekly), or DMSO-paclitaxel (20 mg/kg IV weekly). nab-Paclitaxel treatment resu lted 
in significant tumor inhibition. nab-Paclitaxel at 50 mg/kg IV weekly also demonstrated 
significantly greater antitumor activity compared with DMSO-paclitaxel at 20 mg/kg IV weekly.
In athymic mice bearing RH4 rhabdomyosarcoma xenografts, nab-paclitaxel dosed at 50 mg/kg 
IV weekly for 3 weeks was better tolerated than DMSO-paclitaxel at 30 mg/kg IV weekly for 3 
weeks as shown by [CONTACT_778547].  Animals treated with DMSO-paclitaxel had earlier 
CCIss
rsesrs
coursesurses
: 1 courses: 1 courses
oblastoma, 1 blastoma, 1 
3 rhabdomyo3 rhabdomyo
ft--tissue sarcotissue sarc
or, 1 Merkels or, 1 Merkels
= 56= 56
9999,1$7
response, SDsponse, S
axel inhibitel inhibi
reased survreased sur
entratientrati on oon
ibitibitioion of cof
H3030,,and Rand R
(KHOS). (KHOS).
ll lines (CHl lines (C
ee rhabdoe rhabdo m
ere exposedere expos
ma cell linea cell line
ell viabilitell viabilit y
cell lines well lines w
red by[CONTACT_778548] ((
arate experarate expe
grafts weregrafts wer
g/kg g/kg IVIVwewe
in n significnific
iignificgnific
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069383]-001 Amendment 5.0 Final: [ADDRESS_1069384] rhabdomyosarcoma xenografts, nab-paclitaxel (50 mg/kg) and 
DMSO-paclitaxel (30 mg/kg) dosed IV weekly showed similar body weight change.  However, nab-paclitaxel was significantly more effective than DMSO-paclitaxel in suppressing RD tumor 
growth.  Further, nab-paclitaxel inhibited growth of tumors that continued to progress with 
DMSO-paclitaxel treatment.  
In a separate study with osteosarcoma xenograft nude mice models, nab-paclitaxel demonstrated 
a significantly greater tumor inhibitory rate when compared to adriamycin and conventional 
solvent-based paclitaxel (99 vs 46% and 41% respectively) ( Yang, 2012 ).
The Pediatric Preclinical Testing Program at National Cancer Institute evaluated nab-paclitaxel
against a group of pediatric solid tumor xenografts. Results showed that nab-paclitaxel
administered IV at 50 mg/kg, every 4 days repeated 3 total times was well tolerated in non-tumored and xenograft-bearing SCID mice. Two Ewingâ€™s sarcoma xenografts tested (SK-NEP-1 
and EW8) and the rhabdomyosarcoma xenograft Rh65 showed maintained complete responses 
(MCR) following nab-paclitaxel treatment. Osteosarcoma xe nografts OS-[ADDRESS_1069385] that nab-
paclitaxel, delivered at higher dose than conventional paclitaxel, potentially may achieve clinical 
benefits in pediatric diseases where conventional paclitaxel is not effective ( Zhang, 2013 ).
1.3. Study Rationale
1.3.1. Role of nab-Paclitaxel in Fulfilling the Unmet Medical Need
The prognosis of pediatric patients  with metastatic disease conti nues to be poor. Survival rates 
for patients with localized disease are a pproximately 50% to 70% with the current treatment 
modalities for neuroblastoma, rhabdomyosarcoma, osteosarcoma, and Ewingâ€™s sarcoma. Thus, a 
great unmet medical need remains for patients with metastatic disease or relapsed localized 
disease. In the light of therapi[INVESTIGATOR_778527], nab-paclitaxel 
may be a potentially superior alternative treatment option, due to its unique mechanism of action, 
safety profile (including absence of Cremophor EL), and pharmacodynamics/PK, which 
distinguish it from conventional solvent-based paclitaxel or docetaxel. 
nab-Paclitaxel may offer in children, similarly to the adult population, improved efficacy, with 
lower levels of toxicities as compared to  conventional solvent-based paclitaxel due to:
!Enhanced binding of paclitaxel to albumin, microtubules, and cells and increased 
tissue bioavailability of paclitaxel when compared to conventional solvent-based 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ted ed
l 
bb--paclitaxepaclitax
litaxellitaxel
erated in noated in n
afts tested (fts tested (
ned compled comp
OSOS--9 and9 and
mmor regresor regre
ated that ated that n
e than e than an an eq
or cell lineor cell line
umor pacliumor pacli
axelxeldisplaydispla
ndent fashiondent fashio
ken togetheken togethe
n conventioconventi
conventonvent ioio
lee
Paclitaxel Paclitaxe
diatriiatric c patpatiei
ocalized docalized d
neuroblastoneuroblas
t medical nmedical n
In the lighthe ligh
be a potentibe a potent
etty y profile profile 
didiststinguishinguish
abab-PaPa
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069386]-001 Amendment 5.0 Final: 13 Jul 2016paclitaxel, since the paclitaxel is not trapped in the plasma compartment by 
[CONTACT_778549]
!Increased transendothelial transport by [CONTACT_778550] a 60-kDa 
glycoprotein receptor on the endothelial cell surface, which leads to the formation of caveolae and transcytosis across endothelial cells 
!Increased accumulation of the drug at the tumor level
!Linear pharmacokinetic profile
!Absence of Cremophor EL and alcohol in the formulation of nab-paclitaxel, reducing 
the incidence of hypersensitivity reactions, sensory neuropathy, and central nervous system toxicity in children.
1.3.2. Rationale for Study Design
This study will consist of two parts: a Phas e 1 dose-escalation portion and a Phase 2 expansion 
portion.
In the Phase 1 portion of this pediatric study , the dose will be escalated using the rolling-6 
design, in which cohorts of up to  6 patients will be enrolled, starting with a dose of 120 mg/mÂ² 
weekly, 80% of the maximum weekly dose investig ated in adult patients (150 mg/mÂ²). This 
strategy presumes that children may have a similar or higher threshold for toxicity in comparison 
to adults. The rolling-6 design allows a sufficient number of patients to be evaluated for safety 
and PK at each dose level, while limiting the duration of the study ( Skolnik, 2008 ).
In the Phase 2 portion of this study, patients will be treated at the recommended Phase 2 dose 
(RP2D), determined during the Phase 1 portion of the study to be 240 mg/m
2in patients
weighing > 10 kg (11.5 mg/kg in patients weighing â‰¤ 10 kg), in order to assess antitumor activity 
in neuroblastoma, rhabdomyosarcoma, and Ewi ngâ€™s sarcoma. Antitumor activity in the 
neuroblastoma group will be assessed by [CONTACT_16622]
(RECIST) version 1.1 criteria or 123I-metaiodobenzylguanidine (MIBG)/Curie score, or both,
without crossover between assessment types over time. If both assessment types have been 
performed on a given subject across the assessment time points, to be considered as a partial 
response for the ORR analysis, both methodologies  should show no worse than stable disease 
and at least one method should indicate complete response (CR) or partial response (PR). A 
response is only considered complete if both methodologies indicate CR. This analysis takes into 
account the fact that both methodologies are used in the assessment of response in neuroblastoma patients, and a partial response obtained by [CONTACT_358772] y one method is nevertheless clinically important 
for determining subseque nt treatment options. Studies have shown that high-risk neuroblastoma 
patients with a Curie score > [ADDRESS_1069387] extremely poor 
outcomes, leading to alternative ther api[INVESTIGATOR_778528] ( Yanik, 2013 ). A Simon two-
stage minimax design ( Simon, 1989 ) will be used to limit nab-paclitaxel exposure to 14 patients 
in each group without confirmation of some activity ( â‰¥ 2 patients) before moving forward with 9
additional patients in each group. The Simon tw o-stage design was chosen to minimize the 
number of patients exposed to nab-paclitaxel if the true ORR is le ss than 10% and yet to allow 
the trial to establish that an ORR greater than 10% is efficacious.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ducing ducing 
nervous vous 
a a PhasePhase 2 e2 e
ted using thd using th
ing witg h a dha
ult ult patipatientens
er threshothresho ldd
r of of patientpatie
of the of the studstud
be treated abe treated 
n of the stun of the stu
weighing eighing â‰¤ â‰¤
nd nd Ewingâ€™sEwin
by [CONTACT_778551]
I--metmaiaiodood
ssment tyssment ty pepyyy
t across thet across the
lysissis, both , both 
should indshould in
nsidered coidered co
hat both mhat both m
partipartiala resprel
ning subseqning subse
withhi a Curi a Cuhh
mmes, leadines, leadi
age minimae minima
in n eacheach grgr
addiddititiiiono
b
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069388]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].3.2.1. Rationale for Patient Population
In the Phase 1 dose escalation portion, the study will be conducted in patients â‰¥ 6 months and 
< [ADDRESS_1069389] rapid identification of the MTD/RP2D.  
In the Phase 2 portion, the study will focus on p atients with rec urrent/refractory neuroblastoma, 
rhabdomyosarcoma, and Ewingâ€™s sarcoma. These types of tumors have been selected since they are most likely to be sensitive to nab-paclitaxel based on preclinical data. The age range is
extended to â‰¤ 24 years old (young adults) in the Phase 2 portion of the study to increase the 
likelih ood of including patients with rec urrent and refractory solid tumors. Patients 15 to 24 
years of age are now commonly referred to as â€œteenagers and young adultsâ€; the European 
Society for Medical Oncology (ESMO) is collaborating with the European Society of Pediatric 
Oncology (SIOPE) to target the unmet medical n eeds of adolescents and young adults, due in 
part to the varied interfaces between adult and childrenâ€™s services in different healthcare systems 
(Vassal, 2014 ).  Many patients diagnosed with ne uroblastoma, rha bdomyosarcoma, and Ewingâ€™s 
sarcoma are followed in pediatric clinics up to 24 years of age, particularly in the recurrent and relapsed setting. For example, an analysis of data from 1973 to 2007 from the [LOCATION_002]
National Cancer Instituteâ€™s Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) database shows 
that the median age at diagnosis of Ewingâ€™s sarcoma is mid-to-late teens ( Applebaum, 2011 ), so 
many patients with recurrent disease who have undergone several lines of treatment will be in 
their early twenties. In addition, it will be important to capture instances of confirmed PR as well 
as CR in order to have a proper chance to evaluate treatment effect and ORR (the primary Phase 2 endpoint) using the Simon two-stage minimax desi gn; therefore, the patients will be required to 
have radiologically documented measurable disease (for neuroblastoma, evaluable disease by 
[CONTACT_422955]/Curie score is also acceptable). Patients with these types of tumors may have compromised bone marrow function. In order to preve nt their exclusion in the Phase 2 portion of 
this study, patients with known bone marrow involvement may be enrolled with a platelet level 
â‰¥50 Ã— 10
9cells/L. 
Patients younger than [ADDRESS_1069390] been reported, especially in neuroblastoma and renal cell carcinoma 
(Fritsch, 2004 ; Oluwole, 2009 ), and may occur in the proposed patient population. The current 
practice is to adopt a conservative observation (wait-and-see) strategy for patients identified at 6 
months of age with limited-stage disease. F urthermore, for more advanced pediatric tumors,
surgical treatment (in the case of resectable tu mors), radiotherapy, or combination of 
chemotherapy provide good results as first-line treatment ( Berg, 1991 ; Kim, 2006 ). Therefore, it 
would be highly unlikely that patients 0 to 6 m onths old could be enrolled in the study while a 
wait-and-see strategy is recommended for limited -stage diseases, and as effective treatment 
options are currently available for more advanced tumors; consequently, enrollment in a clinical 
study would not be the preferred treatment option.
[IP_ADDRESS]. Rationale for Pharmacokinetics
Thenab-paclitaxel PK in adult patients has not differed among different tumor types, and is not 
expected to differ among tumor t ypes in pediatric patients. From this perspective, PK results 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e 
o 24 24 
opean opean 
y oof fPediPediatrat
g aduladults, duts, dll
nt healthcarnt healthca
oosarcosarco ma
larlylarly iiyyn thn the
7 frofrom m ththe
d Resuld Re ts ((lS
--latlateteensteen
several lineveral lin
capture instcapture ins
eatment effeatment 
design; theresign; the
sease (for nease (for 
nts with nts with thth
order to preorder to pre
marrow invrrow inv
ololddhave bhave b
been reportbeen repo
20092009 ), and ), a
onservatonserva ive
limitedmited -sta-sta
nt (in nt (in ththe ecac
y provide gprovide g
ighlyghly unlikunlikyy
dd-see stratee strat
ns are currns are cur
udyudywoulwoulyy dd
.3.2.2..3.2.2
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069391]-001 Amendment 5.0 Final: 13 Jul 2016obtained from pediatric patients with various types of solid tumors can be extended to any 
particular type of tumor. 
1.3.3. Rationale for Dosing
The starting dose in the Phase 1 portion of the study is 120mg/mÂ² weekly on days 1, 8, and 15 of 
a 28-day cycle, which represents 80% of the maximu m weekly dose investigated in adult patients 
(150 mg/mÂ²) (see Section 1.2.1 ). Preliminary evaluation of the relationship between paclitaxel 
clearance and body surface area (BSA) or weight suggests that BSA or weight has minimal impact on paclitaxel clearance in adults patients treated with nab-paclitaxel. However, it is 
unknown if this observation can be extrapolated from adults to children. Since the BSA-based 
dosing is more conservative and is the approved dosing approach for adult patients, the nab-
paclitaxel dose will be based on BSA in the pediatric study.
As it is impractical to accurately calculate BSA in children weighing â‰¤ 10 kg, the BSA-based 
dose will be converted to mg per kg of weight in these children. The weight-based dose in each cohort is calculated by [CONTACT_778552] (0.41 mÂ²) with the median 
weight (8.7 kg) for children with weight â‰¤ 10 kg and aged â‰¥ 6 months. Additionally, in order to 
ensure safety in these small children, patients â‰¤[ADDRESS_1069392] cycle.  The dose-limiti ng toxicity (DLT) assessment period in these 
patients will last until the end of Cycle 2.
In three recent adult nab-paclitaxel Phase 3 Celg ene sponsored studies (NSCLC, melanoma, 
pancreatic cancer), nab-paclitaxel was administered weekly alone (melanoma: 150 mg/m
2 
weekly on days 1, 8, and 15 of a 28-day cycle) or in combination (NSCLC: 100 mg/m2 
continuous weekly dosing; pancreatic cancer: 125 mg/m2 weekly on days 1, 8, and 15 of a 28-
day cycle). As a single agent, the weekly dose of 150 mg/m2used in the melanoma Phase 3 trial
and other Phase 1 and 2 studies, the proposed dose level 2 in this trial (See Table 7 ), was safe 
and well tolerated and with manageable toxicities.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ased ased 
nabnab--
he BSAhe BSA --ba
based dosebased dos
Â²) with the Â²) with the 
AdditAddit ioionaln
eatment at atment at
sessment pssment 
sored sored ststudiudi
eekly aloneeekly alone
cocombinatimbina
25 mg/m5 mg/22mww
of 150 mgof 150 mg
ed dose levd dose le
toxitoxicicititiiiese
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069393]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE]. STUDY OBJECTIVES
2.1. Primary Objective
The primary objective of the Phase 1 portion of the study is to determine the pediatric 
MTD/RP2D and characterize the safety and tolerability of nab-paclitaxel administered 
intravenously over approximately 30 minutes on Days 1, 8, and 15 of a 28-day cycle in patients 
â‰¥ 6 months and < 18 years old with recurrent or refractory solid tumors.
The primary objective of the Phase 2 portion of th e study is to determine the antitumor activity 
assessed by [CONTACT_147447] (ORR) of nab-paclitaxel given at the RP2D in patients â‰¥ 6 
months and â‰¤24 years old with several discrete recurrent or refractory solid tumor types 
including neuroblastoma , rhabdomyosarcoma, and Ewingâ€™s sarcoma.
2.2. Secondary Objectives
The secondary objectives of the Phase 1 portion are:
!To evaluate pharmacokinetics (PK).
!To characterize the ORR.
The secondary objectives of the Phase 2 portion are:
!To characterize duration of response (DOR).
!To characterize the disease control rate (DCR).
!To characterize p rogression-free survival (PFS).
!To characterize 1-year survival.
!To confirm safety.
!To evaluate PK.
2.3. Exploratory Objectives
The exploratory objectives of the entire study are:
!In the Phase 1 portion, to assess 123I-metaiodobenzylguanidine (MIBG) response in 
patients with neuroblastoma.
!To explore the potential ut ility of biomarkers of res ponse and resistance in this study 
population.  The most  recent available tumor tissue sample will be optionally 
collected at the time of study entry.  Biomarkers will be priorit ized for analysis in 
these samples after study completion, as informed by [CONTACT_375428].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21tivitivity y 
tiientens sâ‰¥ 6 â‰¥ 6 
tytypespesyy
R)R)..
e (DCRe (DC )).
survival (PFsurvival (PF
alal..
y ObjectivObjectiv
tiveivessofo thef
Phase 1hase 1 popo
entents wis withthiiinh
To Toexplorexplor
populpopul aa
collecoll
thth
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069394]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE]. STUDY ENDPOINTS
3.1. Primary Endpoint(s)
The primary endpoint of the Phase 1 portion of th e study is the incidence of DLTs (defined in 
Section [IP_ADDRESS] ) and the incidence of treatment-emergent adverse events (TEAEs).
The primary endpoint of the Phase [ADDRESS_1069395] met, based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.[ADDRESS_1069396] and/or the Curie scale (MIBG 
response), as specified in Section 6.3.
3.2. Secondary Endpoint(s)
The secondary endpoints for the Phase 1 portion of the study are:
!Pharmacokinetic parameters including the maximum observed concentration in blood 
(Cmax), area under the blood concentration-time curve (AUC), clearance and volume 
of distribution (Vss).
!ORR.
The secondary endpoints for the Phase 2 portion of the study are: 
!DOR in patients with a confirmed objective complete response (CR) or partial 
response (PR).
!DCR is the percentage of patients with a confirmed objective CR or PR, or stable 
disease for at least 16 weeks.
!PFS based on investigator assessment of response using RECIST 1.[ADDRESS_1069397] and/or the Curie 
scale (MIBG response), as specified in Section 6.3.
!Survival at 1 year.
!The incidence of TEAEs.
!Population PK parameters (e g, clearance and volume of distribution).  Data from the 
Phase 1 and 2 portions will be analyzed together for this endpoint.
3.3. Exploratory Endpoints
The exploratory endpoints for the entire study are:
!In the Phase 1 portion only, M IBG response using Curie score.
!Biomarker analysis prioritized after study completion, as informed by [CONTACT_375428].
!In the Phase 2 porti on only, bone marrow biopsy verification of confirmed complete 
response in patients with neuroblastoma.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21rst rst 
a.a.In n 
lele(MIBG (MIBG
erved concerved conce
AUC), cleaAUC), cle
studystudy are:are:yy
ctive complctive comp
ts with a cos with a co
or assessmer assessm
oupoupththe PFSe PF
nse), as spense), as sp
ear.
nce of TEAce of T
atatioion PK pan PK p
ase 1 and 2 se 1 and 
ExplorExplo
exploratoryexplorator
!!
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069398]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE]. OVERALL STUDY DESIGN
4.1. Study Design
This is a Phase 1/2 multicenter, open-label, dose- finding study to assess the safety, tolerability, 
PK, and efficacy of nab-paclitaxel administered intr avenously to  patients â‰¥ 6 months and < 18
years old in the Phase 1 portion and patients â‰¥ 6 months and â‰¤24 years old in the Phase 2 
portion with recurrent and refractory solid tumors. 
The Phase 1 portion will be a dose-finding study (rolling-6 design, see section [IP_ADDRESS] )t o
determine the MTD/RP2D, safety, to lerability, and PK parameters of nab-paclitaxel in pediatric 
patients with recurrent and refractory solid tu mors who have progressed on standard therapy or 
for whom no standard therapy exists. The decis ion to dose-escalate or to declare an MTD/RP2D 
will be determined by [CONTACT_778553] (SMC) each time clinical and laboratory 
safety data for a given cohort are available for review. The SMC will also determine the dose(s)appropriate for the Phase 2 portion of the study (or the RP2D). 
The Phase 2 portion of the study will be conducted at the RP2D, 240 mg/m
2in patients weighing 
> 10 kg and 11.5 mg/kg in patients weighing â‰¤ 10 kg, to determine: 
1. The antitumor activity of nab-paclitaxel in several solid tumor types (three groups: 
neuroblastoma, rhabdomyosarcoma, and Ewingâ€™s sarcoma).
2. The safety profile and pharmacokinetics of nab-paclitaxel administered at the RP2D.  
During the Phase 2 portion, the SMC will continue to review safety data regularly and make 
recommendations about the study continuation, as appropriate (see Section [IP_ADDRESS] ).
The study will be conducted in compliance wi th the International Council for Harmonisation 
(ICH) of Technical Requirements for Registration of Pharmaceut icals for Human Use/G ood 
Clinical Practice (GCP) and applicable regulatory requirements.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21n pediatric pediatric 
d therapyd therapy ooyy
an MTD/an MTD/ RR
calaland laband labll
determine tdetermine t
0 mg/mmg/m22iin
ne: :
lid tumor tlid tumor 
sarcomasarcoma ).)
bb--paclipacli taxetaxeiii
e to reviewe to revie
n, as approp, as approp
e wie withthii the Ithe Ihh
Registrationegistratio
ble regulatole regula
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069399]-001 Amendment 5.0 Final: 13 Jul 2016Figure 1: Phase 1 Study Design
Screening
Patients â‰¥ 6 months and < 18 years old with recurrent/refractory solid tumors 
excluding patients with brain tumors/metastasis
N = Approximately 12 - 44 patients in DDS
Eligib ility check
Treatment
Rolling-6 design
nab-Paclitaxel weekly on days 1, 8 and 15 of 28 day cycle starting with 120 mg/m2
Cohorts of up to 6 patients per dose level, until MTD/RP2D
Treatment until disease progression, death, w ithdrawal of consent, unacceptable tox icity
Post treatment follow-up
[ADDRESS_1069400]-treatment visit
Tumor evaluation according to protocol until progression or new cancer therapy
Survival follow-up for 1 year or until deathEnd of treatment
Refer to Table 7 for dose levels.
Figure 2: Phase 2 Study Design
Screening
Patients â‰¥ 6 months and â‰¤ 24 years old 
recurrent/refractory solid tumors (radiolog ically documented measurab le disease by [CONTACT_393] 1.1; for neuroblastoma 
evaluable disease by [CONTACT_422955] / Curie is acceptable) fitting one of the three groups (excluding patients with brain 
tumors/metastasis) 
after failing up to three lines of tr eatment
Eligibility check
Treatment
nab-Paclitaxel weekly on days 1, [ADDRESS_1069401]-treatment visit
Tumor evaluation according to protocol until progression or new cancer therapy
Survival follow-up for 1 year or until deathEnd of treatmentGroup 1
Neuroblastoma
N = 14 to 23Group 2
Rhabdomyosarcoma
N = 14 to 23Group 3
Ewingâ€™s Sarcoma
N = 14 to 23
CCI&(&(/*(7$5<,1)250$7,215<,1)250$750$
<,1)2er therapy
/*(1([ZIP_CODE],(7235,(7ning
 and â‰¤ 24 
mente meas
)fitting one
tumors/me
ing up to thr
*(1((352
nab-
Treatment
&(/*(3352
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069402]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].2. Study Duration 
In both the Phase 1 and 2 portions of the study, p atients will enter a 14-day screening period, and 
if eligible (and the cohort/group is open for recruitment) will proceed to the treatment phase.  
Patients may remain on treatment at the discre tion of the investigator until disease progression, 
unacceptable toxicity, until he/she begins a new anticancer therapy, withdrawal of parent/guardian/patient consent/assent, pare nt/guardian/patient refusal, physician decision, or 
death. At the discretion of the investig ator, treatment may continue beyond radiologic 
progression if the patient is benefiting based on other response criteria.  
All patients in both portions of the study will be followed for 28 days after discontinuing 
treatment for safety and monitoring of advers e events, until progression (if applicable) for 
response, and for [ADDRESS_1069403] patient that is required for primary, 
secondary and/or exploratory analysis, as pre -specified in the protocol and/or the Statist ical 
Analysis Plan, whichever is the later date.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21for 
icancer icancer 
d in the d in the PhaPha
he last patiehe last pati
t patientpatient tht
the protocoe protoc
EDMS Doc. Number: nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069404]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE]. TABLE OF EVENTS
The Table of Events is applicable to both the Phase 1 and Phase 2 portions of the study.
Table 4: Table of Events
EventsScreening 
Period Treatment Period
Screening Cycle 1 Subsequent Cycles Follow-up Period
Daya-14 to -1 1 2 3 4 8 15 1 8 15 EOT28 Day 
Safety 
VisitbDisease 
Progression/ 
Survival
STUDY ENTRY
Informed consent and if applicable assent X
Prior cancer history X
Prior cancer therapi[INVESTIGATOR_85142]
X
Complete medical history X
Demographics X
Prior/ concomitant medication evaluation X (-28 from 
screening)Continuous, until 28 days after treatment discontinuation
Prior/ concomitant procedures evaluation X (-28 from 
screening)Continuous, until 28 days after treatment discontinuation
Inclusion/exclusion criteria X
IRT registration X
Archival tumor tissue collection (optional) X, after eligibility confirmation
SAFETY ASSESSMENTS
Adverse event evaluation Continuous starting after informed consent/assent signature, until 28 days after treatment 
discontinuation (and as noted in Section [IP_ADDRESS] )
CCI&(/*priprietet/*(1(352g235,(7$5<,1)250$7,21e Corporae Corpora
21
[ZIP_CODE]
CyclesCycles)2222
181111))),1)
<555<$5$5$5$57$5777$$$
((7$
(((7(7(75,((7555,(,(,(
335,
ContinuContin33353535
))2
35X35353535XX(3333
XX1((1(1(1(1*(((
/*(
EDMS Doc. Number: nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069405]-001 Amendment 5.0 Final: 13 Jul 2016Table 4: Table of Events (Continued)
EventsScreening 
Period Treatment Period
Screening Cycle 1 Subsequent Cycles Follow-up Period
Daya-14 to -1 1 2 3 4 8 15 1 8 15 EOT28 Day 
Safety 
VisitbDisease 
Progression/ 
Survival
Physical examination (source documented only)XX X XX X X X X
Weight X X X X X X X X X
Height X X X X X X X X X
Body surface area calculation X X X X X X
Vital signsdXX X XX X X X X
Hematology laboratory X X X X X X X X X
Chemistry laboratoryeXX X X X
Urine homovanillic acid and 
vanillylmandelic acid (for neuroblastoma 
only)X Every other 
cycle, 
starting in 
Cycle 2XX
LVSF assessment by [CONTACT_6751]/ 
MUGA/ other medically a ppropriate 
methodX Every other 
cycle 
starting in 
Cycle 3X
12-lead electrocardiogram X Every other 
cycle 
starting in 
Cycle 3X
Serum Î²-hCG (if indicated)fX As clinically indicated
Urine Î²-hCG (if indicated)fX As clinically indicated X
CCI&(/*priprietet/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
217,2
0F000
1515 EOTEO2200
)2250
XXXX))2)222
1)22
XX111,1 XX<,1,1,1,1
XX5<$5XX$5$5$57$5XXXX777$$$
((7$
(((7(7(7,((7,(,(,(((
[ZIP_CODE],((
22232323
355223
XX(333
(13
(1(1(1(*
(/*
EDMS Doc. Number: nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069406]-001 Amendment 5.0 Final: 13 Jul 2016Table 4: Table of Events (Continued)
EventsScreening 
Period Treatment Period
Screening Cycle 1 Subsequent Cycles Follow-up Period
Daya-14 to -1 1 2 3 4 8 15 1 8 15 EOT28 Day 
Safety 
VisitbDisease 
Progression/ 
Survival
Pharmacokinetic samplesgXXXX
EFFICACY ASSESSMENTS
Tumor evaluation (CT/MRI, see
Section 6.3)X (-28 to -1) Every 8 weeks (Â± 5 days) from Cycle 1 Day 1, until progression or new anticancer treatment
MIBG scan (in patients with 
neuroblastoma)X (-28 to -1) If assessable by [CONTACT_778554], every 8 weeks (Â± 5 days) from Cycle 1 Day 1, until 
disease progression or new anticancer treatment.  If not assessable by [CONTACT_728734], at screening 
and suspected progression only.
Bone marrow biopsy (in patients with neuroblastoma)Only at confirmation of complete response
Lansky performance status (in patients < 12 
years old)XX X X X
Karnofsky performance status (in patients â‰¥ 
12 years old)XX X X X
INVESTIGATIONAL PRODUCT (IP)
Administer nab-paclitaxel X X X X X X
FOLLOW-UP
Survival follow-up Every 1 month 
for 1 year
Anticancer therapy since nab-paclitaxel 
discontinuationX At every 
survival follow-
up visit for 1 
year
CCI&(/*priprietet/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
217,2
0F000
1515 EOTEO28200
2250
))2)222)22
1)))
e 1 Day 1, une 1 Day 1, ,1
at screening, at screening
anticancer trnticancer t
and sand 5<
Only anly7$(((7(7(7
35,((7
35353522335VESTIGATVESTIGA22232323 XX55525252355235353553333
1(
/*(1
EDMS Doc. Number: nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069407]-001 Amendment 5.0 Final: 13 Jul 2016Î²-hCG = Î²human chorionic gonadotropin, C#D# = Cycle number Day number, CR= complete response, CT = computed tomography scan, EOT = end of  
treatment visit, IRT = Integrated Response Technology, LVSF = left ventricular shortening fraction, MIBG = 123I- metaiodobenzylguanidine scan, MRI= 
magnetic resonance imaging, MUGA = multi-gated acquisition scan.
aAn administrative window of Â± 2 days is permitted for all visits except C1D1.
bIf the EOT visit occurs within 7 days of the 28 day safety visit, laboratory evaluations only need to be repeated for abnormal parameters at the EOT visit.
cPrior cancer therapi[INVESTIGATOR_778529], radiation, stem cell transplant, systemic or any other therapy for the patient's cance r.
dVital sign measurements must be recorded in the database at screening and EOT only, and kept in the source documents at all oth er visits.  However, if an 
abnormal (out of range) value is reported at a given visit, that parameter should be collected in the case report form (CRF) at  every subsequent scheduled visit 
until it returns to normal.  
eIn patients with neuroblastoma ferritin will be analyzed.
fFor all female patients of childbearing potential (see Inclusion 8), a serum pregnancy test will be done at screening.  A urine  pregnancy test will be repeated 
within [ADDRESS_1069408] occurred > [ADDRESS_1069409] samples taken on C1D2, C1D3, and C 1D4 as described in 
Section 6.4.
CCIpriprietet,1)250$7,21e Corporae Corpora
21EOT = endEOT = end
idineidin scan, Mscan, M
arameters at tameters at 
at all at all other vother v
CRF) RF) at everyat every
ening.  A ening.  A uri
t EOTOT..PrPreg
es taken on Ces taken on
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069410]-001 Amendment 5.0 Final: [ADDRESS_1069411] of this trial, under any circumstances.
Safety laboratory analyses and all assessments  (with the exception of PK and biomarker 
analyses) will be performed locall y. Laboratory normal ranges must be submitted to the Celgene 
or designated contract research organization (CRO) data manager. Screening laboratory values 
must demonstrate p atient eligibility, but may be repeated  within the screening window if 
necessary.
The following will be pe rformed at screening as specified in the Table of Events, after informed 
consent/assent has been obtained:
!Cancer history (including specific information regarding diagnosis, staging, and 
histology)
!Demographics (initials, date of birth, sex, race, and ethnicity-if allowed by [CONTACT_13125])
!Prior cancer therapi[INVESTIGATOR_014]:  includes surger y, radiation, stem cell transplant, systemic or 
any other therapy for the patientâ€™s cancer 
!Complete medical history (all relevant medical conditions occurring more than 28 
days before screening should also be included)
!Prior and concomitant procedures (including all procedures occurring â‰¤ 28 days 
before screening)
!Prior and concomitant medication ev aluation (including those taken â‰¤ 28 days before 
screening, except for those taken for cancer)
!Archival tumor sample collection (optional): If available and consented, the sample 
should be retrieved and sent after patient eligibility is confirmed.  It is recommended that this be sent before the end of Cycle 1
!Physical examination (source documented only), height, weight
!Vital signs (including blood press ure, temperature, and heart rate)
!Performance status
âˆ€Lansky performance status recommended in patients < 12 years old at the time of 
informed consent/assent
âˆ€Karnofsky performance status recommended in patients â‰¥ 12 years old at the time 
of informed consent/assent
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21Celgene elgene
oryoryvalvaluesuesll
dow if dow if 
vents, aftervents, afte
diagnosis, iagnosis,
nd ethnicitd ethnicit y
adiation, adiation st
er er 
ant medicant medica
so be includo be includ
edures (incldures (inc
nt mnt medicatedicat ii
fofor r ththose taose ta
or sample cor sampl
retrietrieved aneved
be bsent besent be
ysicalsical examexa
ViVitalali signsignll
!!Perfoerfo
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069412]-001 Amendment 5.0 Final: 13 Jul 2016âˆ€An individual patient should be evaluated by [CONTACT_778555]
!Left ventricular shortening fraction (LVSF) assessment by [CONTACT_6751], multi-
gated acquisition (MUGA) s can, or other medically a ppropriate method (eg, magnetic 
resonance imaging, MRI). Patients with a historical LVSF assessment performed      â‰¤ [ADDRESS_1069413] dose need not repeat the assessment for the purposes of 
screening.
!12-lead electrocardiogram (ECG). Patients with a historical ECG performed â‰¤ [ADDRESS_1069414] dose need not repeat the ECG for the purposes of screening.
!Response assessment/ tumor evaluation (see Section 6.3). Patients with historical 
tumor scans evaluable per RECIST 1.1 (and MIBG scan for neuroblastoma) 
performed â‰¤ [ADDRESS_1069415] dose need not repeat scans for the purposes of 
screening 
âˆ€Patients who are symptomatic for brain metastases must have a brain scan at 
screening to confirm eligibility
!Complete blood count (CBC) with differential,  including but not limited to red blood 
cell (RBC) c ount, hemoglobin, hematocrit, wh ite blood cell (WBC) count, absolute 
neutrophil count (ANC), and platelet count. ANC should be measured with automated 
count where available
!Chemistry panel including, but not limited to, sodium, potassium, chloride, 
bicarbonate, calcium, magnesium, phosphorus, blood urea nitrogen (BUN), creatinine, glucose, albumin, total protein, alkaline phosphatase, bilirubin (total and 
direct), aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(AST/SGOT), alanine aminotransferase (ALT/SGPT), lactate dehydrogenase/serum glutamic pyruvic transaminase (LDH), and uric acid
!For neuroblastoma the following will also be assessed: 
âˆ€Urine homovanillic acid (HVA) and vanillylmandelic acid (VMA)
âˆ€Blood ferritin
!Pregnancy test is required for all female patients of childbearing potential defined as 
beingâ‰¥ [ADDRESS_1069416] did not already occur with 72 hours of dosing
!Adverse event assessment begins when the parent/guardian/patient signs the informed 
consent/assent form
!IRT registration: If the patient meets all eligibility criteria, registration in IRT should 
be performed as described in Section 8.3
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21g.g.
torical orical 
mma) a) 
he purposeshe purposes
ave a brainave a b
ng but not g but not 
ood cell (ood cel W
C should beC should be
d to, sodiumd to, sod
sphorus, blsphorus, b
protein, alkaotein, alk
se/serum glse/serum g
ransferase ransferase 
nase (LDH)nase (LDH
follfollowing owin
ninillic acid (llic acid 
ititin
y test is reqtest is re
â‰¥ 12 yâ‰¥ [ADDRESS_1069417]
off dos dosff
!!AA
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069418]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].1. Treatment Period
The patient will begin treatment at the assigned dose upon confirmation of eligibility and 
authorization from the sponsor that there is a spot available in the current cohort/group(s) (see 
Section 8.3). The patient must start treatment within 14 days of signing the informed consent 
form (ICF).  For all subsequent visits, an administrative window of Â± 2 days is permitted.
Treatment cycles are 28 days in duration. 
The following evaluations will be performed at the frequency specified in the Table of Events, 
Table 4 . The evaluations should be performed prior to dosing on the visit day, unless otherwise 
specified:
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Physical examination (source documented only)
!Vital signs: In general, on-treatment vital sign measurements will be source 
documented only.  However, if an abnormal (out of range) value is reported at any given visit, that parameter should be co llected in the case report form (CRF) at every 
subsequent scheduled visit until it returns to normal
!Weight 
!Height 
!Complete blood count with differential
!Chemistry panel (with ferritin for neuroblastoma)
!Urine HVA and VMA for neuroblastoma: every other cycle starting in Cycle 2
!Performance status 
!LVSF assessment 
oEvery other cycle starting in Cycle 3
oIf the results are abnormal, the assessment should be repeated as clinically 
indicated
!12- lead ECG: every other cycle starting in Cycle 3
!Adverse event evaluation (continuously)
!Response assessment/ tumor evaluation (see Section 6.3)
!Pharmacokinetic sampling (see Section 6.4)
6.1.1. End of Treatment
An end of treatment (EOT) evaluation should be performed for patients who are withdrawn from 
treatment for any reason as soon as possible af ter the decision to permanently discontinue 
treatment has been made. 
CCIwise ise 
will be sowill be
) value is rvalue is 
ase report foe report f
neuroblastoeuroblasto
roblastomaroblastoma
er cyer cy cle stacle sta
results are results a
icatedcated
ad ECG: evad ECG: ev
ddverse eveverse eve
ResponsRespon
!
&PharPha
[IP_ADDRESS].1
en
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069419]-001 Amendment 5.0 Final: 13 Jul 2016The following evaluations will be performed as specified in the Table of Events:
!Physical examination (source documented only), height, and weight
!Vital signs 
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Performance status
!LVSF assessment 
!12-lead ECG
!Adverse event evaluation
!Complete bl ood count with differential
!Chemistry panel (with ferritin for neuroblastoma)
!Urine HVA and VMA for neuroblastoma
!Urine Î²-hCG (for females of childbearing potential)
!Response assessment/ tumor evaluation will be continued at the schedule defined in 
the Table of Events, and does not need to be performed specifically for the EOT visit
except as specified in Section [IP_ADDRESS].[ADDRESS_1069420] dose of IP, as well as SAEs made known to the investigator at any time thereafter that are suspected of being related to IP, as described in Section 11.1. If the 28-day Follow-up visit 
occurs within 7 days of the EOT visit and EOT laboratory values are not of clinical significance, 
laboratory collection is not required at the 28-day Follow-up visit.  The 28-day Follow-up assessments include:
!Physical examination (source documented only), height, and weight
!Vital signs 
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Performance status
!Adverse event evaluation
!Complete blood count with differential 
!Chemistry panel (with ferritin for neuroblastoma) 
!Urine HVA and VMA for neuroblastoma
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ontntinued atinued a
erformed sperformed s
rtingingofonnfewe
made knowmade kno
as describedas describe
T visit andT visit an
required at equired a
examinatxaminat ioi
 signs signs 
ConcomitanConcomita
!ConcomConco
!!PPere
!!
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069421]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].2.1.1. Special Monitoring
Neuropathy (eg, motor neuropathy, sensory neuropathy, peripheral neuropathy) AEs present at 
the time of treatment discontinua tion should be followed until 1 of the following are met, but no 
less than the minimum 28 days required in Section 6.2.1 and Section 11.1:
!Improvement to â‰¤ Grade 1
!At least [ADDRESS_1069422] elapsed without improvement or worsening
!The patient initiates any other an ticancer therapy during the follow-up
6.2.2. Efficacy Follow-up
All patients who discontinue treatment for reasons  other than disease progression, start of a new 
anticancer therapy, or withdrawal of consent from the entire study will be followed for response
and new anticancer therapi[INVESTIGATOR_72602] 6.3.
6.2.3. Survival Follow-up
After the EOT visit, all patients w ill be followed for survival until death, lost to follow-up, or one 
year after EOT, whichever occurs first. This evaluation should be conducted monthly for [ADDRESS_1069423] review (including public records) and/or 
telephone contact [CONTACT_10970], family, or the patientâ€™s treating physician.
6.3. Response Assessments
Response assessments (tumor evaluations) s hould be performed at screening (up to 28 days 
before the start of IP) and every 8 weeks (Â± 5 days) from Cycle [ADDRESS_1069424] 1.1 guidelines. In the Phase 2
portion of the study, patients with neuroblastoma  will also be assessed at screening for response 
using MIBG evaluation and the Curie score, as described in Section [IP_ADDRESS].1 , and then (if 
evaluable by [CONTACT_778554]) every 8 weeks (Â± 5 days) from Cycle [ADDRESS_1069425] a subsequent MIBG 
scan at suspected progression only.
New anticancer therapi[INVESTIGATOR_778530] s ame schedule. New anticancer therapy 
includes (but is not limited to) any systemic or local-regional medication, surgery, radiation, or 
any other therapy intended to treat the patientâ€™s cancer.  
If necessary, an independent (central) assessmen t of response may be conducted by [CONTACT_778556].  
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21art of a newart of a new
ed for respoed for respo
ath, lost toath, lost to
conducted onducted
llected lected at t
(i(ncluding ncluding
ententâ€™s treatinâ€™s tre
shoulhould be pd be 
s ( (Â±Â±5 days)5 day
r therapyr therapy ,o
performed performed 
thth neuroblneuroblhh
the Curie the Curi
at screeninat scree
art of aart of new
hout MIBGut MIBG
d progressiod progress
ncer therapi[INVESTIGATOR_778531]
(but iut s not ls not l
her therapyher therapy
necessary, necessary, 
affter studyter studyfff
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069426]-001 Amendment 5.0 Final: [ADDRESS_1069427] 1.1.  Response assessments include computed 
tomography (CT) scan or MRI.  The regions to be imaged are the chest and abdomen/pelvis, as 
well as any other studies required for tumor imaging. The same mode of imaging for lesion evaluation at screening must be used consistently throughout the study. 
The CT imaging should include contrast unless medically contraindicated. Conventional CT 
should be performed with contiguous cuts of [ADDRESS_1069428] should be 
performed by [CONTACT_2363] a 5 mm c ontiguous reconstruction algorithm.
All patients with evidence of objective tumor response (CR or PR) should have the response 
confirmed with repeat assessments at the next scheduled scan, but after no less than [ADDRESS_1069429] occurred â‰¥ 6 weeks from Cycle 1 Day 1 to be considered as
stable disease (SD) for a best response.
Additional details and definitions of re sponse are found in A ppendix A in Section 19.1.
[IP_ADDRESS]. Other Assessments
Patients who are symptomatic for brain metastasis at screening must undergo a brain scan to 
confirm eligibility.
Additional scans, including further brain scans, MRI of the head, or nuclear medicine bone scan,
may be performed if clinically indicated (eg, symptoms of brain metastasis) at the discretion ofthe investigator.
[IP_ADDRESS].1. Other Assessments for Neuroblastoma
Patients with neuroblas toma should be a ssessed at screening for MIBG response using the Curie 
score.  The Curie score is a semi-quantitative scoring system for the comparison of sequential 
whole-body MIBG scans in children with neuroblastoma ( Ady, 1995 ).
Patients with MIBG-evaluable lesions should be  assessed for response using the Curie score 
(Section 19.2 Appendix B) at screening (up to 28 days before the start of IP) and every 8 weeks 
(Â± 5 days) from Cycle [ADDRESS_1069430] and MIBG/Curie score, both methodologies must show confirmed objective CR.  
6.4. Pharmacokinetics
Pharmacokinetic blood samples will be collected for the first dose (Cycle 1 Day 1) from all patients in both the Phase 1 and 2 portions of the study to analyze paclitaxel concentrations in 
blood. 
Samples will be collected from all patients enrolled  in the Phase 1 portion of the study according 
to a dense PK sampling strategy as specified in Table 5 .
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e
nse se 
weeks.weeks.   
sidered assidered as
ctictonon19.19.
st undergo st underg
headhead ,,or nuor nu
of brain mef brain me
mama
sed at ed at screescree
tive scoringtive scorin
ith h neuroneu blb
onsnsshoulouldd
creening (upreening (u
[ADDRESS_1069431] sho
PharmPharm
armarmaccokineokine
patipatientents in s in 
blood. lood. 
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069432]-001 Amendment 5.0 Final: 13 Jul 2016Samples will be collected from all remaining patients  enrolled in the study according to a sparse 
PK sampling strategy as specified in Table 6 , or if optionally consented according to a dense PK 
sampling strategy. 
Table 5: Dense PK Sampling
Sample 
Number Sample Time (hours)Patients â‰¥ 6 
Years OldPatients < 6 
Years Old
1 1-2 minutes prior to the end of infusion (no 
window, must be collected before end of infusion)XX
2 15 minutes after end of infusion (Â± 5 minutes) X X
3 1 hours after end of infusion (Â± 5 minutes) X
4 3 hours after end of infusion (Â± 10 minutes) X X
5 5 hours after end of infusion (Â± 10 minutes) X X
6 8 hours after end of infusion (Â± 1 hour, 
recommendeda
)X
7 24 hours after end of infusionb
(Â± 3 hours) X X
8 48 hours after end of infusionc
(Â± 3 hours) X
9 72 hours after end of infusiond
(Â± 3 hours, 
recommendede
)X
aRecommended sample at [ADDRESS_1069433] da y.  Patients living far from the center may omit this sample.  
Table 6: Sparse PK Sampling
Sample 
Number Sample Time (hours)Patients â‰¥ 6 Years 
OldPatients < 6 Years 
Old
1 15 minutes after end of infusion (Â± 5 min) X X
2 3 hours after end of infusion (Â± 10 minutes) X X
3 24 hours after end of infusion (Â± 3 hours)a
XX
a24-hour sample may occur on st udy Day [ADDRESS_1069434] be captured in the CRFs for Cycle 1, Day 1 through Day 4: 
!The dose level and total dose administered (Day 1 only)
!The exact time of the start and end of infusion (Day 1 only)
!The exact time of each PK sample collection in addition to the scheduled time point 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7X$7$7$70$XX5025)2)2)2)2)2
X,1XX<,XX5<
7$7$7$7$formed in anyormed in 
an outn ou -patientpatien
on the on the timingtimi
g on the timig on the timi
dingingon thon th e e t
on should be on should b
ving far fromving far 
mplingpling
mple Timemple Tim35
after end oafter end o(s after end s after end 1(hours afterhours afte(1*(sample may ople may
e fofollollowingwin
!
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069435]-001 Amendment 5.0 Final: [ADDRESS_1069436] recently available tumor tissue sample will be optionally collected at the time of study 
entry.  The study laboratory manual will include procedures for providing these samples, which 
will be used to study tumor characteristics and their correlation with patient outcomes and 
treatment response.  The specific use of these s amples is not being pre-specified and will be 
determined based on emerging data and methodological advances.  A potential use of these 
samples is to assess in the pediatric patients in this study the value of markers of response to nab-
paclitaxel that may be identified in studies of adult patients.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21studystudy
s, which s, which 
s and s and 
nd will be d will be 
use of thesuse of th
rs of responrs of respo
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069437]-001 Amendment 5.0 Final: [ADDRESS_1069438] 12 to a pproximately 64 patients with various solid 
tumors will be enrolled, depending on the number of dose escalation cohorts and the number of 
additional patients enrolled at dose levels evaluated as safe by [CONTACT_4484].
In the Phase 2 portion of the study, up to 69 e fficacy evaluable patients will be enrolled, in 3 
different groups ( â‰¤23 with neuroblastoma, â‰¤ 23 with rhabdomyosarcoma, and â‰¤ 23 with 
Ewingâ€™s sarcoma), with at least [ADDRESS_1069439] meet all of the following criteria to be enrolled in the study:
1. Patient is male or female, meeting the following age requirements at the time the 
informed consent document (and a ssent form, if applicable) is signed.
a. Phase 1: patient is â‰¥6 months to < 18 years of age
b. Phase 2: patient is â‰¥6 months to â‰¤24 years of age
2. Patient has a confirmed solid tumor diagnosis according to the following:
a. Phase 1: patien t has a recurrent or refractory solid tumor that has progressed or 
did not respond to standard therapy, or for which no standard anticancer therapy 
exists
b. Phase 2: patient has radiologic ally documented measurable disease by [CONTACT_393] 
1.1 (for neuroblastoma, evaluable dis ease by [CONTACT_422955]/Curie score is also 
acceptable) in one of the following tumor types and has failed up to three lines of treatment
i. Group 1: neuroblastoma (patients with bone marrow disease only are not 
permitted)
ii. Group 2: rhabdomyosarcoma
iii. Group 3: Ewi ngâ€™s sarcoma
3. The patient has a Lansky/ Karnofsky performance status score of â‰¥ 70%
4. The patient has adequate serum chemistry levels, evidenced by [CONTACT_148617]
a. AST (SGOT), ALT (SGPT) â‰¤ 2.5 Ã— upper limit of normal range (ULN) 
b. Total bilirubin â‰¤ 1.5 Ã— ULN
c. Creatinine â‰¤ 1.5 Ã— ULN
5. The patient has adequate bone marrow function, evidenced by [CONTACT_716]:
a. Absolute neutrophil count â‰¥ 1.0 Ã— 10
9cells/L
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ts at theat the tim
 signed.signed.
e
f agef age
cording to tording to
fractory soractory s l
yy, or f, or f or whrwf
ggicically docally do
valuvaluable dable 
he fohe fo llollowin
1: : nneurobleurob
mitted)tted)
GroupGroup 2: 
ii.i.GroupGroup
tiiententhas a has a
e patipatiententhah
valuesvalues
a.a.
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069440]-001 Amendment 5.0 Final: 13 Jul 2016b. Platelets â‰¥ 80 Ã— 109cells/L (transfusion independent, defined as not receiving 
platelet transfusions within 7 days prior to la boratory sample). In the Phase 2
portion, for patients with know n bone marrow involvement, platelets â‰¥ 50 Ã— 109
cells/L
c. Hemoglobin â‰¥ 8 g/dL (transfusion is permitted to fulfill this criterion)
6. The patient (when applicab le) or patientâ€™s parent(s) or legal guardian(s) understand(s) 
and voluntarily signed an informed consent document prior to any study-related assessments/procedures being conducted. Where locally applicable, the patient also 
understands and voluntarily provides his/her assent prior to any study-related 
assessments/procedures being conducted.
7. Male patients of childbearing potential must use a condom during sexual intercourse and 
shall not father a child during the study and for [ADDRESS_1069441] dose of study
medication.
8. Female patients of childbearing potential [defined as all female patients â‰¥ [ADDRESS_1069442]] must have both of the following:
a. Agree to the use of two physician-approved contraceptive methods 
simultaneously or practice complete abstinence while on study medication or for a 
longer period if required by [CONTACT_427]
i. True abstinence: When this is in line with the preferred and usual lifestyle 
of the patient. Periodic abstinence (eg, calendar, ovulation, 
symptothermal, postovulation methods) and withdrawal are not acceptable 
methods of contraception. 
ii. Acceptable contraceptive methods include: oral, injectable, or implantable 
hormonal contr aceptive; tubal ligation; intra-uterine devi ce; barrier 
contraceptive with spermicide; or vasectomized partner) including at least one barrier method.
b. Have negative serum pregnancy test result at screening confirmed by [CONTACT_778557] [ADDRESS_1069443] dose of IP (if serum test occurred > [ADDRESS_1069444] dose); pregnancy test with sensitivity of at least 25 
mIU/mL
7.3. Exclusion Criteria
The presence of any of the following will exclude a patient from enrollment:
1. The patient has a primary brain tumor(s) or brain metastasis (unless metastasis is treated 
and stable for > 28 days). In patients who are symptomatic, a brain scan is required to 
exclude metastasis.
2. The patient has â‰¥ Grade 2 peripheral neuropathy by  [CONTACT_78182] (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) at screening.
3. The patient has received therapeutic dose chemotherapy or radiotherapy â‰¤ 21 days prior 
to start of IP.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ercourse anercourse a
se of studyse of study
tieientnts s â‰¥ 12â‰¥12
both of thboth of t
ceptive meteptive me
while on stuwhile on stu
ine witne wit h thh 
nce (eg, calnce (eg, cal
n n methodsmethods
n. . 
ptive methotive metho
eptive; tubaeptive; tuba
witwith spermih spe
methodthod.
serum pregnrum preg
ncy dipstncy dipst ic
> 72 hours > 72 hou
LL
lusion Crusion Cr
ce of ane of an y y ofof
The Tpatipatienten
and staband sta
excluexclu
2.T
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069445]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE]. The patient has received maintenance dose chemotherapy (eg, low dose 
cyclophosphamide) â‰¤ [ADDRESS_1069446] dose of IP.
5. The patient has received any investigational therapy â‰¤ [ADDRESS_1069447] that is not approved in the country of treatment for any indication, adult or pediatric. 
6. The patient has received any biological therapy â‰¤ 7 days prior to the start of IP, or 
monoclonal antibody â‰¤ [ADDRESS_1069448] dose 
of IP.
7. The patient has received allogeneic hematopoietic stem cell transplantation (HSCT) â‰¤ [ADDRESS_1069449] â‰¤ 21 days prior to start of IP.
8. The patient has had major surgery or significant trauma â‰¤ 14 days prior to start of IP.
9. The patient has not recovered from the acute toxic effects of prior chemotherapy, 
radiation, or major surge ry/significant trauma.
10. The patient has had minor surgery â‰¤ 7 days from the start of study treatment (excluding 
the placement of central/peripheral lines, skin biopsy).
11. The patient has a known history of stroke, myocardial infarction, peripheral vascular 
disease, or recent (within 3 months) uncontrolled deep venous thrombosis.
12. The patient has a known history or current diagnosis of HIV infection, regardless of 
treatment status.
13. The patient has an uncontrolled intercurrent illness including but not limited to ongoing 
or active infection requiring antibiotic, antifungal, or antiviral therapy, symptomatic heart 
failure, cardiac arrhythmia, or psychiatric illness/social situations that would li mit 
compliance with study requirements.
14. The patient has any significant medical condition, laboratory a bnormality, or psychiatric 
illness that would prevent the patient from participating in the study.
15. The patient has any condition, including the presence of laboratory abnormalities, that 
places the patient at unacceptable risk if he/she were to participate in the study.
16. The patient has any condition that confounds the ability to interpret data from the study.
17. The patient or parent(s)/guardian(s) is/are una ble to comply with the study visit schedule 
and other protocol requirements, in the opi[INVESTIGATOR_871].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e e 
T) T) â‰¤ 3 â‰¤ [ADDRESS_1069450] ion, pe
p venous thp venous t
osis osis of fHIVH
nt illness innt illness i
antntifuifungalngal
atriatric illnesc illnes
ntsnts..
nt medical cnt medica
the epatipaenten
nditnditioion,nincin
t unacceptaunaccept
any conditany condi
or parent(or parent(
er protocol er protocol 
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069451]-001 Amendment 5.0 Final: [ADDRESS_1069452](s)
nab-Paclitaxel, the IP, will be supplied by [CONTACT_456] (Celgene) in single-use vials. Each single-
use 50 mL vial will contain paclitaxel (100 mg) and approximately [ADDRESS_1069453] be made available to Celgene or other Celgene 
representatives for verification of proper study drug storage.
To facilitate the administration of small volumes, nab-paclitaxel suspension may alternatively be 
administered using syringe based devices (eg, a syringe pump), provided that a silicone oil-free 
syringe is used to extract the reconstituted nab-paclitaxel suspension from the vial and the 
reconstituted nab-paclitaxel is st ored in the syringe at room tem perature for no longer than 8 
hours.
8.2. Treatment Administration and Schedule
In both the Phase 1 and 2 portions of the study , the treatment will be given until disease 
progression, the patient begins a new anticancer treatment, withdrawal of parent/guardian/patient 
consent/assent, parent/guardian/patient refusal, physician decision, toxicity that cannot be 
managed by [CONTACT_778558] (reductions are prohibited in Cycle 1 [and Cycle 
2 for patients â‰¤ 10 kg] for the Phase 1 portion only), or the study ends for any reason. nab-
Paclitaxel will be administered intravenously over approximately 30 minutes, without 
corticosteroid or antihistamine premedication, week ly on Days 1, 8, and 15 of a 28-day cycle.
Following administration, the intrav enous line s hould be flushed with s odium chloride 9 mg/ml 
(0.9%) solution for injection to ensure admin istration of the complete dose, according to local 
practice.
8.2.1. Phase 1 Portion: Dose Escalation
In the Phase 1 portion of the study, up to 6 p atients will be  assessed at a starting dose of 120 
mg/m2 nab-paclitaxel (80% of the weekly investig ated adult dosage). Dose escalation will occur
according to example dose levels described in Table 7 , using the rolling-6 design (as described in 
Section [IP_ADDRESS] ). Doses not listed in Table 7 , including intermediate doses or doses higher than 
210 mg/m2, may be tested based on study data and recommendations from the SMC. 
For patients who weigh â‰¤ 10 kg the dosage will be calculated per kg, and nab-paclitaxel will be 
administered according to the schedule in Table 7 . In order to ensure their safety, patients
weighing â‰¤ 10 kg will receive a reduced dose (by [CONTACT_778559]) in Cycle 1, and if well tolerated (no 
DLTs) will receive the full dose starting in Cycle 2.  
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21an area an area 
stistitutitutiiion on 
ther Celgenther Celg
sioon n mamayal
ded that a sded that a s
on nfroom mthth
perature foperature fo
eduleedule
treatmtreatm ent ent 
r treatment,treatmen
al,al,physiciaphysicia
alalone one (redu(redu
portion onlyortion on
avenously ovenously
rememedicatiedicati o
intravenouintraveno
n to ensuren to ensur
Porrtion: tion: 
portiporti on ofon o tf
paclitpaclit axelaxel ((ll
g to o exampexamp
nn8.[IP_ADDRESS].1.3 ))
 mmggm/m/m22, m,m
For Fopatienatien
dminidmini
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069454]-001 Amendment 5.0 Final: 13 Jul 2016Table 7: Phase 1 Portion Example Dose Levels
Dose Dose (Patients â‰¤10 kg)
Dose Levela
All Cycles Cycle 1 Subsequent Cycles
-1100 mg/m24.0 mg/kgb
4.5 mg/kg
1 (Starting dose)120 mg/m24.5 mg/kg 5.5 mg/kg
2150 mg/m25.5 mg/kg 7.0 mg/kg
3180 mg/m27.0 mg/kg 8.5 mg/kg
4210 mg/m28.5 mg/kg 10.0 mg/kg
aDose levels are also used for dose reductions in both the Phase 1 and 2 portions, as described in Section [IP_ADDRESS] .
Dose level -1 may reduce to 80 mg/m2and 60 mg/m2, or 3.0/4.0 mg/kg and 2.0/3.0 mg/kg (Cycle 1/Subsequent 
Cycles).
b4.0 mg/kg is the calculated equivalent of 80 mg/m2.
[IP_ADDRESS]. Definition of Dose-limiting Toxicity
The DLT assessment period will be as follows:
!For patients > 10 kg: the first cycle including Cycle 2 Day 1 predose evaluations
!For patients â‰¤ 10 kg: the first two cycles including Cycle 3 Day 1 predose 
evaluations
A DLT is defined as IP-related AE(s) occurring during the DLT assessment period that lead to 
treatment discontinuation or meet one of the following criteria:
!Grade 3 or 4 nonhematologic toxicity (excluding transient transaminitis)
!Grade 3 or 4 nausea or vomiting that persists > 5 days despi[INVESTIGATOR_76303]-emetic 
treatment
!Grade 4 thrombocytopenia or anemia that persists > 7 days or requires transfusion > 7 
days
!Grade 3 thrombocytopenia with bleeding
!Grade 4 uncomplicated neutropenia lasting > 7 days
!Febrile neutropenia with confirmed bacterial infection
!Grade 3 hematologic toxicity re quiring treatment delay > 21 days
Events that are considered DLTs based on their duration will be considered a DLT if they start 
during the DLT assessment period.  
Events due to disease progression or to current underlying disease cannot be considered DLTs. 
Events that are not considered related to IP cannot be considered DLTs.
If a patient experiences a DLT, the dose should be delayed until resolution of the AE to CTCAE 
Grade 1.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7/kgkg$7$7$7
.00mg/mg/kgkg0$50nnSection Section 8.282
Cycle 1/Subsycle 1/Sub
Cycle 2 Daycle 2 Da
ncluding Cycluding Cy
during theduring th
fofollollowing cwing 
toxicittoxicit y (ey
omitmiting thaing th
cycytopenitopenyy a o
hrombocyrombocy toy
4 uncomp4 uncomp
ebrile neutrebrile neutr
Grade 3 Grade 3
nts that are nts that are
uringuring ththe De D
EventEvent s ds
ent
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069455]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].2.1.2. Safety Monitoring Committee
The SMC will decide whether to dose escalate, dose reduce, or declare an MTD, and will 
determine the dose(s) appropriate for the Phase 2 portion of the study (RP2D). During the Phase
2 portion, the SMC will continue to review safety data regularly and make recommendations 
about the study continuation, as appropriate.  
The members of the SMC will include the princip al investigator, all investigators who recruited 
patients into the current cohort (or a subinvestigator designee), the Celgene Clinical Research Physician or designee, the Celgene Clinical Research Scientist or designee, and the Product 
Safety Physician or designee (if applicable). Additional details regarding the composition and 
responsibilities of the SMC are detailed in the SMC charter.
[IP_ADDRESS]. Dose Escalation Procedures
Up to [ADDRESS_1069456] dose level, and subsequent dose escalation will 
proceed using the rolling-6 design. In each cohort a minimum of 2 patients treated and eligible 
for the Dose Determining Set (DDS, refer to Section 10.2) are required to make a dose decision.  
If zero DLTs are observed in the first 3 patien ts eligible for the DDS the SMC may decide to 
escalate the dose for the next cohort.  An additional 3 patients (up to a total of 6 per cohort) may 
be enrolled at the same dose while awaiting the DDS eligibility of [ADDRESS_1069457] dose level,  a -1 dose level will be evaluated (100 mg/m
2).
If two or more patients in a given cohort experience a DLT at any time during enrollment, the 
MTD will have been exceeded and the previous lower dose will be declared the MTD. 
Patients ineligible for the DDS may be replaced at the discretion of the sponsor.For each cohort, the decision whether or not to dose-escalate in the next cohort or to declare the 
MTD/RP2D will be made by [CONTACT_4484]. The SMC will review all available clinical laboratory and 
safety data for a given c ohort and, if applicable, d ata from previous cohorts.  
The SMC decision to escalate to the next dose level will be driven by [CONTACT_129948] (as 
described in Section 8.2.1 ) and the totality of d ata. 
Additional factors for safety evaluation that may be considered by [CONTACT_778560] (but are not 
limited to):
!Incidence of TEAEs and SAEs
!Physical examinations
!Laboratory abnormalities (serum chemis try, hematology, and differentials)
!Dose modifications (skipped doses, reduced doses, dose interruptions, and/or 
treatment discontinuation)
If other safety considerations are noted, th e SMC may take other actions, including expansion of 
the current dose level or declaration of the RP2D despi[INVESTIGATOR_778532]. 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21nd d 
alation willation wi
treated andreated and
o make a dmake
S the he SMC mSMC 
p tooa total ootal 
y yofof33ffpatipae
n, the coho, the coh
LTLTin thesein thes
fetfety y consionsd
--1 dose l1 dose l eve
erience a Derience a D
vious lovious lo wewe
e replaced ae replaced a
her or not r or not 
he Se SMMC. ThC. Th
rt andrt and ,if apif 
calcalate to thto 
[IP_ADDRESS].1 ))andand
s for s for ssafetafet
IncidenceIncidence
!!PhysPhy
!L
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069458]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].2.1.4. Recommended Phase 2 Dose
After the MTD has been established, the SMC will determine the dose to be used in the Phase 2 
portion of the study (RP2D). This dose may be the MTD determined in Phase 1 (or highest dose 
tested if no MTD is determined), but it may be a dose less than the MTD if this dose is determined to have a better risk-benefit profile. The RP2D cannot be greater than the MTD.
Once the RP2D has been formally established, recruiting for Phase 2 may begin immediately. In 
January 2016 the SMC determined that the RP2D is 240 mg/m
2in patients weighing > 10 kg,
and 11.5 mg/kg in patients weighing â‰¤ 10 kg.
8.2.2. Phase 2: Dose Expansion
The Phase 2 portion of the study will be condu cted at the established RP2D (as described in 
Section [IP_ADDRESS] ) at the same schedule as in the Phase 1 portion.  
8.2.3. Treatment Modification
Treatment modifications are applicable during the Ph ase 1 and Phase 2 portions of the study, 
except that dose reductions during Phase 1 Cycle 1 are not permitted as noted below.
[IP_ADDRESS]. Body Surface Area or Weight Changes
If the patientâ€™s BSA (or weight for patients â‰¤10 kg) has changed by â‰¥ 10% from the last value 
used for dose calculations, then the patientâ€™s dos e should be recalculated with the new value. 
Otherwise, dose adjustments should be based on actual body weight/BSA and follow 
institutional guidelines.
[IP_ADDRESS]. Treatment Delay
IP administration should occur within a Â± 2 day administrative window of the scheduled day of 
dosing. IP may be delayed for other reasons based on the guideline below. If Day 8 or Day 15 
treatment is delayed â‰¤ 4 days, the treatment may be administered and the 28 days cycle continues 
per protocol. If the investigator suspects a drug related toxicity, an unscheduled visit with 
additional laboratory assessments may be pe rformed. When treatment (either Day 1, 8, or 15) is 
consecutively delayed for two or more cycles, dos e reduction should be c onsidered.  Patients 
experiencing IP-related toxicities that require a delay  in scheduled dosing of IP for > 21 days will 
be discontinued from further participation in this  study (except if day 22 falls on a weekend or 
holiday, in which case IP may be administered the next business day).
Day 1 Treatment Delay
If the treatment to be given on Day 1 is delayed, the 28-day cycle will not be considered to start 
until the day IP is actually administered to the patient. 
Day 8 Treatment Delay
If the treatment to be given on Day 8 is held for â‰¤ 4 days, the treatment may be administered and 
the 28-day cycle continues per protocol. If Day 8 treatment is delayed > 4 days, the treatment will be considered as missed and will not be made up.
CCIribed in ribed in 
portiporti ons ofons 
as noted bas noted b
anged by [CONTACT_778561] â‰¥
d be rebe re calcalcu
al bodyal body weweyy
22daydayadmadmyy
easons baseeasons base
reatment matment m
suspects a dsuspects a 
ments mayments may bby
[CONTACT_778562]
m further pafurther p
case IP macase IP ma
mentment DelayDelay
tmment to bent to b
he day IP ishe day IP is
ay 8 Treatay 8 Treat
If f thte tretr
e2 828
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069459]-001 Amendment 5.0 Final: 13 Jul 2016Day 15 Treatment Delay
If the treatment to be given on Day 15 is held for â‰¤ 4 days, the treatment may be administered 
and the 28-day cycle continues per protocol. If Da y 15 treatment is delayed > [ADDRESS_1069460].  The next dose (if counts and chemistries permit) becomes Day [ADDRESS_1069461] had a 21-day cycle.  The subsequent cycle 
resumes the scheduled 28-day cycle.
[IP_ADDRESS]. Missed Treatment
A missed Day 8 or Day 15 treatment is defined as IP not administered within â‰¤ 4 days of the 
expected dose day and should be entered in the CRF as a missed dose. If the investigator 
suspects drug-related toxicity, an unscheduled visi t with additional laboratory tests may be 
performed.
Patients with a missed treatment during the DLT assessment period in  the Phase 1 portion of the 
study are not eligible for the DDS (as defined in Section 10.2) and will be replaced at the 
discretion of the sponsor.
[IP_ADDRESS]. Dose Adjustment
For the Phase 1 portion of the study, dose ad justments are not permitted during Cycle 1 (and 
during Cycle 2 for patients â‰¤ 10 kg). 
Starting with Cycle [ADDRESS_1069462] not be increased to the previous level. If a patient experiences a severe 
hypersensitivity reaction, nab-paclitaxel should be permanently discontinued and the patient 
should not be rechallenged.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e 
ayay b by[CONTACT_233300] e 
see1 porti1 porti ono
eplaced at eplaced at 
permitted dpermitt
yy or any or anyyy titiyymm
atologic andtologic a
made accordmade acco
ing the NCng the NC
uced by [CONTACT_778563]. If rmitted. I
r treatment treatme
to the previo the previ
paclitaxel saclitaxel s
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069463]-001 Amendment 5.0 Final: 13 Jul 2016Table 8: Hematologic Toxicity: Recommended Dose Reductions
Adverse Event/ Criteria Occurrence Actiona
Neutropenic fever (with 
confirmed bacterial infection)
ORNeutropenia Grade [ADDRESS_1069464] occurrence Dose reduction to the next lower level for 
subsequent cycles once ANC is â‰¥1000 cells/mm
3.
2nd occurrence Dose reduction to the next lower level for 
subsequent cycles once ANC is â‰¥1000 cells/mm3.
3rd occurrence Discontinue treatment
Thrombocytopenia Grade 4 that 
persists > 7 days or requires 
transfusion > [ADDRESS_1069465] occurrence Dose reduction to next lower level; initiation of next 
cycle is delayed until platelet count is 80,000 
cells/mm3.
For Phase 2 patients with known bone marrow 
involvement, initiation of next cycle is delayed until 
platelet count is 50,000 cells/mm3.
2nd occurrence Discontinue treatment
ANC =  absolute neutrophil count.
aFor the Phase 1 portion of the study, dose adjustments are not permitted during Cycle 1. Patients with bone 
marrow disease should not be considered for dose reduction if the AE is related to the disease.
Table 9: Nonhematologic Toxicity: Recommended Dose Reductions
Adverse Event Occurrence Actiona
Grade [ADDRESS_1069466] occurrence Interrupt treatment until toxicity improves to â‰¤ Grade 
1. When treatment is resumed, reduce by [ADDRESS_1069467] occurrence Discontinue treatment
CCI&(Any otheAny oth
nhe&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7n of next of next
,000 000 
bone marrowbone marrow
cycle is delacycle is del
/mm/mm3.$7$7$7
)21) ng Cycle 1. Pg Cycle 1. P
lated to the dated t
ed Dose Red Dose R
7$ nterrupt treanterrupt trea
1. When t1. When t(75enceence DiscD55535currencecurrence23333
2nd occ2nd oc3533rdrd33(3oxicityoxicity1((((
is or diarrhis or diarr(1
rade 4 mucrade 4 muc(/&(
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069468]-001 Amendment 5.0 Final: 13 Jul 2016aFor the Phase 1 portion of the study, dose adjustments are not permitted during Cycle 1.
bNeuropathy should be followed as described in Section [IP_ADDRESS] .
cCutaneous toxicity should be considered for dose reductions only if clinically indicated, at the discretion of the 
investigator.
dThe degree of adverse event resolution depends upon the t ype of nonhematologic toxicity seen and the course that 
is chosen to be medically most sound in the judgment of the physician investigator.
[IP_ADDRESS]. Intrapatient Dose Escalation
Intrapatient dose escalation beyond the dose initially assigned to a patient is not permitted during 
Cycle 1 (or anytime in the Phase 2 portion). Once a patientâ€™s dose has been reduced, it must not 
be increased to the previous level.
During the Phase [ADDRESS_1069469] one 
cohort of other patients in this study. In these instances, additional PK evaluation at the higher dose level may be conducted.
8.2.4. Overdose
On a per dose basis, an overdose of nab-paclitaxel is defined as 10% over the protocol-specified 
dose of IP assigned to a given patient, regardless of any associated adverse events or sequelae. 
On a schedule or frequency basis, an overdose is defined as anything more frequent than the protocol required schedule or frequency. On an infus ion rate basis, an overdose is defined as any 
rate faster than the protocol-specified rate. For nab-paclitaxel, an infusion completed in less than 
25 minutes may increase C
maxby [CONTACT_3450] 20% which is the threshold for clinical 
relevancy.  For infusions completed between 25 and 30 minutes, there is no clinical significance.
Anab-paclitaxel infusion completed in less than 25 mi nutes will therefore meet the infusion rate 
criterion for an overdose.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentio nal, should be re ported in the case report form.  See Section 
11.1 for the reporting of adverse events associated with overdose.
8.3. Method of Treatment Assignment
In the Phase 1 portion of the study, patients will be  assigned to a dose level using the Integrated 
Response Technology (IRT). The investigator or designee (eg, subinvestigator, study 
coordinator) will register the patient in the IR T system. Upon confirmation of eligibility, the 
patient will enrolled into the current dose level in the IRT system. If there is no availability 
within the current cohort, the CRP/CRS will permit enrollment via IRT at the last dose level 
evaluated as safe by [CONTACT_4484]. The date of the next SMC meeting, after which patients may be screened for the next cohort, will be provided to the investigator.
In the Phase 2 portion of the study, patients w ill be included in one of three indication-based 
groups as described in Inclusion criterion 2.b. Patients will be registered in IRT and upon 
confirmation of eligibility, enrolled to one of the three groups. Enrollment for each group w ill 
remain open according to a Simon two-stage design as described in Section 10.3. One or more 
groups may be closed while one or more groups remain open for enrollment.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ng ng 
t not not 
who have who have 
evelveliillncreancre
y at least onat least o
atatioion at then at th
10% over 10% 
ciciated adveated adv
as anyas any ththyyyingi
n rate basisn rate basi
paclitaxel, paclitaxel
20%20% whichwhich
[ADDRESS_1069470]
lologygy(IRT)(IRTyy
will registerll registe
enrolled inenrolled in
he current che current 
ated as safeated as sa
reened for teened for t
In the n the PhPh
oupup
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069471]-001 Amendment 5.0 Final: 13 Jul [ZIP_CODE].4. Packaging and Labeling
The label(s) for IP will include sponsor name, address, and telephone number, the protocol 
number, IP name, dosage form and strength (where applicable), amount of IP per container, lot 
number, expi[INVESTIGATOR_5695] (where applicable), medication identification/kit number, dosing 
instructions, storage conditions, and required caution statements and/or re gulatory statements as 
applicable. Additional information may be included on the label as applicable per local 
regulations.
8.5. Investigational Product Accountability and Disposal
Celgene (or designee) will review with the inve stigator and relevant site personnel the process 
for Investigational Product return, disposal, and/or destruction including responsibilities for the 
site vs Celgene (or designee).
Only completely unused IP vials should be retained by [CONTACT_15944] a representative from 
Celgene or other Celgene-designated personnel have  completed an inventory. Partially used and 
completely used vials should be destroyed according to local guidelines, and disposition should 
be recorded on the Investigational Drug Accountability Record Form.
The investigator, or designee, shall record the dispensing of IP to patients in the IP accountability 
record. The IP record will be made available to Celgene, or other authorized Celgene-designated 
monitoring personnel, for the purpose of accounting for the IP supply. Inspections of the IP supply for inventory purposes and assurance of proper storage will be conducted as necessary. 
Any significant discrepancy will be recorded and reported to Celgene or its designee and a plan 
for resolution will be documented.
Investigational product will not be loaned or dispensed by [CONTACT_778564].
8.6. Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the patientâ€™s CRF and source documents. The investigator or designee is responsible for accounting 
for all study-specific IP both administered or in their custody during the course of the study.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21process process 
tties for theies for the
ntative fromntative from
oryry. Parti. Parti allall
s, and dispo, and dis
.
o patipatents insi
ther authorther autho
e IP supplyIP suppl
storage willtorage wi
ported to Ceorted to 
dispensed bdispensed b
ucuct Compt Com
ministration inistration
uments. Thuments. Th
th administh adminis
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069472]-001 Amendment 5.0 Final: [ADDRESS_1069473] its 
metabolism, pharmacokinetics, or excretion, please see the nab-paclitaxel (ABRAXANE) local 
package insert.
9.1. Permitted Concomitant Medications and Procedures
Erythropoietin may be administered at the discr etion of the investigator, consistent with 
institutional guidelines. Granulocyte colony-stimulating factors may not be given during the DLT assessment period, but subsequently may be given according to institutional guidelines for 
the treatment of neutropenic fever or infections associated with neutropenia and for the 
prevention of febrile neutropenia in patients with an ANC < 500 cells/ Î¼L.
9.2. Prohibited Concomitant Medications and Procedures
Granulocyte colony-stimulating factors may not be given during the DLT assessment period.
Radiotherapy is not allowed during the study, except for palliative purposes for nontarget 
lesions. Surgical intervention as anticancer therapy during Cycle 1 will require the patient to 
discontinue from study treatment. Minor surgical intervention in subsequent cycles will be 
assessed on a case by [CONTACT_778565]. 
Although patients with neuroblastoma will be assessed for response using 123I-MIBG scans, 
administration of 131I-MIBG therapy (eg, for neuroblastoma treatment) is prohibited.  
Administration of other chemotherapy, immunotherapy, antitumor hormonal therapy, 
investigational therapy, or other anticancer  therapy during the study is not allowed. 
Administration of Coumadin or coumarin derivatives is not allowed during this study; low-
molecular weight heparin should be used instead. 
The potential drug-drug interaction precautions contained in the nab-paclitaxel prescribing 
information will be applied to this study (refer to the local prescribing information). Specifically, 
the metabolism of paclitaxel  is catalyzed by [CONTACT_9058] P [ADDRESS_1069474] dose of IP until 
permanent discontinuation. Such medications include but are not limited to: 
!Strong inducers of CYP3A4: avasimibe, carbamazepi[INVESTIGATOR_050], phenytoin, rifampin, and St. 
Johnâ€™s wort.
Strong inhibitors of CYP3A4 and CYP2C8 should be avoided whenever possible from the first 
dose of IP until permanent discontinuation. If possible, patients should be switched to other 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21E) local local 
nsistent witnsistent wi
be given de give
instinstititututioionana
utropenia autropenia 
0 cells/Î¼L.  cells
and Procand Pro
ven duringven during
cept for palept for pa
rapy duringrapy durin
rgirgicalcal inter interl
cussicussi on wion 
ma will be ama will be
apy (apy ( eg, eg, fofo
motherapymotherapy ,ii
other antither anti cc
mmadin or cadin or c
eparin shoueparin shou
rugrug-drug indrug
will be appwill be app
olism oism o f f p
ng inducers g inducer
rmrmanent dianent di
!
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069475]-001 Amendment 5.0 Final: 13 Jul 2016medications for the comorbidity prior to starti ng IP. Such medications include but are not 
limited to:
!Strong inhibitors of CYP2C8: gemfibrozil
!Strong inhibitors of CYP3A4: boceprevir, clarithromycin, conivaptan, grapefruit 
juice, itraconazole, ketoconazole, lopi [INVESTIGATOR_054]/ritonavir, mibefradil, nefazodone, 
posaconazole, telaprevir, telithromycin, and voriconazole.
Caution is recommended when administering nab-paclitaxel concomitantly with any substrates 
or inhibitors of the cytochrome P450 isozymes CYP2C8 and CYP3A4. Similarly, drugs, herbal 
preparations, and/or dietary supplements known to  influence the expression of CYP3A (eg, 
garlic supplements) and/or CYP2C8 should be used with caution (see www.drug 
interactions.com for a regularly updated list of drug interactions with cytochrome P450 isozymes). 
Please check the prescribing information of the concomitant medication for full information on 
the CYP interaction potential.
Patients and parent(s)/guardian(s) must be made aware that the following medications are not 
allowed to be taken concomitantly with nab-paclitaxel: ritonavir, saquinavir, indinavir, 
nelfinavir, or investigational drug(s) other than described as a treatment regimen in this study.
9.3. Required Concomitant Medications and Procedures
Not applicable.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21rbalbal
eg, g, 
450 450 
full informull informfff
wing medicing medic
saquinavir,aquinavir
reatment reeatme
and Procend Proce
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069476]-001 Amendment 5.0 Final: 13 Jul 201610. STATISTICAL ANALYSES
10.1. Overview
The Phase 1 portion uses a rolling-6 patient dos e escalation design to establish the MTD/RP2D,
and the Phase 2 portion us es a Simon two-stage minimax design to monitor p atient enrollment 
for each group sepa rately.
Statistical analyses will be performed by [CONTACT_45968], dose level, and tumor group as needed or 
applicable. 
10.2. Study Population Definitions
The study population definitions are as follows:
!Enrolled Population â€“ All patients enrolled; ie, all patients who are marked as 
enrolled in the clinical database regardless of whether they have received IP.
!Safety Population â€“ All patients who take at least one dose of IP
!Efficacy Evaluable (EE) Population â€“ All treated patients who meet eligibility 
criteria, complete at least one dose of invest igational product, and have baseline and 
at least one postbaseline efficacy assessment if having not discontinued the investigational product prior to postbaseline efficacy assessment due to disease 
progression or symptomatic deterioration. Here efficacy assessment means 
radiological assessment of the tumor or tumor assessment by [CONTACT_778566].Investigational product discontinuation due  to disease progression or symptomatic 
deterioration must be documented as the primary reason for treatment discontinuation 
in the treatment discontinuation CRF.
!Dose Determining Set (DDS ) â€“ The primary endpoint for the Phase 1 portion of the 
study, determination of the MTD/RP2D, will be performed on the DDS. In patients 
weighing > 10 kg, the DDS includes all patients  who experienced a DLT, or received 
all 3 weekly doses of nab-paclitaxel at the cohort planned dose during Cycle 1 and 
had adequate safety assessments during the DLT assessment period (Cycle 1 
including predose assessments on Cycle 2 Day 1). In patients weighing â‰¤ 10 kg, the 
DDS includes all patients who experienced a DLT, or received all 6 weekly doses of 
nab-paclitaxel at the cohort planned doses during Cycles 1 and 2 and had adequate 
safety assessments during the DLT assessment period (Cycle 1 and 2 including predose assessments on Cycle 3 Day 1).
!Pharmacokinetic Population â€“ The pharmacokinetic population includes all patients 
who received at least 1 dose of nab-paclitaxel and had evaluable concentration data.
10.3. Sample Size and Power Considerations
During the Phase 1 portion, a rolling-6 patient dose escalation design will be used to establish the 
MTD/RP2D, and up to approximately  24 patients will be enro lled into the DDSs, depending on 
the number of dose levels evaluated. Patients who are ineligible for the DDS in a given cohort 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d or or 
o are markeo are mark
ave receiveve rece
ose of e of IPIP
patiatientens wh
nalnal producprodull
having nohaving no
e efe eficacyficacyf aayy
n. Here effi. Here ef
or tumr tum or asor a
tioion due ton due to
ed as the prd as the p
on CRF.on CRF.
DDSDDS ))â€“ThT
of the f the MTDMTD
the DDSthe DDS ini
ses of es of nabnab
 safetsa y yasseas
predose aspredose a
ncludes all pcludes all 
paclitaxel paclitaxel 
afetafety yassessasses
predose apredose a
!!Pharha
ww
[IP_ADDRESS].
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069477]-001 Amendment 5.0 Final: 13 Jul 2016will be replaced at the discretion of the spons or, and additional non-DDS patients may be 
enrolled at dose levels evaluated as safe by [CONTACT_4484].  A minimum of 12 patients will be treated 
in the Phase 1 portion of the study, regardless of the number of dose levels tested.
In the Phase 2 portion, up to 69 additional efficacy evaluable patients ( â‰¤ 23 patients in each of 
the 3 groups) will be enrolled at the RP2D determined in the Phase [ADDRESS_1069478] stage, 14 efficacy evaluable patients will be enrolled. If < 2
of the 14 patients has a response, the enrollment for this gr oup will be stopped upon 
determination of the number of responders. If â‰¥ [ADDRESS_1069479] a response, the 
enrollment will continue until 23 efficacy evaluable patients are enrolled. At the final analysis, 
the regimen will be concluded with more than a 5% true response rate if â‰¥ [ADDRESS_1069480] a 
response. The acceptance rate for the second stage will be 21.74% response rate, at 80% power 
and 10% significance having fixed the lower and upper boundaries to 10% and 28%, 
respectively. The response rate in the Phase [ADDRESS_1069481] and the MIBG/Curie score.
A minimum of 14 patients will be treated in each tumor group.
10.4. Demographic and Baseline Characteristics
In the Phase 1 portion of the study, the baseline characteristics of patients will be summarized by 
[CONTACT_778567]. In th e Phase 2 portion of the study, 
the baseline characteristics of patients will be summarized by [CONTACT_778568]. The age, wei ght, height, and other continuous demographic 
and baseline variables will be summarized using descriptive statistics (sample size, mean, 
standard deviation, median, minimum, and maximum). Lansky/Karnofsky performance status, 
gender, race, and other categorical variables will be summarized with frequency tabulations. Medical history data will be summarized using fre quency tabulations by [CONTACT_39812].
10.5. Patient Disposition
Patient disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percentage.  A listing of 
patients with protocol violations or protocol deviations will be provided.
10.6. Efficacy Analysis
Efficacy endpoints will be analyzed for both th e safety population and the efficacy evaluable 
population. Efficacy will be analyzed by [CONTACT_778569]. The efficacy variable of primary interest is overall response rate (ORR). Tumor response will be based on RECIST 1.1 and will be assessed by [CONTACT_1188]. Patients 
with neuroblastoma additionally will be asse ssed for MIBG response using the Curie score 
(Phase 2 only). For patients in the neuroblastoma group, ORR will be based on either the RECIST criteria or the Curie score, or both, wit hout crossover between assessment types over 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21If If < 22
e, the , the
final analyfinal analy
f 23 pati23 patif enen
e rate, ate rate, at 8080
0% and 28%% and 2
will be deterill be dete
p.
eristicsristics
racteristracteri icics
opulatopulat ionn
summarizesummarize
, weiweight, heght, h
ed using deed using 
mm,,and mand m axi
variables wvariables w
mmarized ummarized u
Dispositionispositio
(analysis p(analysis p
ntntinuatinuat ion)
protocolprotocol vvll
EfficaEffica
ficacy endpcacy endp
populpopu atatioionn
omompletplemm
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069482]-001 Amendment 5.0 Final: [ADDRESS_1069483], and additionally 
for neuroblastoma using MIBG/Curie score as  applicable, will be provided. A descriptive 
analysis of other evidence of antitumor activity will be provided based on clinical, radiographic, and biologic assessments of efficacy. If there are sufficient data, Kaplan-Meier estimates will be 
provided for duration of response, PFS, and 1-year survival. 
Data listings will be provided for all relevant data collected during the study.Full details of the efficacy analysis will be given in the statist ical analysis plan (SAP).
10.7. Safety Analysis
All patients in the Safety population will be include d in the safety analyses. Adverse events, vital 
sign measurements, physical examination findings, clinical laboratory information, ECG, L VSF 
assessment, Lansky/Karnofsky  performance status, and concomitant medications and procedures 
will be tabulated and summarized by [CONTACT_45968] (Phase 1 or 2 portion), dose level, and tumor 
group, as appropriate.
During the Phase 1 DLT assessment period, DLTs and all available safety data will be reviewed 
on an ongoing basis by [CONTACT_778570]. 
Adverse events observed during both Phase 1 and Phase 2 will be coded using the MedDRA 
classification system. The severity of the AEs will be graded according to the NCI CTCAE
version 4.0 whenever possible. 
Adverse events will be analyzed in terms of treatment-emergent AEs. Treatment-emergent 
adverse events (TEAEs) are defined as any AEs that begin or worsen in grade after the start of IP 
through [ADDRESS_1069484] dose of IP.
The frequency of AEs will be tabulated by [CONTACT_61121]. In 
the by-patient analysis, a patient reporting the same event more than once will be counted only 
once. Adverse events will also be summarized by [CONTACT_210079]. If a patient reports the same AE more than once, the event with the maximum grade will be tabulated in â€œby [CONTACT_479]â€ 
tables. The incidence of serious adverse events (SAEs) and AEs that lead to dose reduction, drug 
interruption, or discontinuation of study drug will  be summarized. Adverse events of special 
interest based on the Risk Management Plan will also be summarized. Listings of patients who 
discontinued study drug due to an AE, patients with SAEs, and deaths will be presented. 
Clinical laboratory data will be summarized. Laboratory data will be graded according to NCI 
CTCAE version 4.[ADDRESS_1069485] severity grade 
observed during treatment will be displayed in cross-tabulations by [CONTACT_778571]. 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21aphic, aphic, 
s will be will be
an (an (SAPSAP))
analyses. Aanalyses. 
oratoryratory iynfo
omitant momitant m
[ADDRESS_1069486] based
didiscontinuscontinu
linicalinica
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069487]-001 Amendment 5.0 Final: [ADDRESS_1069488]-IP initiation.
Performance status by [CONTACT_778572]. 
Graphical displays will be provided where useful in the interpretation of results.
Full details of the safety analysis will be given in the SAP.
10.8. Interim Analysis
During the Phase 2 portion of the study, a Simon two-stage minimax design will be used to 
monitor patient enrollme nt and tumor response rate for each group separately, as described in 
Section 10.3.
10.9. Other Topi[INVESTIGATOR_1102]
10.9.1. Pharmacokinetic Analysis
Pharmacokinetic data from patients in the Phase 1  and 2 portion of the study will be analyzed 
together.
Noncompartmental PK analysis will be performed using the blood concentration versus time data 
obtained from patients participating in dense PK sampling to estimate C max, AUC, clearance 
(CL), volume of distribution at the steady state (Vss), and half-life (t 1/2). If data allow, main PK 
parameters (CL and Vss) will be summarized by [CONTACT_483031] (eg, < 2 years, 2 to < 6 
years, 6 to < 12 years, and 12 to â‰¤ 24 years).  
Population PK analysis will be performed using nonlinear mixed effect modeling. Concentration 
data obtained from both dense and sparse PK sampling will be combined to develop the 
population PK model. Effect of age and body size on nab-paclitaxel PK will be assessed. Other 
relevant covariates for the main PK parameters will also be identified. The between-patientvariability for PK parameters will be estimate d, as appropriate. The relationship between 
systemic drug exposure and selected efficacy and toxicity endpoints may be explored.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d to o 
cribed in ribed in 
the studythe study wy
e blood conblood con
ng to estimag to estim
and haand ha lf-lf-lifli
gegegroup asgroup as
sing nonlinsing nonlin
e PK sampl PK sampl
nd bodynd body sizy
K parameterparamete
lll b blle estimae estim
elected effielected eff
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069489]-001 Amendment 5.0 Final: 13 Jul 201611. ADVERSE EVENTS
11.1. Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a patient during the course of a study. It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or any concomitant impairment of the patientâ€™s h ealth, 
including laboratory test values (as specified by [CONTACT_65801]), regardless of etiology. Any worsening (ie, any clinically significant adverse ch ange in the frequency or intensity of a pre-
existing condition) should be considered an AE.  A diagnosis or syndrome, rather than the 
individual signs or symptoms of the diagnosis or syndrome, should be recorded on the AE page of the CRF. 
Clinically significant signs and symptoms associated with disease progression are expected to be 
reported as AEs; however, study indication progre ssive disease (PD) that is asymptomatic or 
solely documented radiographically per RECIST 1.1/MIBG does not require reporting as an AE.
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If an overdose is associated with an AE, the overdose and adverse event should be reported as 
separate terms. See Section 8.2.4 for the definition of overdose.  In the event of overdose, the 
patient should be monitored as appropriate and s hould receive supportive measures as necessary. 
There is no known specific antidote for nab-paclitaxel overdose. Actual tr eatment should depend 
on the severity of the clinical situation and the j udgment and experience of the treating physician.
All patients will be monitored for AEs during the study.  Assessments may include monitoring of 
any or all of the following parameters:  the patientâ€™s clinical symptoms, laboratory, pathological, 
radiological or surgical findings, physical examination findings, or other appropriate tests and 
procedures.
All AEs and serious adverse events (SAEs) will be recorded by [CONTACT_778573]/guardian/patient signs the informed consent/assent document (if applicable) to [ADDRESS_1069490] dose of IP and during the EOT vi sit.  Serious adverse events made known to the 
investigator at any time thereafter that are suspected of being related to IP will also be recorded.  
AEs and SAEs will be recorded on the AE page of the CRF and in the patientâ€™s source 
documents.  All SAEs must be reported to Celgene Drug Safety within 24 hours of the investigatorâ€™s knowledge of the event by [CONTACT_6972], or other appropriate method, using the SAE 
Report Form, or approved equivalent form.
11.2. Evaluation of Adverse Events
A qualified investigator will evaluate all adverse events as to: 
11.2.1. Seriousness 
A SAE is any AE occurring at any dose that:
!Results in death
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ny
re--
he 
he AE pagehe AE page
n are expectre expec
s asymptomasymptom
quire reportire rep
d wiwiththii an Aan Ahh
hould be reuld be r
se event shse event 
dose. In those. In th e
eceive suppeceive sup
l overdosel overdose
gmgment and ent and 
the studythe study
patipatiententâ€™s câ€™s c
al examinatal examin
nts (SAEs)nts (SAEs)
he einformeinform
d during theduring th
thereafter tthereafter
e recorded e recorde
AEs must bAEs must b
nowlnowl edge oedge o
, or approv, or approv
EvaluEvalu
qualified ualified inin
[IP_ADDRESS].2.1.
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069491]-001 Amendment 5.0 Final: 13 Jul 2016!Is life-threatening (ie, in the opi[INVESTIGATOR_1072], the patient i s at immediate 
risk of death from the AE)
!Requires inpatient hospi[INVESTIGATOR_27588] 
(hospi[INVESTIGATOR_19357], regardless of length of stay)
!Results in persistent or significant disabilit y/incapacity (a substantial disruption of the 
patientâ€™s ability to conduct normal life functions)
!Is a congenital anomaly/birth defect
!Constitutes an important medical event.
Important medical events are defined as thos e occurrences that may not be immediately life 
threatening or result in death, hospi[INVESTIGATOR_059], or disability, but may jeopardize the patient or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]:
!A standard procedure for protocol therapy administration.  However, hospi[INVESTIGATOR_72612] a complication of therapy administration will be 
reported as an SAE. 
!Routine treatment or monitoring of the studi ed indication not associated with any 
deterioration in condition.
!The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospi[INVESTIGATOR_5186] n or prolonged hospi [INVESTIGATOR_272] a comp lication 
of such transfusion remains a reportable SAE.
!A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospi[INVESTIGATOR_778533] a co mplication of such procedures 
remains a reportable SAE.
!Hospi[INVESTIGATOR_27591], practical, or social 
reasons, in absence of an AE.
!A procedure that is planned (ie, planned prior to starting of treatment on study); must 
be documented in the source document and the CRF.  Hospi[INVESTIGATOR_27589] a complication remains a reportable SAE.
!An elective treatment of a pre-existing condition unrelated to the studied indication. 
!Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE form/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21yylife life yy
patientpatient or or 
ted above.  ted above. 
h an AE shh an AE sh
on.  Howevn.  Howe
herapy admerapy 
ed indicatiindicat
et transfusiot transfusi
oon or prolon or prolo
eportable SAortable S
iseaseease--relrelatat
r llaboratoryaborator
ongedonged hoshos
le SAE.le SAE.
n or prolonn or pro
absence of absence of
edure that iedure that i
ocumocum entedented
ospi[INVESTIGATOR_778534]
!!EmEm
f an AEf an A
t
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069492]-001 Amendment 5.0 Final: 13 Jul 201611.2.2. Severity / Intensity
For both AEs and SAEs, the investigator must assess the severity / intensity of the event. 
The severity / intensity of AEs will be grade d based upon the patientâ€™s symptoms according to 
the current active minor version of the NCI CTCAE, Version 4.0.
AEs that are not defined in the NCI CTCAE should be evaluated for severity / intensity
according to the following scale:
!Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe â€“ marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospi[INVESTIGATOR_27594]
!Grade 4 = Life threatening â€“ extreme limita tion in activity, significant assistance 
required; significant medical intervention/therapy required, hospi[INVESTIGATOR_380725]
!Grade 5 = Death - the event results in death
The term â€œsevereâ€ is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is notthe same as â€œseriousâ€ which is 
based on patient/event outcome or action criteria associated with events that pose a threat to a 
patientâ€™s life or functioning.  
Seriousness, not severity, serves as a gui de for defining regulatory obligations.
11.2.3. Causality 
The investigator must determine the relations hip between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: Means a causal relationship of the adverse event to IP 
administration is unlikely or remote , or other medications, 
therapeutic interventions, or underlying conditions provide a sufficient explanation for the observed event
Suspected: Means there is a reasonable possibility that the administration 
of IP caused the adverse event.  â€˜Reasonable possibilityâ€™ means there is evidence to suggest a causal relationship between the IP 
and the adverse event
If an event is assessed as suspected of being related to an ancillar y treatment that has not been 
manufactured or provided by [CONTACT_27718], please provide the name [CONTACT_778597].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21nce mayce may bby[CONTACT_778574]
d, hospi, hospi [INVESTIGATOR_778535]
f a specificf a specific
ver, may bever, may b
n n is is notnottht
associaassoc ted ed
e ffor definior definifff
the relatthe relat ioio
Not SuspecNot Suspe
Means a Means 
adminadm
ththe
spected:ected:
fa n  e vfa ne v
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069493]-001 Amendment 5.0 Final: [ADDRESS_1069494] of the start and stop dates of the 
event.
11.2.5. Action Taken
The investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation or reduction of IP, as  appropriate) and report if concomitant and/or 
additional treatments were  given for the event. 
11.2.6. Outcome
The investigator will report the outcome for both AEs and SAEs. All SAEs that have not 
resolved upon discontinuation of the patientâ€™s participation in the study must be followed until 
recovered, recovered with sequelae, not recovered, or death (due to the SAE). 
11.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study;
!requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a part of a diagnosis or syndrome, then the laborat ory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be r ecorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thro mbocytopenia rather than decreased platelets).
11.4. Pregnancy
All pregnancies or suspected pregnancies occurring in either a female patient or partner of a male 
patient are immediately reportable events.
11.4.1. Females of Childbearing Potential
For the purposes of this study, a female patient is considered of childbearing potential if she is â‰¥ 
[ADDRESS_1069495].
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female patient occurring while the patient is on IP, within 28 days of the 
patientâ€™s last dose of IP, or at the EOT visit are considered immediately reportable events.  IP is 
to be discontinued immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test 
must be reported to Celgene Drug Safety immediately by [CONTACT_6972], or other appropriate method, 
using the Pregnancy Initial Report Form, or approved equivalent form.  
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e not e not 
ollolowed unwed un
mmalialitytyiii::
IP dose, or P dose, or
ortance.ortance.
ormormalialtiies es
vent. ent. 
nent of a dinent of a di
e AE page/sAE page/
n the ln the l aborabo
iitytyii shshyyoulouldd
g, record thrg, record th
yy
uspected pspected p
diately repodiately rep
Females ofFemales of
purposes opurposes o
ears old or ears old or
PregnanciePregnancie
didisease ssease
ien
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069496]-001 Amendment 5.0 Final: [ADDRESS_1069497] (not necessarily one with 
reproductive toxicity experience) or another appropriate healthcare professional for further 
evaluation.
The investigator will follow the female patient until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow- up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous or therapeutic abortion), the 
investigator should report the abnormal outcome as  an AE.  If the abnormal outcome meets any 
of the serious criteria, it must be reported as  an SAE to Celgene Drug Safety by [CONTACT_6972], or 
other appropriate method, within 24 hours of the investigatorâ€™s knowledge of the event using the SAE Report Form, or approved equivalent form.
All neonatal deaths that occur within [ADDRESS_1069498] to 
causality, as SAEs.  In addition, any infant d eath after 28 days that the investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
[CONTACT_6972], or other appropriate method, within 24 hours of the investigatorâ€™s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2. Male Patients
If a female partner of a male patient taking investigational product becomes pregnant, the male 
patient taking IP should notify the investigator, and the pregnant female partner should be advised to call their healthcare provider immediately.
11.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in addition to being recorded on the AE form/screen of the CRF.  All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the investigatorâ€™s knowledge of the event by [CONTACT_6972], 
or other appropriate method, using the SAE Report Form, or approved equivalent form.  This instruction pertains to initial SAE report s as well as any follow-up reports.
The investigator is required to ensure that the data on these forms are accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study (from the time the parent/guardian/patient signs i nformed cons ent/assent form (if applicable) to
[ADDRESS_1069499] dose of IP and at the EOT vi sit), and those made known to the investigator 
at anytime thereafter that are suspected of being related to IP.  SAEs occurring prior to IP administration (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include summaries of 
hospi[INVESTIGATOR_27598].  If a patient died and an autopsy has been performed, copi[INVESTIGATOR_27599] d eath certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by [CONTACT_19666], the investigator is responsible for informing the Institutional 
Review Board/ Ethics Committee (IRB/EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event. The investigator must keep copi[INVESTIGATOR_184609]/EC.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ny y
or 
using the using the
t regard to t regard to
gator suspegator susp
e Drug SafeDrug Safe
torâ€™s knowlrâ€™s kno
product roduct becbec
pregnant femegnant f
e EventsEvents
E requires t requires t
mm/screen o/screen ommm
of the of the iinve
the SAE Rhe SAE R
AE reports aE reports a
to ensure tto ensure
to all SAEto all SA
ent/guardiaent/guar
st dosdose of Ie of I
after that aafter that a
n (af(after siter sifff g
E report shoport sho
alal records arecords al
formormed, coed, co
SafSafetetffy yas sas s
SAE ReSAE R
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069500]-001 Amendment 5.0 Final: 13 Jul 201611.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by [CONTACT_648].
11.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events suspected of being related to nab-paclitaxel based on the Investigator Brochure.
For countries within the European Econo mic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) in accordance with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized represe ntative shall notify the investigator of the following information 
!Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (ie, S[LOCATION_003]R);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human patients including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by [CONTACT_19666], the investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s ) or significant ri sks to patients.
The investigator must keep copi[INVESTIGATOR_27601]/EC.  (See Section 15.[ADDRESS_1069501] retention 
information).
Celgene Drug Safety Contact [CONTACT_778575], pleas e refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pre gnancy Report Form Completion Guidelines.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21in accordanin accorda
and and 
atioional proal pro
uiirements.  rements.  iii
the fothe fo llolloww
his studyis study oroyy
at suggests suggest
icitity, teratoy, tera
shall notifyshall not
ficant risks icant risks
nent safetnent safet y
/EC.  (See /EC.  (See 
ormationrmation
ct it informatnformaii
es or to the s or to th
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069502]-001 Amendment 5.0 Final: 13 Jul 201612. DISCONTINUATIONS
12.1. Treatment Discontinuation
Patients who are discontinued from IP for any reason are not discontinued from the study, and 
will continue to be followed as described in Section 6.2until study discontinuation (Section 
12.2). 
The following events are considered sufficient reasons for discontinuing a patient from the IP:
!Dose-limiting toxicity
!Adverse event(s)
!Disease progression
!Symptomatic deterioration (global deterioration of h ealth s tatus without objective 
evidence of disease progression)
!Physician decision
!Withdrawal by [CONTACT_4676]
!Withdrawal by [CONTACT_7078]/guardian
!Death
!Lost to follow up
!Protocol violation
!Pregnancy
!Other (to be specified on CRF)
The reason for discontinuation s hould be recorded in the CRF and in the source documents.
The decision to discontinue a patient from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by [CONTACT_456].  However, prior to discontinuing a patient, the investigator may contact [CONTACT_198521].
12.2. Study Discontinuation
The following events are considered sufficient reasons for discontinuing a patient from the study
follow-up periods:
!Withdrawal by [CONTACT_4676]
!Withdrawal by [CONTACT_7078]/guardian
!Death
!Lost to follow up
!Protocol violation
!Other
The reason for discontinuation s hould be recorded in the CRF and in the source documents.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21PP::
itithout objehout obje
be recordee recorde d
nt from treafrom tre
ayed or refayed or ref
y contact [CONTACT_778576] c
riodsiods::
WitWhdrhdraw
!!WitWithh
!!DD
!
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069503]-001 Amendment 5.0 Final: [ADDRESS_1069504] the responsible Clinical Research 
Physician/Medical Monitor or designee by [CONTACT_27722](s) listed on the Emergency 
Contact [CONTACT_27723] (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact [CONTACT_27724] (after title page).This global Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are responsible 
for obtaining your call-back information and contact[CONTACT_81694]- call C elgene/CRO Medical 
Monitor, who will then contact [CONTACT_27726].
Note: The back-up 24-hour global emergency contact [CONTACT_292053](s) or Medical Monitor or designee for 
emergency calls. 
13.2. Emergency Identification of Investigational Products
This is an open-label study; therefore, IP will be identified on the package labeling.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21not be ot be
ted on d on 
EmergencyEmergenc
responsibleesponsible
O Medical O Medical 
onlyonly bby[CONTACT_778577] s e
or or designr or desig
nal Produnal Pro
d on the pad on the pa
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069505]-001 Amendment 5.0 Final: [ADDRESS_1069506], evaluation, and 
documentation of this study are designed to ensure  that Celgene, its authorized representative, 
and investigator abide by [CONTACT_23663] (GCP), as described in ICH Guideline E6 and in 
accordance with the general ethical principles outlined in the Declaration of Helsinki. The study will receive approval from an IRB/EC prior to commencement. The investigator will conduct all 
aspects of this study in accordance with applicable national, state, and local laws of the pertinent 
regulatory authorities.
14.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all investigators, who in turn will select their staff.
The investigator should ensure that all persons assi sting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions,including obligations of confidentiality of Celgene information. The investigator should maintain 
a list of subinvestigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The investigator is responsible for keepi[INVESTIGATOR_007] a record of all patients/parents/guardians who sign an 
informed consent/assent document and are screened  for entry into the st udy.  Patients who fail 
screening must have the reason(s) recorded in the patientâ€™s source documents.
The investigator, or a designated member of the investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve que ries and allow direct acce ss to patient r ecords (eg, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study-related charts) for source data verification.  The investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by [CONTACT_184689]) is considered Celgene confidential 
information.  Only information that is previously disclosed by [CONTACT_184690] a public registry 
website may be freely disclosed by [CONTACT_432915], or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example, on the investigatorâ€™s or their institutionâ€™s website) without express 
written approval from Celgene.  Information proposed for posting on the investigatorâ€™s or their 
institutionâ€™s website must be submitted to Celgene for review and approval, providing at least 5 business days for review.
14.3. Patient Information and Informed Consent / Assent
The investigator must obtain informed consent of a patient or legal representative (parent/guardian) prior to any study-related procedures, and where applicable assent from the 
patient.  A patient considered adult by [CONTACT_427] (eg, patients who are â‰¥ 18 years old, 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21n n 
dyy
uct all uct all 
pertinent pertinent
ical Practicical Practic
evaluate anvaluate
studyud are arey
studystudy -relaterel
atioonn. The . The i
ed persons ed person
ord of all rd of al pap
reened for eeened for e
d in the in the patipat
ber of the er of the ii
olve querieolve quer
ospi[INVESTIGATOR_198477]
d in the pron the pro
yy Celgene Celgeneyy
nfformormfff ataioionn
reely discloreely disclo
ent.  Celnt.  Cel genge
for exampleor example
approvalroval ffllrfff
utitionâ€™s webonâ€™s web
siness daysness days
[IP_ADDRESS].
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069507]-001 Amendment 5.0 Final: 13 Jul 2016emancipated minors, mature minors) must provide informed consent for him/herself.  In this 
section, it is implied that where applicable, the patient must also provide his/her assent for 
participation at the time of his/her parent/guardian consent.
Documentation that informed consent/assent occurred prior to the study patientâ€™s entry into the 
study and of the informed consent/assent process should be recorded in the study patientâ€™s source 
documents, including the date.  The original informed consent/assent document, signed and 
dated by [CONTACT_4694]â€™s parent/guard ian or patient (when  applicable) and by [CONTACT_778578]â€™s entry into the study, must be maintained 
in the investigatorâ€™s study files and a copy given to the study patientâ€™s parent/guardian or to the 
patient (when applicable).  In addition, if a protocol is amended and it impacts on the content of the informed consent, the informed consent document must be revised.  Study patients 
participating in the study when the amended protocol is implemented must be re-consented with 
the revised version of the informed consent document.  The revised informed consent document,signed and dated by [CONTACT_4694]â€™s parent/guardian/patient (when applicable) and by [CONTACT_778579], must be main tained in the investigatorâ€™s study files and a 
copy given to the study patient.  
14.4. Confidentiality
Celgene affirms the patient's (parentsâ€™/guardiansâ€™) right to protection against invasion of privacy 
and to be in compliance with ICH and other local regulations (whichever is most stringent). 
Celgene requires the investigator to permit Celgene representatives, and when necessary, representatives from regulatory aut horities, to review and/or copy any medical records relevant 
to the study in accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
patientâ€™s parent/guardian signed informed consent document, it is the responsibility of the 
investigator to obtain such permission in writing from the appropriate individual.
14.5. Protocol Amendments
Any amendment to this protocol must be approved by [CONTACT_184693]/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the investigator name, protocol number, study title, and amendment numbe r(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/EC approval but will be submitted to the IRB/EC for 
information purposes.
14.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document (assent document if 
applicable), and any other appropriate documents will be submitted to the IRB/EC with a cover 
letter or a form listing the documents submitted, their dates of issue, and the site (or region or 
area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will 
also be submitted to the authorities in accordance with local legal requirements.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d d 
the he 
ntent of ent of 
nsented winsented w
nsent nsent docudocu
ble) and by[CONTACT_778580]) and by
râ€™s studys study ffyyililfff
otection agaotection a
ns (whiches (which
resentativesresentative
w and/or copand/or c
re a waiverre a waiver
consent doconsent do
n writn writ ing ng fr
entsents
col must becol must b
r.  Amendm Amendm
be obtainedbe obtaine
valvalffllromromfff thtmm
studytudy titiyytltliie,e
in nature doin nature
purposes.purposes.
Institnstit
anan
Before theBefore th
pplicapplica
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069508]-001 Amendment 5.0 Final: [ADDRESS_1069509] of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in acc ordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by [CONTACT_1201]/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a commi ttee memb er. Before the first patient is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent/assent
document should also be revised.
The investigator must keep a record of all comm unication with the IRB/EC  and, if applicable, 
between a Coordinating Investigator [INVESTIGATOR_72616] /EC. This statement also applies to any 
communication between the investigator (or coordinating investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit patients for th e study must be reviewed by [CONTACT_27734]/EC prior to use.  
14.7. Ongoing Information for the Institutional Review Board / Ethics 
Committee
If required by [CONTACT_27735]/EC, the investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible 
!Periodic reports on the progress of the study
!Deviations from the protocol or anything th at may involve added risk to patients.
14.8. Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons. Any premature disc ontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities).
In addition, the investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment
!GCP noncompliance
!Inaccurate or incomplete data collection
!Falsification of records
!Failure to adhere to the study protocol.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e 
y, allall
t protocol t protocol
be evaluate evaluat
ed consented consent /
RB/EC andB/EC and
ment also apnt also ap
tigator, if igator
yymmust be reust be mmm
InInstitutiostitut
, the the iinvestnve
r unexpecteunexpec
he progresshe progress
the prothe pro tocoto
of the Stuf the Stu
he rihe right to ght to 
reasons. Anreasons. An
local requilocal requ
on, the the iinvnv
g the studyg the study
!!UU
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069510]-001 Amendment 5.0 Final: 13 Jul 201615. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] 
15.1. Data / Documents
The investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed, and 
retained.  Examples of source documents include: hospi[INVESTIGATOR_1097]; clinic and office charts; laboratory notes; memoranda; patientâ€™s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_27602]; microfiche; x-ray film and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copi[INVESTIGATOR_27603]-ROMs.
15.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene standard operating procedures (SOPs). This data will be electronically verified through use of 
programmed edit checks specified by [CONTACT_6098].  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all changes made to the data.
15.3. Record Retention
Essential documents must be retained by [CONTACT_249317] a minimum of [ADDRESS_1069511] retain these 
documents for the time period described above or according to local laws or requirements, whichever is longer.  Essential documents include, but are not limited to, the following:
!Signed informed consent documents for all patients (and assent documents where 
applicable)
!Patient identification code list, screen ing log (if applicable), and enrollment log
!Record of all communications between the investigator and the IRB/EC
!Composition of the IRB/EC
!Record of all communications between the investigator, Celgene, and their authorized 
representative(s)
!List of subinvestigators and other appropriately qualified persons to whom the 
investigator has delegated significant study-related duties, together with their roles in the study, curriculum vitae, and their signatures
!Copi[INVESTIGATOR_3110] (if paper) and of documentation of corrections for all patients
!IP accountability records
!Record of any body fluids or tissue samples retained
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21on as na s  
macymacy , and , and
elgene elgene stanstan
hrough use hrough us
es in the das in the da
nnel, if necnel, if nec
witithin the shin t
stigator for stigator fo
region and egion and
CH region,CH region,
pment of thpment of th
ed above ored above o
umments inclents inc
nsent docunsent docu
ificatficion con c
of all coall co mmmm
mmposiposimm titiiion oon
Record of Record of 
represenreprese
!!LisLis
i
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069512]-001 Amendment 5.0 Final: 13 Jul 2016!All other source documents (patient records , hospi[INVESTIGATOR_1097], laboratory records, etc.)
!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial)
The investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location, or is unable to retain them for a specified period.  The investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the investigator is unable to meet this obligation, the investigator must ask Celgene 
for permission to make alternative arrang ements. Details of these arrangements should be 
documented. 
All study documents should be made availabl e if required by [CONTACT_27737]. 
Investigator/instituti on should take measures to prevent accidental or premature destruction of 
these documents.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21s. s. 
struction oftruction of
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069513]-001 Amendment 5.0 Final: [ADDRESS_1069514] 
operating procedures.
16.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during, and after 
the study.  All aspects of the study are reviewed  with the investigator and the staff at a study 
initiation visit and/or at an investigator meeting.  Prior to enrolling patients into the study, a 
Celgene representative will review the protoc ol, CRFs, procedures for obtaining informed 
consent/assent, record keepi[INVESTIGATOR_007], and reporting of AEs/SAEs with the investigator.  Monitoring 
will include on-site visits with the investigator and his/her staff as well as any appropriate 
communications by [CONTACT_2319], email, fax, or telephone.  During monitoring visits, the facilities, investigational product storage area, CRFs, patientâ€™s source documents, and all other study
documentation will be inspected/reviewed by [CONTACT_292060].
Accuracy will be checked by [CONTACT_778581] d ata verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the investigator and/or his/her staff.  Any necessary corrections will be made directly to the CRFs or via queries by [CONTACT_1755]/or his/her 
staff. Monitoring procedures require that informed consents/assents, adherence to 
inclusion/exclusion criteria, and documentation of SAEs and their proper recording be verified.  
Additional monitoring activities may be outlin ed in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accorda nce with Celgene SOPs to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The investigator is required to permit direct acce ss to the facilities where the study took place, 
source documents, CRFs, and applicable supporting records of study patient participation for 
audits and inspections by [CONTACT_1744]/IECs, regulatory authorities (eg, FDA, European Medicines 
Agency, Health Canada) and company authorized representatives.  The investigator should make 
every effort to be available for the audits and/or inspections.  If the investigator is contact[CONTACT_398976], he/she should contact [CONTACT_27740].
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21fter fter 
udydy
udydy, a , a 
formed formed 
.  Monitorin.  Monitori
appropriatappropria
ts, the facils, the facil
and all othnd all o
tiive in accove in accii
oon that in that s a
rce documece docum
d/or his/her /or his/he
queries by [CONTACT_380791] t
d consentsd consents /a/
ofof SAEs a SAEs ff
ined in a stined in a st
s
ng procedung procedu
presentativeresentative
Celgene SCelgene
s.
quired to pquired to 
CRFsCRFs ,,andand
ectectioions by [CONTACT_72653] I
alalththll Canada Canadahh
ort to be avato be av
gulatorygulatory auauyy
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069515]-001 Amendment 5.0 Final: [ADDRESS_1069516] authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable), and contribution to abstract, presentation, and/or publication development.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ttific ific 
pplies to plies to 
edical edical 
se developmse develop
nd maynd may bbye
d id its results resulii tsl
stries, as wries, as w
healtalth authouth
t authorshipt authorsh
ibution to pi[INVESTIGATOR_198478] p
, participati participat
sentationentation ,,a
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069517]-001 Amendment 5.0 Final: 13 Jul 201618. REFERENCES
Abraxane [package insert]. Summit, NJ, [LOCATION_003]: Celgene Corporation; 2012.
Ady N, Zucker JM, Asselain B, Ediline V, Bonnin F, Michon J, et al. A New 123I-MIBG Whole 
Body Scan Scoring Method-Application to the Prediction of the Response of Metastases to 
Induction Chemotherapy in Stage IV Neuroblastoma. Eur J of Cancer 1995;31A(2): 256-61.
Agarwala S. Pediatric rhabdomyosarcoma and nonrhabdomyosarcoma soft tissue sarcoma. J 
Indian Assoc Pediatr Surg 2006;11(1):15-23.
Allwood MC, Martin H. The Extraction of Diethylhexylphthalate (DHEP) from Polyvinyl 
Chloride Components of Intravenous Infusion Con tainers and Administration Sets by [CONTACT_778582]. Int J Pharmaceut 1996;127:65-71.
Alvarez-Gallego R, Cubillo A, Rodriguez-Pascual J, Quijano Y, De Vicente E, Garcia L, et al. 
Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer [abstract].  
American Society of Clinical Oncology Annual Meeting (ASCO); 2012 Jun 1-5; Chicago, IL.
Abstract no. 4040.
American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 
2012.
AndrÃ© N, Meille C. Taxanes in paediatric oncology: and now?  Cancer Treat Rev 2006;32(2):65-
73.
Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, et al. Clinical features 
and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011;117(13):3027-32.
Arndt CAS. Soft tissue sarcomas. In: Kliegman RM, Stanton BF, St. Geme III JW, Schor NF, 
Berhrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Saunders; 2011. p. 
1760-3.
Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of 
irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's 
Oncology Group study. J Clin Oncol 2011;29(2):208-13
Berg SL, Grisell DL, DeLaney TF, Balis FM. Principles of treatment of pediatric solid tumors. 
Pediatr Clin North Am. 1991 Apr;38(2):249-67.
Blackwell KL, Hamilton EP, Rocha G, Gain ey M, Trieu V, Motamed K, et al. SPARC 
microenvironment signature (SMS) in patients tr eated with nab-paclitaxel (nab-P)/carboplatin 
(C)/bevacizumab(B) for triple negative metastatic breast cancer (TNMBC) [abstract]. 
Proceedings of the European Society for Med ical Oncology Congress; 2010 October 8-12; Milan 
Italy. Abstract no. 181.
Blaney SM, Seibel NL, Oâ€™Brien M, Reaman GH, Berg SL, Adamson PC, et al. Phase I trial of 
docetaxel administered as  a 1-hour infusion in children w ith refractory solid tumors: a 
collaborative paediatric branch, National Cancer In stitute and Childrenâ€™s Cancer Group trial. J 
Clin Oncol 1997;15:1538-43. 
CCI&(/yy(/*(1([ZIP_CODE],(7$5<,1)250$7,21nyl nyl
by[CONTACT_778583]
E, Garcia LE, Garcia L
atic cancer ic cancer 
2Jun 1Jun 1 -5-5;C
a: Americaa: America
now?  Cannow?  C
R, NeuhauR, Neuha
wing sarcomng sarcom
gman RM, man RM, 
k of Pedof Ped iatia
r LM, Vossr LM, Vos
in childrenin children
lin Oncoin Onco ll2
DeLaney TFDeLaney T
Am. 1991 Am. 1991 A
HamilHamil tontolllEEn
nment signanment sign
izumab(B)umab(B)
dings of thdings of th
..Abstract Abstract 
BlBlaneyaney  SM SMyy
docetaxocetax
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069518]-001 Amendment 5.0 Final: 13 Jul 2016Brenn T, McKee PH. Melanoma in children and adolescents. Diagn Histopathol 2007;14(1):18-
27.
Chui CH. Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS). Surg Oncol 2007 
Nov;16(3):187-93.
Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, et al. Initial patient 
characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin 
Oncol 2008;26(3):406-13.
Dasgupta R, Rodeberg D. Update on rhabdomyosarcoma. Sem Pediatric Surg 2012;21:68-78.
Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor 
paclitaxel concentrations, and endothelial cell tr ansport of cremophor-free, albumin-bound 
paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res
2006;12(4):1317-24.
Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC Expression Correlates with Tumor 
Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol 
2009;2(2):59-64.
Dome JS, Rodriguez-Galindo C, Spunt SL, Santana VM. Pediatric solid tumors. In: Abeloff MD, 
Armitage JO, Niederhuber JE, Kastan MB, Gillies MCKenna W, eds. Abeloff's Clinical 
Oncology, 4th ed. Philadelphia: Churchill Livingstone; 2008. p. 2075-129.
Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, et al. Phase I trial and 
pharmacological study of a 3-hour paclitaxel infusion in  children with refractory solid tumours: a 
SFOP study. Br J Cancer 2001 Mar 2;84(5):604-10.
Eisenhauer EA, Tharasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumors: Revise d RECIST guideline (ver sion 1.1). Eur J Cancer
2009;45:228-47.
Fritsch P, Kerbl R, Lackner H, Urban C. "Wait and see" strategy in localized neuroblastoma in 
infants: an option not only for cases detected  by [CONTACT_778584]. Pediatr Blood Cancer 
2004;43(6):679-82.
Gardner ER, Dahut WL, Scripture CD, Jones J,  Aragon-Ching JB, Des ai N, et al.  Rando mized 
Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel. ClinCancer 
Res 2008;14(13):4200-5.
Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and 
advantages of vehicle selection for drug formulation. Eur J Cancer 2001 Sep;37(13):1590-8.
Geller J, Wall D, Perentesis J, Blaney SM, Bernstein M. Phase I Study of Paclitaxel with 
Standard Dose Ifosfamide in Children with Re fractory Solid Tumors: A Pediatric Oncology 
Group Study (POG 9376). Pediatr Blood Cancer 2009;52:346-50.
Harris M, Hurwitz C, Sullivan J, Larsen E, Pratt C. Taxol in Pediatric Solid Tumors: A Pediatric 
Oncology Group (POG) Phase II Study (POG #9262) [Abstract]. Proc Am Soc Clin Onc; 1999. Abstract no. 2170.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21..
ratumumor or 
ound und 
lates with lates with 
ts. s. Transl OTran
c sosolid tumtum
W, eds. W, eds. Ab
8. p.. p.2075-2075-
oretti S, et aoretti S, et 
n in children in child
0.0.
wartz LH, Swartz LH, S
d RECIST d RECIST 
an C. "Wain C. "Wa
ases detecteases detecte
Scripture CScriptur
netnetic Studyic Study
200200--5.5.
Verweij J, Verweij 
of vehicle sof vehicle s
, Wall D, P Wall D, P
ard Dose Iard Dose
roup Studyroup Study
Harris MHarris M
nconcoll
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069519]-001 Amendment 5.0 Final: 13 Jul 2016Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML; Pediatric Oncology Group 
Study. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid 
tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 2003;25(7):539-42.
Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epi[INVESTIGATOR_778536]: a 
review. Paediatr Perinat Epi[INVESTIGATOR_5541] 2009;23(2):125-43.
Hersh E, Del Vecchio M, Brown M, Kefford R, L oquai C, Teston A, et al. Phase 3 randomized, 
open-label, multicenter trial of nab-paclitaxel (nab-P) vs decarbazine (DTIC) in previously untreated patients with metastatic malignant mela noma (MMM). Pi[INVESTIGATOR_79306]
2012;25(6):863.
Hinkle AS. Osteosarcoma. In: Lynn CG, Jeffrey MK, Christy C, eds. Pediatric Clinical Advisor 
(Second Edition). Philadelphia: Mosby; 2007. p. 416-7.
Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, et al. Children's 
Oncology Group.  A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.  Pediatr Blood Cancer 
2008;50(4):788-92.
Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, et al. Phase I 
trial of paclitaxel in children with refractory so lid tumors: a Pediatric Oncology Group Study. J 
Clin Oncol 1993;11(12):2324-9.
Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, et al. Paclitaxel for 
the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II 
study. J Pediatr Hematol Oncol 2001;23(5):277â€“81.
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and 
Pharmocokinetic Study of ABI-007, a Cremophor-Free, Protein-Stabilized, Nanoparticle 
Formulation of Paclitaxel. Clin Cancer Res 2002 May;8(5):1038-44.
Izbicka E, Campos D, Marty J, Carrizales G, Mangold G, Tolcher A. Molecular determinants of 
differential sensitivity to docetaxel and p aclitaxel in human pediatric cancer models. Ant icancer 
Res 2006;26(3A):1983-8.
Jain S, Kapoor G. Chemotherapy in Ewing's sarcoma. Indian J Orthop 2010;44(4):369-77.Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol 2009;27(6):529-36.
Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In:
Macleod CM, editor. Evaluation of Chemotherapeuti c Agents. [LOCATION_001]: Columbia University 
Press; 1949. p. 199-205.
Kim S, Chung DH. Pediatric solid malignancies: neuroblastoma and Wilms' tumor. Surg Clin 
North Am 2006 A pr;86(2):469-87, xi.
Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, et al. Response to 
paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated 
neuroblastoma treated in an upfront phase II i nvestigational window: a pediatric oncology group 
study. J Clin Oncol 2004;22(20):4119-26.
Lansky S, List M, Lansky L, Ritter-Sterr C, Miller D. The measurement of performance in 
childhood cancer patients. Cancer 1987;60:1651-6.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21Advisor Advisor 
Children's Children
for the treafor the tr
atr Blatr Bl ood Cood
J, Strother D, Strother
iiatriatric Oncoc Onco
s MB, FrieMB, Fr
rain tumorsain tumors
..
P, TheriaultP, Theriaul
mophorophor -FreFre
Res 2002 MRes 2002 M
izales G, Mzales G, 
el and pacliel and pac
herapyerapy iyn EnE
antant-Kels JMKels JM
chenalhenal J. TJ. T
ediditor.toriii EvalEv
p. p. 199-19920520
Chung DHChung DH
h Am 2006 h Am 200
Kretschmar Kretschmar
paclitaxepaclitaxe
urobrob
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069520]-001 Amendment 5.0 Final: 13 Jul 2016Levy CF. Rhabdomyosarcoma and other soft-tissue sarcomas. In: Lanzkowsky P, ed. Manual of 
Pediatric Hematology and Oncology. 5th ed. [LOCATION_001]: Elsevier; 2011. p. 715-38.
Lewis KG. Trends in pediatr ic melanoma mortality in the [LOCATION_002], 1968 through 2004. 
Dermatol Surg 2008;34(2):152-9.
Liu L, Vapi[INVESTIGATOR_78006] N, Munoz LK, Winick NJ, Weitman S, Strauss LC, et al. A phase I study of 
cranial radiation therapy with concomitant conti nuous infusion p aclitaxel in children with brain 
tumors. Med Pediatr Oncol 2001;37(4):390â€“2.
Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of 
early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response 
and event-free survival in Stage IV neuroblastoma. J Clin Oncol 2003;21(13):2486-91.
Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for 
evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report 
for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102(9):1319-26.
Mills O, Messina JL. Pediatric melanoma: a review. Cancer Control 2009;16(3):225-33.
Modak S, Cheung N. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat 
Rev 2010;36(4):307-17.
Moore J, Grasso J, Barbarotta L, Nelson W, Fischer D. When Prevention Fails, Policy for 
Accidental Chemotherapy Overdose.  ONS-Oncology Nursing Society [ADDRESS_1069521].
Morelli JG. Chapter 643. Cutaneous Nevi. In: Kliegman RM, Stanton BF, St. Geme J, Schor N, 
Behrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Saunders; 2011.
Nyman DW, Campbell, KJ, Hersch E, Richardsom, K, Patrick K, Trieu B, et al. A Ph ase I trial 
of ABI-007, nanoparticle paclitaxel, administered to subjects with adva nced non-hematologic 
malignancies. J Clin Oncol 2004, ASCO Annual Meeting Proceedings (Post-Meeting 
Edition);22(14)([ADDRESS_1069522]):2027.
Oberline O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, et al. Prognostic factors in 
metastatic rhabdomyosarcomas: results of a pool ed analysis from [LOCATION_002] and European 
cooperative groups. J Clin Oncol 2008; 26(14): 2384-9.
Oluwole O, Samaila M. Spontaneous tumour regression [Internet]. Internet J Pathol 2009;8(1). 
Available from:  http://www.ispub.com/IJPA /8/1/[ZIP_CODE]. Acce ssed 16 Mar 2015.
Paulussen M, Bielack S, Jurgens H, Casali PG. Ewing's sarcoma of the bone: ESMO clinical 
recommendations for diagnosis, treatment a nd follow-up. Ann Oncol. 2009;[ADDRESS_1069523] 4:140-14.
Pfeifer RW, Hale KN, Cronquist SE, Daniels M. Precipi[INVESTIGATOR_778537]. Am J Hosp Pharm 1993 Dec;50:2518-21.
Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) Program (www.seer.cancer.gov) 
SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973-2009) 
<Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCC PS, Surveillance Research Program, Surveillance 
Systems Branch, released April 2012, based on the November 2011 submission.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21of of
onse onse 
alal. Cri. Criteriateriii
stomstom a: a rea: a
ncer ncer
2009;16(3):009;16(3)
clinical enlinical en
hen Prevenhen Preven
Nursing SocNursing So
gmgmananRM, RM,
trics. 19th rics. 19th 
ardsoardso m, K,m, K,
nistered tonistered to
O Annual  Annual 
Biisogno G, sogno G, 
mamas: resuls: resu tl
n Oncoln Oncol 20
M. SponM. Spon tantnn
ttp://www.tp://www
BiBielack S, elack S
datatioionsnsfoforr
RW, Hale RW, Hale 
p. Amp. Amm  J HJ Hmm
SurveillancSurveillanc
SEER*SEER*
t
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069524]-001 Amendment 5.0 Final: 13 Jul 2016Seibel NL, Blaney SM, O'Brien M, Krailo M, Hutchinson R, Mosher RB, et al. Phase I trial of 
docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a 
collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group 
trial. Clin Cancer Res 1999;5(4):733-7.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric 
phase I trials: the rolling six design. J Clin Oncol 2008 Jan 10;26(2):190-5.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. 
Weekly nab-paclitaxel in combination with ca rboplatin versus solvent-based paclitaxel plus 
carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final 
results of a phase III trial.  J Clin On col 2012; 30(17):2055-62.
Song DI, Hsu Li-Fen, Au JL-S. Binding of taxol to plastic and glass containers and protein under 
in vitro conditions. J Pharm Sci 1996 Jan;85(1):29-31.
Sparreboom A, van Zuylen L, Brouwer E, Loos W, de Bruijn P, Gelde rblom H, et al. Cremophor 
EL-mediated alteration of paclitaxel distributio n in human blood: clinical pharmacokinetic 
implications. Cancer Res 1999;59:1454-57.
Spunt SL, Skapek SX, Coffin CM. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. 
Oncologist 2008;13(6):668-78.
Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk  factor and survival 
analysis of the surveillance, epi[INVESTIGATOR_778538]. J Clin Oncol
2005;23(21):4735-41.
Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, Pappo AS, et al; Soft Tissue 
Sarcoma Commit tee of the Childrenâ€™s Oncology Group. Late events occurring five years or more 
after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue 
Sarcoma Commit tee of the Ch ildrenâ€™s Oncology Group. Eur J Cancer 2004 Aug:40(12):1878-85.
Taxol [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2011.
Taxotere [package insert]. Bridgewater (NJ): [COMPANY_011]-Aventis; 1996.
ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation 
vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42(7):665-85.
Ullrich NJ. Neuroblastoma. In: Ferri FF, editor. Ferriâ€™s Clinical Advisor. 1st ed. Philadelphia: 
Mosby; 2012. p. 692-3.
Vassal G, Fitzgerald E, Schrappe M, Arnold F, Kowalczyk J, Walker D, et al. Challenges for the 
Children and Adolescents With Cancer in Europe: The SIOP-Europe Agenda. Pediatr Blood
Cancer 2014;61(9):1551-7.
Venkataramanan R, Burckart GJ, Ptachcinski RJ, Blaha R, Logue LW, Bahnson A, et al. 
Leaching of Diethylhxyl Phthalate from Polyvinyl Chloride Bags into Intravenous Cyclosporine 
Solution. Am J Hosp Pharm 1986 Nov;43:2800-2.
Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Randomized 
phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21.
us us 
final inal 
and proteinand prot
bloom mH,H,et a
nical pharmical pharm
coma soft coma s
memelanolanomm
esulsults dts dllatabat
SL, Crist WSL, Crist W
cologycology GroGroyy
habdomyabdomy oo
â€™s Oncologs Oncolo
n n ((NJNJ): B): Briri
Bridgewaterridgewat
Loos WJ, Loos WJ, S
sfofor cancer canc
oblastoma.oblastoma.
p. 692p. 692 -3.3.
Fitzgerald itzgerald
n and Adon and Ado
cer 2014;6cer 2014;6
VenkataramVenkataram
LeachinLeachi
t
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069525]-001 Amendment 5.0 Final: 13 Jul 2016with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2013; s34; abstract 
LBA148. 
Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH, et al. Phase I targeted 
systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer 
Res 1999;5(3):543-9.
Xu QA, Trissel LA, Zhang Y. P aclitaxel Compatib ility with the IV E xpress FilterTMUnit. Int J 
Pharm Compd 1998 May-June;2(3):243-5.
Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. 
Semiquantitative mIBG scoring as a prognostic indicator in patients with Stage 4 neuroblastoma: 
a report from the Childrenâ€™s Oncology Group. J Nucl Med 2013;54(4):541-548.
Yang Y, Niu X, Zhang Q, Hao L, Ding Y, Xu H. The efficacy of abraxane on osteosarcoma 
xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J 
Med Sci 2012 Sep;344(3):199-205.
Yardley DA, Raefsky E, Castillo R, Lahiry A, LoCicero R, Thompson D, et al. Results of a 
multicenter pi[INVESTIGATOR_778539]-paclitax el, carboplatin with bevacizumab, and trastuzumab 
as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. [abstract] Proceedings of the 45th American Society of Clinical Oncology Annual Meeting 
(ASCO); 2009 May 29 - June 2; Orlando, FL. J Clin Oncol 2009;27([ADDRESS_1069526]):527.
Zhang L, Marrano P, Kumar S, Leadley M, Elias E, Thorner P, et al. Nab-Paclitaxel Is an Active 
Drug in Preclinical Model of Pediatric Solid Tumors. Clin Cancer Res 2013;19:5972-83.
Zwerdling T, Krailo M, Monteleone P, By[CONTACT_26752] R, Sato  J, Dunaway R, et al. Phase II investigation 
of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Ca ncer 2006;106(8):1821â€“8.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21astoma: astoma: 
osarcomosarcom a a
ysteine. Amysteine. A
, et alet al. Res. 
vacizumab, acizumab,
with SPARwith SPAR
OncoOnco logy
009;009;27(15(15
rner P, ner P, eteta
Clin CanceClin Canc
ato J, Dunaato J, Dun
t solid tumsolid tum
â€“â€“8.8.
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069527]-001 Amendment 5.0 Final: 13 Jul 201619. APPENDICES
19.1. Appendix A:  RECIST 1.1
The following information is extracted/summarized from Eisenhauer, 2009 , New response 
evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Please refer to the 
primary reference for further information.
19.1.1. Definitions
At screening, tumor lesions/lymph nodes will be categorized as measurable or nonmeasurable.
[IP_ADDRESS]. Measurable Disease
Tumor Lesions.   Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
!10mm by [CONTACT_3610] (CT scan slice thickness no greater than 5 mm)
!10mm caliper measurement by [CONTACT_461] (les ions which cannot be accurately 
measured with calipers should be recorded as nonmeasurable)
!20mm by [CONTACT_13190] X-ray
Malignant Lymph Nodes. To be considered pathologically enlarged and measurable, a lymph 
node must be â‰¥ 15mm in short axis when assessed by [CONTACT_3610] (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed. 
[IP_ADDRESS]. Nonmeasurable Disease
All other lesions are considered nonmeasurabl e, including small lesions (longest diameter 
<10mm or pathological lymph nodes with â‰¥ 10 to < 15mm short axis) as well as truly 
nonmeasurable lesions. Lesions considered truly nonmeasurable include: leptomening eal disease, 
ascites, pleural or pericardial effusion, inflammatory  breast disease, lymphangitic involvement of 
skin or lung, abdominal masses/abdominal organomegaly identified by [CONTACT_87415].
[IP_ADDRESS]. Special Considerations for Lesion Measurability
Bone lesions, cystic lesions, and lesions previ ously treated with local (radiation) therapy should
be considered measurable or nonmeasurable according to Eisenhauer, 2009 .
19.1.2. Tumor Response Evaluation
[IP_ADDRESS]. Target Lesions
When more than one measurable tumor lesion is present at baseline all lesions up to a maximum 
of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21urable.urable.
gest digest ameame
5 mm)5 mm)
which cannhich cann
easurable)easurab
gicallygically enlaenlayy
by [CONTACT_778585] â‰¥â‰¥
s consideres conside
all effusi effusill onon
masses/abdmasses/a
ucible imagucible im
ial ialConsidConsid
s, cystis, cysti c lesc le
dered measued measu
.2..2. TuTu
[IP_ADDRESS].[IP_ADDRESS].
hen
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069528]-001 Amendment 5.0 Final: [ADDRESS_1069529] meet the measurable 
criterion of a short axis of â‰¥ [ADDRESS_1069530] scan and only the short axis of these nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis â‰¥ 10 mm but < 
15 mm) should be considered nontarget lesions. Nodes that have a short axis < 10 mm are 
considered nonpathological and should not be recorded or followed. At baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes: overall maximum of 5) is to be recorded.
After baseline, a value should be provided on the CRF for all identified target lesions for each 
assessment, even if very small. If extremely small and faint lesions cannot be accurately measured but are deemed to be present, a default value of 5 mm may be used. If lesions are too 
small to measure and indeed are believed to be absent, a default value of 0 mm may be used.
[IP_ADDRESS]. Nontarget Lesions
All nonmeasurable lesions (or sites of disease) plus any measurable lesions over and above those 
listed as target lesions are considered nontarget lesions. Measurements are not required but these 
lesions should be noted at bas eline and should be followed as â€œpresent,â€ â€œabsent,â€ or 
â€œunequivocal progression.â€
[IP_ADDRESS]. Response Criteria
Target and nontarget lesions are evaluated for response separately, and then the tumor burden as 
a whole is evaluated as the Overall response.
[IP_ADDRESS].1. Target Lesion Response
Target lesions will be assessed as follows:
!Complete Response (CR). Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or nontarget) must have reduction in short axis to <10 mm.
!Partial Response (PR). At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.
!Progressive Disease (PD). At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute in crease of at least 5 mm. (N ote: the appearance 
of one or more new lesions is  also considered progression).
!Stable Disease (SD). Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on 
study.
[IP_ADDRESS].2. Nontarget Lesion Response
Nontarget lesions will be assessed as follows:
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ch h 
ssare too are too 
y be used.y be used.
s over ands over and
are not reqare not re
entt,â€ â€œabsenâ€ â€œabsen
separatelyseparately
DisappeaDisappea
arget or nonget or no
e (PR)e (PR) ..At
g as referenas refe
ve Diseaseve Diseas
, taking as taking as 
at is the smat is the sm
must almust al so deso d
ofof one orone f
!!StabSta
inin
1
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069531]-001 Amendment 5.0 Final: 13 Jul 2016!Complete Response (CR). Disappearance of all nontarget lesions and normalisation 
of tumor marker level. All lymph nodes must be nonpathological in size (<10mm short axis).
!Non-CR/Non-PD. Persistence of one or more nontarget lesion(s) and/or 
maintenance of tumor marker level above the normal limits.
!Progressive Disease (PD). Unequivocal progression (see comments below) of 
existing nontarget lesions. (Note: the app earance of one or more new lesions is also 
considered progression).
When the patient also has measurable disease. In this setting, to achieve â€œunequivocal 
progressionâ€ on the basis of the nontarget disease, there must be an overall level of substantial 
worsening in nontarget disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
â€œincreaseâ€ in the size of one or more nontarget lesions is usually not sufficient to qu ality for 
unequivocal progression status. The designation of overall progression solely on the basis of 
change in nontarget disease in the face of SD or PR of target disease will therefore be extremely rare. 
When the patient has only nonmeasurable disease. This circumstance arises in some phase III 
trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance there is no measurable disease 
assessment to factor into the interpretation of an increase in nonmeasurable disease burden. 
Because worsening in nontarget disease cannot be  easily quantified (by [CONTACT_108]: if all lesions 
are truly nonmeasurable) a useful test that can be applied when assessing patients for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in nonmeasurable disease is comparable in magnitude to the increase that would be required to declare PD for measurable disease: ie, an increase in tumor burden representing an 
additional 73% increase in â€œvolumeâ€ (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from â€œtraceâ€ to â€œlarge,â€an increase in lymphangitic disease from localised to widespread, or may be described in 
protocols as â€œsufficient to require a change in therapy.â€ If â€œunequivocal progressionâ€ is seen, the 
patient should be considered to have had over all PD at that point. While it would be ideal to have 
objective criteria to apply to nonmeasurable disease, the very nature of that disease makes it 
impossible to do so: therefore, the increase must be substantial.
[IP_ADDRESS].3. Overall Response
Overall response should be assessed according to Table 10 for patients with target lesions, and 
Table 11 for patients with only nontarget lesions.
CCIbstantial stantial 
sease, the sease, the 
pypy. A. AmmAAodeode
nt tot toqualitality
elylyon the bon the byy
ll thereforell therefo
mstance arstance a
ble diseaseble diseas
nce there ise there i
e in nonmee in nonm
asilysilyquantquanyy i
applied whapplied w
crease in orease in o
able in magable in mag
ease: ease: ieie, a
(which is eq(which is eq
ude an incree an incr
ase froase fro m lom lo
quire a chanuire a chan
ed to havd to hav ehe
ly to nonmly to nonm
thhereforeerefore t
rall rallRespoRes
ponponse shouse shou
for rpatipatienen
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069532]-001 Amendment 5.0 Final: 13 Jul 2016Table 10: Time Point Response: Patients With Target (Â± Nontarget) Disease
Target Lesions Response Nontarget Lesi on Response New Lesions Overall Response
CR CR No CR
CR Non-CR/ non-PD No PR
CR Not evaluated No PR
PR Non-PD or not all evaluated No PR
SD Non-PD or not all evaluated NO SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = inevaluable.
Table 11: Time Point Response: Patients With Nontarget Disease Only
Nontarget Lesions Response New Lesions Overall Response
CR No CR
Non-CR/ non-PD No Non-CR/ non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
aâ€œNon-CR/non-PDâ€ is preferred over â€œstable diseaseâ€ for nontarget disease since SD is increasingly used as 
endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = inevaluable.
[IP_ADDRESS]. Symptomatic Deterioration
Patients with a global deterioration of heal th status requiring discontinuation of treatment 
without objective evidence of disease progre ssion at that time should be reported as 
â€˜symptomatic deteriorationâ€™. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptom atic deterioration is not a descriptor of an 
objective response: it is a reason for stoppi[INVESTIGATOR_12003]. The objective response status of such patients is to be determined by [CONTACT_664247].
19.2. Appendix B: Curie Scale for MIBG Response
The Curie score is a semiquantitative scoring system for the comparison of sequential whole-body MIBG s cans in children with neuroblastoma.  The following information is 
extracted/summarized from Ady, 1995 ,a n d Matthay, 2003 .  Please refer to the primary
references for further information.
CCI&(/*(1([ZIP_CODE],(YesYes5,(7$5<,1)250$7,[ZIP_CODE]$7$7$7$7PDD0$ PDPD50PDPD25)2sease, NE = ease, NE = 
isease Onlyease Onl
<,5<5<5<5<5<$5555
7$s or Noor No(75,(35iseasesease â€â€foror
me trials so toe trials so
response, SDresponse, SD
Deteriorateteriorat
deterideteri oratiorati
vidence of dence of 
teriorationterioration
contontinuatinuat ioio
esponse: it sponse: it 
tients is to btients is to 
9.2..2. AA
The CuriThe Curi
dyd
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069533]-001 Amendment 5.0 Final: [ADDRESS_1069534] 1.1 ( Matthay, 2010 ;Bagatell, 2011 ).
19.2.2. Tumor Response Evaluation
The body is divided into nine anatomic sectors for osteomedullary lesions, with a tenth general 
sector allocated for any extra-osseous lesions. In each region, the absolute extension score of the 
lesions is graded as: 
!0 = no site per segment 
!1 = one site per segment 
!2 = more than one site per segment 
!3 = massive involvement (> 50% of the segment) 
The absolute score is obtained by [CONTACT_6780], as shown in Figure 3 and 
listed here: (1) head and face; (2) neck and back vertebral column; (3) ribs and sternum; (4) lumbar and sacral column; (5) pelvis; (6) arms; (7) forearms and hands; (8) thighs; (9) legs and 
feet; and (10) any soft tissue involvement.
Figure 3: Curie Score Anatomical Regions
Source:  Ady, 1995 .
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21l 
of the the ff
nts, as shownts, as sh
mn; (3) ribs mn; (3) ribs 
and hands; and hands

EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069535]-001 Amendment 5.0 Final: 13 Jul 2016The relative score is calculated by [CONTACT_778586]. 
19.2.3. Response Criteria
The relative score of each patient is calculated at each response assessment time point and 
classified as below:
!Complete Response:   Postscreening absolute score = 0. All areas of uptake on MIBG 
scan completely resolved.
!Partial Response:   Relative score â‰¥ 0.1 (lesions almost disappeared) to â‰¤ 0.5 (lesions 
strongly reduced).
!Stable Disease (nonresponse):   Relative score > 0.5 (lesions weakly but significantly 
reduced) to < 1 (lesions not reduced).
!Progressive Disease:   New lesions on MIBG scan, regardless of relative score.
19.3. Appendix C: Performance Status
19.3.1. Lansky Performance Status
The Lansky performance status is a play-performance scale designed for pediatric cancer patients 
(Lansky, 1987 ).  The Lansky performance status is reco mmended in this st udy for patients < 12
years of age.  The parent/caregiver should select the scale that is most representative (average) of
the childâ€™s activity over the past week according to Table 12 .
Table 12: Lansky Performance Scale
Score Description
100 Fully active, normal
90 Minor restrictions in physical strenuous activity
80 Active, but tires more quickly
70 Both greater restriction of, and less time spent in, active play
60 Up and around, but minimal active play; keeps busy with quieter activities
50 Gets dressed, but lies around much of the day; no active play; able to participate in all 
quiet play and activities
40 Mostly in bed; participates in quiet activities
30 In bed; needs assistance even for quiet activities
20 Often sleepi[INVESTIGATOR_007]; play entirely limited to very passive activities
10 No play; does not get out of bed
0 Unresponsive 
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21(lesiolesio nsns
ut significaut signific
f relf reatative scive s
designed fdesigned f
mmended mended in
cale caleththat iat iss
TableTable 1212
5,35physical strphysical 23more quickmore quic52r restrictionestriction35around, buaround, b(3 ts dressed, bts dressed, b
quiet play aquiet play1(
MostlyMostly*(*0 In In/*/*/*/* 2020(////
1010&(&
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069536]-001 Amendment 5.0 Final: 13 Jul 201619.3.2. Karnofsky Performance Status
The Karnofsky performance status is an assessmen t of the patientâ€™s ability to perform normal 
activity and care for himself/herself.  The Karnofsky perform ance status is recommended in this 
study for patients â‰¥12 years of age.  The research staff should interview the patient and 
determine the patientâ€™s Karnofsky performance status according to Table 13 .
Table 13: Karnofsky Performance Status Scale
ConditionPerformance 
Status % Comments
A. Able to carry on normal 
activities and to work.  No 
special care is needed100 Normal. No complaints. No evidence of disease
[ADDRESS_1069537] of his/her needs
[ADDRESS_1069538] of his/her needs.
C. Unable to care for self. 
Requires equivalent of 
institutional or hospi[INVESTIGATOR_10422]. 
Disease may be progressing rapi[INVESTIGATOR_375]40 Disabled. Requires special care or assistance
30 Severely disabled. Hospi[INVESTIGATOR_130023]
20 Hospi[INVESTIGATOR_20545], very sick active 
supportive treatment necessary
10 Moribund. Fatal processes progressing rapi[INVESTIGATOR_375].
0D e a d
Adopted from Karnofsky, 1949 .
19.4. Appendix D: Pharmacokinetic Sample Handling Instructions
19.4.1. Blood Sample Labeling
Labels must contain the following information:
!Protocol No.: ABI-007-PST-001
!Patient ID number
!Part: ie, Dense PK or Sparse PK
!Nominal Time: eg, 1 h or 5 h after end of infusion
!Sample Type: Primary or Back-up
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,2177$7seasease$7$7$7
or signs or or signs or 0$
me signs orme signs or25
carry on norarry on no1)
onal assistanonal assistan
s/her needss/her need<,[ADDRESS_1069539] of his/hest of his/he5<
isabled. sabled. ReqReq7$
SeverSever elyely
althoualthou(75 00 H35555
1010255523353399.
ndix D: dix D: PP
ood Samplod Samp
ust contain t contain 
!!Protoro
!P
EDMS Doc. Number:nab-Paclitaxel
Protocol ABI-007-PST-[ADDRESS_1069540]-001 Amendment 5.0 Final: 13 Jul 2016It is recommended that all blood collection tubes and storage vials should be labeled prior to
sample collection and processing.
19.4.2. Blood Sample Collection:
Blood samples should be co llected as follows:
!Collect approximately 0.5 mL of whole blood into a K3 EDTA tube. For PK samples 
collected at 1-2 minutes prior to, and 15 minutes after and 1 hour after the end of 
infusion, the bl ood should be drawn from the arm contralateral to the arm used for 
drug infusion.
!Accurately record the time of blood collection.
!Gently invert the tube 3 to 5 times.
!Transfer approximately 0.25 mL of blood into each of the two prelabeled, prechilled, 
polypropylene storage tubes (one primary a nd one back-up).  If the blood draw 
volume is less than 0.[ADDRESS_1069541] aliquot (primary sample) should be filled with 0.25 mL of blood, and the second aliquot (b ack-up) with the remaining volume.  
Keep storage tubes on ice until they are ready to be transferred into a freezer (-20ÂºC 
or colder) where they will remain stored until shippi[INVESTIGATOR_007].
19.4.3. PK Sample Shipment
All PK sample label information on the storage tubes have to be checked against the requisition 
form and then the samples must be shipped frozen and on dry ice to the central lab.
[IP_ADDRESS]. Sample Collection Documents to Accompany Shipment(s)
A copy of the completed specimen manifest must  accompany the shipment, and must list the 
following information at minimum:
!Sponsor name: [CONTACT_184707]
!Celgene Study Number: ABI-007-PST-001
!Subject ID Numbers
!Group: ie, Dense PK or Sparse PK
!Nominal co llection times: e g, 1 h or 5 h after end of infusion
!Sample collection date: eg, 10 Jan 2013
!Sample type: Primary or Backup
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21abeled, prebeled, pr
the blood dthe blood d
) should be should
he remhe rem aininainin
nsferred intsferred in
ng.ng.
have to be have to be 
and on dryand on dry
o Accompa Accompa
est must acest must ac
e Corpe Cor
mbermber : : ABIABI
mbersmbers
DenseDense PKP
nal conal co llectllectii
amample colleple collemm
SamSample plem
EDMS Doc. Number:
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_13695].
8VHU1DPH
7LWOH'DWH:HGQHVGD\-XO\30(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
CCI[COMPANY_003]
[COMPANY_003]
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
EDMS Doc. Number:nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069542]-001 Amendment # 5.0 Final: 13 Jul [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Updated Inclusion Criterion 1b for Phase 2 to Allow Enrollment of Patients â‰¥ 6 
Months to â‰¤ 24 Years of Age
In the Phase 2 portion of the study, the original protocol permitted enrollment of patients â‰¤ 
21 years of age. Limitation of the age to 21 years does not represent the entire population of 
patients seen by [CONTACT_778587]. Patients 15 to 24 years of age are now commonly 
referred to as â€œteenagers and young adultsâ€; the European Society for Medical Oncology (ESMO) is collaborating with the European Society of Pediatric Oncology (SIOPE) to target 
the unmet medical needs of adolescents and young adults, due in part to the varied interfaces 
between adult and childrenâ€™s services in different healthcare systems (Vassal, 2014).  Many patients diagnosed with neuroblastoma, rhabdomyosarcoma, and Ewingâ€™s sarcoma are 
followed in pediatric clinics up to 24 years of age, particularly in the  recurrent and relapsed 
setting. For example, an analysis of data from 1973 to 2007 from the [LOCATION_002] National Cancer Instituteâ€™s Surveillance, Epi[INVESTIGATOR_623], and End Results (SEER) database shows that 
the median age at diagnosis of extraskeletal Ewingâ€™s sarcoma is 19.5 years and that of 
skeletal Ewingâ€™s sarcoma is 16.3 years (Applebaum, 2011). By [CONTACT_778588] 21 to 24 years old. 
(Protocol Summary and Sections [IP_ADDRESS], 2.1, 4.1, 7.2, and 10.9.1) 
!Updated Inclusion Criterion 2b for Phase [ADDRESS_1069543] or second line 
treatment thus prevents the participation of a majority of patients (who have failed three previous lines and for whom new treatment options are limited).
In addition, the phrase â€œor has evidence of refractory diseaseâ€ is now removed in order to 
avoid ambiguity concerning the number of previous  lines of treatment. (Figure 2 and Section 
7.2)
!Modification of Exclusion Criterion 7 to Differentiate Between Autologous and 
Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
The protocol required that patients should not  have received any hematopoietic stem cell 
transplant (HSCT) â‰¤ [ADDRESS_1069544] (IP).
Allogeneic HSCT carries a substantial risk of graft-versus-host disease. Therefore, it is sound 
clinical practice to delay the start of new chemotherapy for a period of at least [ADDRESS_1069545] does not share this risk, and so it is clarified that the 
exclusion period prior to start of IP is â‰¤ [ADDRESS_1069546]. (Section 7.3)
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21â‰¤ â‰¤
ioion of of 
moonlynly
ncolncologyogy
IOPE) to taIOPE) to t
he varied invaried in
Vassal, 2014Vassal, 201
wingâ€™s sarcongâ€™s sa
the  recurrehe  recurre
m mthhe Unite Un
sulults (SEERts (ll
cocoma ma is 19.19
2011). By2011). By [CONTACT_778589]
1, 7.2, 1, 7.2, and and
hase 2 to Aase 2 to 
TreatmentTreatment
e eligible toe eligible
y hay haddevidenev
orth Americh Ameri
eligibiliteligibilit y y
he partihe parti cipacipa
whom newwhom new
hrase â€œor hahrase â€œor 
y y concerninconcerni
dification dification 
Allogeneic geneic
The protocoThe protoc
transpltranspl ana
AlloAll
cl
EDMS Doc. Number:nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069547]-001 Amendment # 5.0 Final: 13 Jul 2016!Updated Assessment of the Primary Endpoint (Overall Response Rate [ORR]) in 
the Phase 2 Neuroblastoma Group Using Both the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.[ADDRESS_1069548] criteria or the Curie score without crossover between assessment types over time; should both assessment types have been performed on a given subject across the 
assessment time points, the less favorable asse ssment type (in terms of achievement of 
response) would be considered for the ORR analysis. 
However, response obtained by [CONTACT_778590] a measurement of stable disease; response in neuroblastoma patients is not 
adequately assessed by [CONTACT_778591]. Studies have shown that high-risk 
neuroblastoma patients with a Curie score > [ADDRESS_1069549] 
extremely poor outcomes, leading to alternative therapi[INVESTIGATOR_778528] (Yanik, 
2013). Even in patients who have received several previous lines of treatment, a response assessed by 
123I-metaiodobenzylguanidine (MIBG)/Curie score is clinically important in 
determining subsequent treatment options.
With the implementation of Protocol Amendment 5, if both assessment types have been 
performed on a given subject across the assessment time points, to be considered as a partial 
response for the ORR analysis, both methodologies should show no worse than stable disease 
and at least one method should indicate complete response (CR) or partial response (PR). A response is only considered complete if both methodologies indicate CR. (Sections 1.3.2 and 
10.6)
!Clarification of Definition of the Efficacy Evaluable Population
Per the Phase 2 Simon two-stage design in Section 10.3 (Sample Size and Power 
Considerations), for each of the 3 groups in the firs t stage, 14 efficacy evaluable patients will 
be enrolled. If < 2 of the 14 patients has a response, the enrollment for this group will be stopped upon determination of the number of responders. If â‰¥ [ADDRESS_1069550] a 
response, the enrollment will continue until 23 efficacy evaluable patients are enrolled.
However, the Efficacy Evaluable Population was defined in Protocol Amendment 4 Section 
10.2 (Study Population Definitions) as â€œAll tr eated patients who meet eligibility criteria, 
complete at least two doses of investigational product, and have baseline and at least one 
postbaseline efficacy assessment. Here efficacy  assessment means radiological assessment of
the tumor or tumor assessment by [CONTACT_778592].â€ P atients may experience 
symptomatic deterioration (a measure of clinical progression in the absence of objective 
radiological tumor assessment) prior to a post- baseline efficacy assessment, and may have 
had only one dose of investigational product. 
With the implementation of Protocol Amendment 5 the definition of the Efficacy Evaluable 
Population is updated as  follows to accurately include patients with clinical progression in 
the analysis of ORR:  â€œAll treated patients who meet eligibility criteria, complete at least one
dose of investigational product, and have baseline and at least one postbaseline efficacy 
assessment if having not discontinued the investigational product prior to postbaseline efficacy assessment due to disease progression or symptomatic deterioration. Here efficacy 
assessment means radiological assessment of the tumor or tumor assessment by [CONTACT_778593]&(/*(1([ZIP_CODE],(7$5<,1)250$7,21other other 
is not is not 
apypyhave have yy
tions (Yaniions (Ya
tment, a restment, a re
nically impi[INVESTIGATOR_897] i
sessment tyessment t
oints, to be nts, to
uld show nold show n
ponse (CR)onse (CR)
odologies iodologies i
cacy Evaluacy Evalu
n ininSectSectioio
oups in theoups in th
nts has a rents has a
the numbee numbe
ll contl cont inueinue
Evaluable Pvaluable
on Definion Defin tii
two doses owo dose
fficacyficacy  asse asseyy
r tumor assr tumor ass
mmatatic deterioic deteri
ogicalgical tumtumll
d onlyd on one oney
WitWith the h the 
PopulPopul
ththee
d
EDMS Doc. Number: nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069551]-001 Amendment # 5.0 Final: [ADDRESS_1069552] be documented as the primary reason for treatment 
discontinuation in the treatment discontinuation CRF.â€  In addition, the definition of 
symptomatic deterioration in Section 12.1 Treatment Discontinuation is updated from â€œSymptomatic deterioration (global deterioration of health status)â€ to â€œSymptomatic 
deterioration (global deterioration of h ealth status w ithout objective evidence of disease 
progression).â€ (Sections 10.2 and 12.1)
!Addition of Definition of nab-Paclitaxel Overdose
Section 8.2.[ADDRESS_1069553] protocol language 
concerning nab-paclitaxel overdose. (Section 8.2.4)
!Identification of the Recommended Phase 2 Dose (RP2D)
During the Phase 1 portion of the study, the Safety Monitoring Committee (SMC) 
determined that the RP2D is 240 mg/m2 in patients weighing > 10 kg, and 11.5 mg/kg in 
patients weighing â‰¤ 10 kg. This information is added to the protocol. (Protocol Summary and 
Sections 1.3.2, 4.1, and [IP_ADDRESS]) 
!Updated Phase 1 Enrollment Numbers
During the Phase 1 portion of the study, 6 dose cohorts (a total of 44 patients in the Dose 
Determining Sets) were evaluated, and about 20 additional patients were enro lled at dose 
levels evaluated as safe by [CONTACT_4484]. This information is added to the protocol. (Protocol 
Summary, Figure 1 and Section 7.1)
!Allowance for the Use of Historical Left Ventricular Shortening Fraction (LVSF) 
Assessments and Electrocardiograms (ECGs) at Screening
The protocol required that LVSF assessments and ECGs be performed at screening after 
informed consent/assent has been obtained. In order to avoid subjecting young patients to 
repeated stressful procedures during a short time period, with the implementation of Protocol Amendment 5 if a patient has a historic LVSF assessment or ECG that was performed prior 
to informed consent/assent for non-study reasons, the procedure does not need to be repeated 
for screening. The procedure must have been performed within [ADDRESS_1069554] dose of nab-paclitaxel. (Section 6)
References: 
Applebaum MA, Worch J, Matthay KK, Goldsby R, Neuhaus J, West DC, et al. Clinical features 
and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011;117(13):3027-32.
Vassal G, Fitzgerald E, Schrappe M, Arnold F, Kowalczyk J, Walker D, et al. Challenges for the 
Children and Adolescents With Cancer in Europe: The SIOP-Europe Agenda. Pediatr Blood 
Cancer. 2014;61(9):1551-7.
Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. 
Semiquantitative mIBG scoring as a prognostic indicator in patients with Stage 4 neuroblastoma: 
a report from the Childrenâ€™s Oncology Group. J Nucl Med. 2013;54(4):541-548.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21age g
(SMC) SMC) 
nd 11.5 mgnd 11.5 m
(Protocol SProtocol 
total of 44 total of 4
nal patnal pat ieientn
n is addedis adde
ft Ventricut Ventricu
ms (ECGs) ms (ECGs) 
ssments anssments an
obtained. Intained. In
ring a shoring a sho
 a historic a historic
for nonfor non --sts
edure mustdure mus
ioion 6)n6 )
MA, WorcMA, Worc
omes in pates in p
al G, Fitzgal G, Fitzg
hildren andhildren and
CancerCancer .22
niki
EDMS Doc. Number: nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069555]-001 Amendment 4.0 Final: 25 Mar [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Increased Scope of Dense Pharma cokinetic (PK) Sample Collection
This protocol amendment increases dense PK sampling from the first 18 to 24 patients 
(regardless of study phase) to all patients enrolled in Phase 1. The PK sampling scheme in 
the original protocol was based on the assu mption that up to approximately 4 dose level 
cohorts would be enrolled, each with 6 patients. However, it was not taken into account that 
there were patients who had undergone PK sampling but did not meet all criteria for 
inclusion in the Dose Determining Sets (DDS); these patients were replaced and PK samples were collected, as per protocol and in agreement with the Safety Monitoring Committee 
(SMC). In addition, patients were also enrolled at a dose previously determined to be safe 
during the interim period between the closing of one cohort and an SMC dose escalation decision to open a new cohort; therefore, the number of patients who had PK samples 
collected is higher than anticipated. In order to permit full noncompartmental PK analysis of 
all Phase 1 dose levels, and in particular the dose determined to be the Recommended Phase 2 Dose (RP2D), dense PK sampling will be ob tained for all patients enrolled in Phase 1 (up 
to approximately 40 patients).
!Change of the Third Solid Tumors Group in Phase 2 from Mixed Tumors to 
Ewingâ€™s Sarcoma
For the Phase 2 portion of the study the original protocol was designed to d etermine the 
antitumor activity of nab-paclitaxel in patients with several discrete solid tumor types: 
neuroblastoma, rhabdomyosarcoma, and a mixed solid tumor group (eg, 
nonrhabdomyosarcoma soft tissue sarcomas, melanoma, or tumors in which the drug showed 
activity during the Phase 1 part of the study and/or in preclinical studies). Study investigators
strongly advised that the third group should be changed to include only one patient category, 
ie, patients with Ewingâ€™s sarcoma. Analysis of a miscellaneous group of tumors would not 
lead to meaningful Phase 2 results since it may not be possible to accrue enough patients in any of the other indications to signal significant activity.  This recommendation by [CONTACT_778594]â€™s 
sarcoma, and occurred following review of the patients enrolled to date in the Phase [ADDRESS_1069556]-001.
!Harmonization of Sample Size and Simon Two-Stage Minimax Design for the Three 
Groups in Phase [ADDRESS_1069557] Phase 2 group will include only Ewingâ€™s sarcoma patients and not mixed 
tumor types, a Simon two-stage minimax design will now be used to evaluate treatment 
effect in this group as well.  In addition, based on feedback that in the Phase [ADDRESS_1069558] stage, 14 efficacy evaluable patients will be enro lled. If < 2 of the 14
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21that hat 
PKKsamplessamples
ommittee ommittee 
ined to be sned to be
dose escaldose esca
had PK samhad PK sam
partpartmementntalal
be the Rece the Rec
patieients enrnr
hase [ADDRESS_1069559] inin
studyudy
ideide
EDMS Doc. Number: nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069560]-001 Amendment 4.0 Final: 25 Mar 2015patients within a group has a response, the enrollment for this group will be stopped upon 
determination of the number of responders. If â‰¥ [ADDRESS_1069561] a response, the 
enrollment will continue until 23 efficacy evaluable patients are enrolled. At the final 
analysis, the regimen will be concluded with a greater than 5% true response rate if â‰¥ [ADDRESS_1069562] a response according to the maximum likelihood estimator. The sample size is 
based on an 80% power and 10% significance, having fixed the lower and upper boundaries 
to 10% and 28%, respectively.
!Updated Inclusion Criterion 2 for Phase 2 to Require Radiologically Documented 
Measurable Disease by [CONTACT_16622] (RECIST) 
Version 1.1 (for Neuroblastoma Evaluable Di sease by [CONTACT_422955]/Curie Score is also 
Acceptable)
The primary endpoint of Phase 2 is Overall Response Rate (ORR); evaluation of instances of 
confirmed partial response (PR) in addition to complete response (CR) will be necessary in 
order to have a chance to properly evaluate treatment effect and ORR using the Simon two-stage minimax design.  Patients will therefore be  required to have radiologically documented 
measurable disease (for neuroblastoma, evaluable disease by [CONTACT_422955]/Curie score is also 
acceptable).
!Updated Assessment of the Primary Endpoint (Overall Response Rate [ORR]) in 
the Phase 2 Neuroblastoma Group to Use Both the Response Evaluation Criteria in 
Solid Tumors (RECIST) Version 1.1 Criteria and the Curie Score 
In the original study protocol the response in all Phase 2 patients is assessed by [CONTACT_33456] (CT) or magnetic resonance imag ing (MRI) using RECIST criteria, with an 
exploratory endpoint of determination of response using 
123I-metaiodobenzylguanidine (MIBG)
and Curie score in the neuroblastoma group. Based on investigator feedback that the lack of 
MIBG assessment would potentially weaken the significance of the study results, and could 
potentially make it diff icult to enroll subjects in the neuroblastoma group, the assessment of 
ORR in the Phase [ADDRESS_1069563] cr iteria and the Curie 
score when possible.  The Curie score is a semiquantitative scoring system for the comparison of 
sequential whole-body MI BG scans in children with neuroblastoma ( Ady, 1995 ), and MIBG 
scans are now considered the most sensitive and specific method of staging and response 
evaluation in neuroblastoma ( Matthay, 2010 ). Using both methods will allow for a more 
comprehensive and relevant evaluation of response in neuroblastoma patients who do not have 
measurable disease by [CONTACT_13407]. With this amendment, the ORR for patients in the 
neuroblastoma group will be based on either the RECIST criteria or the Curie score without 
crossover between assessment types over time. Should both assessment types have been 
performed on a given subject across the assessment time points, the less favorable assessment 
type (in terms of achievement of response) will be considered for the ORR analysis. In addition, 
consequently, this assessment of MIBG response in neuroblastoma patients is no longer 
considered an exploratory objective in Phase 2.
!Confirmation of Complete Response in Phase [ADDRESS_1069564] or by [CONTACT_778595]. This has been added as an exploratory endpoint in Phase 2.
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21T) ) 
also so 
ofofinstanceinstanc
l be necessabe neces
ing the Siming the Si
ioolologigicallyc
G/Curie scoG/Curie sc
rall Responrall Re
e e ResponsRespons
nd the Cund the 
se 2 patiente 2 patie
((MRIMR )usinusin
nse using se using [ADDRESS_1069565] se
oma (om MatthMa
elevant elevant evaev
e by [CONTACT_778596]
d on a givenon a given
n terms of an terms of a
sequentsequent ly, tly, 
onsidered aonsidered 
!!
EDMS Doc. Number: nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069566]-001 Amendment 4.0 Final: 25 Mar 2015!Decreased Minimum Platelet Level in Inclusi on Criterion [ADDRESS_1069567] udied (particularly neuroblastoma) can have bone 
marrow involvement resulting in low platelet levels due to th eir disease and to previous 
treatment regimens. In order to allow their enrollment, Inclusion Criterion 5 is updated to allow 
plateletsâ‰¥ 50 Ã— 109cells/L for patients with known bone marrow involvement; these levels are 
considered acceptable for treatment in clinical practice and will not increase the risk to patients.
The amendment also includes several other minor clarifications and updates:
!Addition of guidance on flushing of the intravenous line following administration of nab-
paclitaxel (Section 8.2)
!Addition of statements regarding study conduct in compliance with International 
Conference on Harmonisation (ICH) Good Clinical Practices (GCPs) to align with updated company standard protocol language ( Study Summary and Overall Study 
Design )
!Clarification of Phase 1 sample size to include additional patients enrolled at dose levels 
evaluated as safe by [CONTACT_4484] ( Protocol Summary )
!Update to length of Phase 1 (from 12 months to up to 18 months) ( Protocol Summary )
!Clarification of SAE reporting during the 28-da y follow-up period to align with updated 
company standard protocol language (Section 6.2.1 )
!Update to the description of response assessments to include that the sponsor may 
conduct an independent assessment of response after study completion (Section 6.3)
!Update to Inclusion Criterion [ADDRESS_1069568] Risk Language  
(Section 7.2)
!Clarification that the safety analysis will include summarization of adverse events of 
special interest (Section 10.7)
!Update to treatment discontinuation information concerning the treating physicianâ€™s 
responsibilities (Section 12.1)
!Update to Section 14.[ADDRESS_1069569] protocol language 
concerning investigator responsibilities for handling of confidential information
!Update to Section 17to align with current company standard protocol language 
concerning publication
!Addition of references (Section 18)
!Clarification that the MIBG tumor response assessment includes a 10th segment for any 
soft tissue involvement (Section 19.2.2 )
CCI&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ofofnabnab-
atioional nal 
o align witalign wi h
Overall StuOverall St
entnts enros enro lll
18 months)18 month
folloloww--up pup p
[IP_ADDRESS].1))
ssments ssments to to 
esponse aftsponse a
align wiign wi ththiicchh
analysis winalysis w
0.70.7))
discontdiscont inuain
ectiection on 12.[ADDRESS_1069570] igatigat
e to Sectionto Sectio
cerning pubcerning pu
AdditAddit ioion ono
!!ClCarifarif
sofsof
EDMS Doc. Number: nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069571]-001 Amendment 3.0 Final: 11 Jun [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Update to the new IND number for nab-paclitaxel for the pediatric solid tumors
indication.
 
CCICCI C
CI
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2150$
nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069572]-001 Amendment 2.0 Final: 12 Mar [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!In the Phase 2 portion of the study, a change to the sample size for the Phase 2 
neuroblastoma arm, and modifications of the Simon two-stage minimax design to implement acceptance rates of approximately 20% response rates for the neuroblastoma and rhabdomyosarcoma arms.
!The addition of â‰¥ Grade 2 peripheral neuropathy to the exclusion criteria.
!The addition of information concerning the use of syringe-based devices for 
administration of small volumes of nab-paclitaxel suspension.
!A change from cautionary use to prohibition of concomitant medications classified as 
strong inducers of cyto chrome P450 isoz ymes CYP2C8 and CYP3A4, and additional 
guidance on the use of strong inhibitiors of the same isozymes.
Other minor changes included in this amendment are summarized below:
!An administrative change to the Medical Monitor title and contact [CONTACT_3031].
!An administrative change to include the approval of nab-paclitaxel in the [LOCATION_003] and 
EU for the treatment of first-line metastatic pancreatic adenocarcinoma.
!Clarification and updates to the descript ion of the rolling-6 design for the Phase 1 
portion of the study.
!The addition of the use of â€œother medically appropriate methodâ€ for left ventricular 
shortening fraction (LVSF) assessment.
!The addition of company standard language for the description of investigational 
product.
!Clarification of permitted dose reductions from dose level -1 in the Phase 1 portion of 
the study.
!Clarification of recommendation concerning labeling of pharmacokinetic (PK) 
samples.
!Administrative changes to clarify protocol language and provide one additional 
literature reference.
!Administrative changes to correct minor formatting errors    
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21es for s for 
dicatdicat ioionsnscc
CYP3A4YP3A ,a
ymes.mes.
rized belowized belo
nitor titor tii tltliie ane
approval ofapproval 
static pancrstatic panc
escriptescript ioion on o
â€œother medâ€œother med
SF) assessmF) assess
mpany pany standstan
n of permittn of permi
ficatficatioion of no f
mplmples.es.
AdAdminisminis
literaterat
!!AA
nab-Paclitaxel
Summary of Changes ABI-007-PST-[ADDRESS_1069573]-001 Amendment 1.0 Final:  10 Sep [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!A global administrative change of Sponsor name [CONTACT_18904]â€˜Abraxis BioScience, LLC, a 
wholly-owned subsidiary of Celgene Corporationâ€™ to â€˜Celgene Corporationâ€™ to reflect 
the retirement of the legacy entity â€˜Abraxis BioScience, LLC, a wholly-owned 
subsidiary of Celgene Corporationâ€™ as Sponsor Name. 
!The addition of echocardiogram/multi-gated acquisition (MUGA) scans for increased 
cardiotoxicity monitoring.
!Modification of the schedule of events  to increase the frequency of 12-lead 
electrocardiogram (ECG) testing.
!The addition of a 3-month washout period for hematopoietic stem cell transplantation 
(HSCT) to the exclusion criteria.
!A decrease in the volume of blood drawn for pharmacokinetic (PK) sampling.
!An administrative change to clarify the PK sampling requirements for samples 
collected up to 1 hour after the end of study drug infusion. 
!Removal of Cycle 1 Day 1 urine homovanillic acid and vanillylmandelic acid testing.
!Clarification and updates in the statistical analysis section (e.g. safety analysis).
!An administrative change to include the use of Integrated Response Technology 
(IRT) for patient enrollment
!Addition of company standard language for End of Trial, overdose, Adverse Events, 
Serious Adverse Events, pregnancy language, site responsibilities and monitoring, and administrative procedures.  
!Administrative changes to correct minor errors and inconsistencies within the 
document and/or Case Report Forms. 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21eased ased 
ad ad 
m cell transpm cell tran
netetic (PK) sic (PK) 
requiremenquireme
nfusinfusi onon. . 
acid and vacid and v
analysis seanalysis se
he use of Inhe use of I
llanguage fanguage 
egnancy langnancy la
dures.  dures.  
ges to correges to corr
Case RepoCase Repo